

Cochrane Database of Systematic Reviews

Strategies for partner notification for sexually transmitted infections, including HIV (Review)

Ferreira A, Young T, Mathews C, Zunza M, Low N

Ferreira A, Young T, Mathews C, Zunza M, Low N. Strategies for partner notification for sexually transmitted infections, including HIV. *Cochrane Database of Systematic Reviews* 2013, Issue 10. Art. No.: CD002843. DOI: 10.1002/14651858.CD002843.pub2.

www.cochranelibrary.com



TABLE OF CONTENTS

HEADER	1
ABSTRACT	1
PLAIN LANGUAGE SUMMARY	2
SUMMARY OF FINDINGS	4
BACKGROUND	10
OBJECTIVES	11
METHODS	11
Figure 1	14
Figure 2	15
RESULTS	16
Figure 3	18
Figure 4	22
Figure 5	24
Figure 6	25
Figure 7	25
Figure 8	26
Figure 9	
Figure 10	
Figure 11	
DISCUSSION	
AUTHORS' CONCLUSIONS	32
ACKNOWLEDGEMENTS	33
REFERENCES	34
CHARACTERISTICS OF STUDIES	
DATA AND ANALYSES	
Analysis 1.1. Comparison 1 Enhanced patient referral versus simple patient referral, Outcome 1 Re-infection in index patient.	81
Analysis 1.2. Comparison 1 Enhanced patient referral versus simple patient referral, Outcome 2 Number of partners elicited	81
Analysis 1.3. Comparison 1 Enhanced patient referral versus simple patient referral, Outcome 3 Number of partners notified	
Analysis 1.4. Comparison 1 Enhanced patient referral versus simple patient referral, Outcome 4 Number of partners presenting for care.	
Analysis 1.5. Comparison 1 Enhanced patient referral versus simple patient referral, Outcome 5 Number of partners testing positive.	83
Analysis 1.6. Comparison 1 Enhanced patient referral versus simple patient referral, Outcome 6 Number of partners treated	84
Analysis 2.1. Comparison 2 Enhanced patient referral versus other enhanced patient referral, Outcome 1 Partners elicited	85
Analysis 2.2. Comparison 2 Enhanced patient referral versus other enhanced patient referral, Outcome 2 Number of partners presenting for care.	85
Analysis 2.3. Comparison 2 Enhanced patient referral versus other enhanced patient referral, Outcome 3 Number of partners treated.	85
Analysis 3.1. Comparison 3 Expedited partner therapy (EPT) versus simple patient referral, Outcome 1 Re-infection in index	86
patients Analysis 3.2. Comparison 3 Expedited partner therapy (EPT) versus simple patient referral, Outcome 2 Number of partners	87
elicited. Analysis 3.3. Comparison 3 Expedited partner therapy (EPT) versus simple patient referral, Outcome 3 Number of partners	87
notified Analysis 3.4. Comparison 3 Expedited partner therapy (EPT) versus simple patient referral, Outcome 4 Number of partners presenting for care.	87
Analysis 3.5. Comparison 3 Expedited partner therapy (EPT) versus simple patient referral, Outcome 5 Number of partners	88
treated. Analysis 3.6. Comparison 3 Expedited partner therapy (EPT) versus simple patient referral, Outcome 6 Number of harmful	88
events reported Analysis 4.1. Comparison 4 Expedited partner therapy (EPT) versus enhanced patient referral, Outcome 1 EPT vs. enhanced patient referral.	89
patient reienat.	



Analysis 4.2. Comparison 4 Expedited partner therapy (EPT) versus enhanced patient referral, Outcome 2 EPT vs. enhanced patient referral.	
Analysis 4.3. Comparison 4 Expedited partner therapy (EPT) versus enhanced patient referral, Outcome 3 Enhanced patier referral plus EPT vs. simple patient referral.	nt
Analysis 5.1. Comparison 5 Contract referral versus simple patient referral, Outcome 1 Number of partners elicited.	
Analysis 5.2. Comparison 5 Contract referral versus simple patient referral, Outcome 2 Number of partners notified.	
Analysis 5.3. Comparison 5 Contract referral versus simple patient referral, Outcome 3 Number of partners presenting for care.	
Analysis 5.4. Comparison 5 Contract referral versus simple patient referral, Outcome 4 Number of partners testing positive.	
Analysis 5.5. Comparison 5 Contract referral versus simple patient referral, Outcome 5 Number of partners treated.	
Analysis 5.6. Comparison 5 Contract referral versus simple patient referral, Outcome 6 Number of harmful events reported.	
Analysis 6.1. Comparison 6 Contract referral versus enhanced patient referral, Outcome 1 Number of partners elicited	•••
Analysis 6.2. Comparison 6 Contract referral versus enhanced patient referral, Outcome 2 Partners presenting for care	
Analysis 6.3. Comparison 6 Contract referral versus enhanced patient referral, Outcome 3 Partners testing positive.	
Analysis 7.1. Comparison 7 Contract referral versus expedited partner therapy (EPT), Outcome 1 Re-infection in index patient.	
Analysis 8.1. Comparison 8 Provider referral versus simple patient referral, Outcome 1 Provider referral vs. simple patier referral.	
Analysis 8.2. Comparison 8 Provider referral versus simple patient referral, Outcome 2 Choice between provider or simple patient referral vs. simple patient referral.	
Analysis 9.1. Comparison 9 Provider referral versus enhanced patient referral (disease intervention specialist), Outcome Number of partners elicited.	
Analysis 9.2. Comparison 9 Provider referral versus enhanced patient referral (disease intervention specialist), Outcome Number of partners testing positive.	
Analysis 9.3. Comparison 9 Provider referral versus enhanced patient referral (disease intervention specialist), Outcome Number of partners treated.	
Analysis 10.1. Comparison 10 Provider referral versus contract referral, Outcome 1 Number of partners elicited.	
Analysis 10.2. Comparison 10 Provider referral versus contract referral, Outcome 2 Number of partners presenting for care.	•••
Analysis 10.3. Comparison 10 Provider referral versus contract referral, Outcome 3 Number of partners located.	
Analysis 10.4. Comparison 10 Provider referral versus contract referral, Outcome 4 Number of partners tested.	•••
Analysis 10.5. Comparison 10 Provider referral versus contract referral, Outcome 5 Partners testing positive.	•••
Analysis 10.6. Comparison 10 Provider referral versus contract referral, Outcome 6 Number of partners treated.	
Analysis 10.7. Comparison 10 Provider referral versus contract referral, Outcome 7 Number of harmful events reported	
DITIONAL TABLES	
ENDICES	
AT'S NEW	•••
ITRIBUTIONS OF AUTHORS	
CLARATIONS OF INTEREST	•••
JRCES OF SUPPORT	
FERENCES BETWEEN PROTOCOL AND REVIEW	•••
EX TERMS	

Strategies for partner notification for sexually transmitted infections, including HIV

Adel Ferreira¹, Taryn Young^{2,3}, Catherine Mathews⁴, Moleen Zunza⁵, Nicola Low⁶

¹Faculty of Medicine and Health Sciences, Stellenbosch University, Cape Town, South Africa. ²Centre for Evidence-based Health Care, Faculty of Medicine and Health Sciences, Stellenbosch University, Cape Town, South Africa. ³South African Cochrane Centre, South African Medical Research Council, Cape Town, South Africa. ⁴School of Public Health and Family Medicine, University of Cape Town, Cape Town, South Africa. ⁵Department of Paediatrics and Child Health , Faculty of Medicine and Health Sciences, Stellenbosch University, Tygerberg, South Africa. ⁶Institute of Social and Preventive Medicine (ISPM), University of Bern, Bern, Switzerland

Contact address: Nicola Low, Institute of Social and Preventive Medicine (ISPM), University of Bern, Finkenhubelweg 11, Bern, CH-3012, Switzerland. low@ispm.unibe.ch.

Editorial group: Cochrane STI Group. **Publication status and date:** New search for studies and content updated (no change to conclusions), published in Issue 10, 2013.

Citation: Ferreira A, Young T, Mathews C, Zunza M, Low N. Strategies for partner notification for sexually transmitted infections, including HIV. *Cochrane Database of Systematic Reviews* 2013, Issue 10. Art. No.: CD002843. DOI: 10.1002/14651858.CD002843.pub2.

Copyright © 2013 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

ABSTRACT

Background

Partner notification (PN) is the process whereby sexual partners of an index patient are informed of their exposure to a sexually transmitted infection (STI) and the need to obtain treatment. For the person (index patient) with a curable STI, PN aims to eradicate infection and prevent re-infection. For sexual partners, PN aims to identify and treat undiagnosed STIs. At the level of sexual networks and populations, the aim of PN is to interrupt chains of STI transmission. For people with viral STI, PN aims to identify undiagnosed infections, which can facilitate access for their sexual partners to treatment and help prevent transmission.

Objectives

To assess the effects of different PN strategies in people with STI, including human immunodeficiency virus (HIV) infection.

Search methods

We searched electronic databases (the Cochrane Central Register of Controlled Trials (CENTRAL), MEDLINE and EMBASE) without language restrictions. We scanned reference lists of potential studies and previous reviews and contacted experts in the field. We searched three trial registries. We conducted the most recent search on 31 August 2012.

Selection criteria

Published or unpublished randomised controlled trials (RCTs) or quasi-RCTs comparing two or more PN strategies. Four main PN strategies were included: patient referral, expedited partner therapy, provider referral and contract referral. Patient referral means that the patient notifies their sexual partners, either with (enhanced patient referral) or without (simple patient referral) additional verbal or written support. In expedited partner therapy, the patient delivers medication or a prescription for medication to their partner(s) without the need for a medical examination of the partner. In provider referral, health service personnel notify the partners. In contract referral, the index patient is encouraged to notify partner, with the understanding that the partners will be contacted if they do not visit the health service by a certain date.

Data collection and analysis

We analysed data according to paired partner referral strategies. We organised the comparisons first according to four main PN strategies (1. enhanced patient referral, 2. expedited partner therapy, 3. contract referral, 4. provider referral). We compared each main strategy



with simple patient referral and then with each other, if trials were available. For continuous outcome measures, we calculated the mean difference (MD) with 95% confidence intervals (Cl). For dichotomous variables, we calculated the risk ratio (RR) with 95% CI. We performed meta-analyses where appropriate. We performed a sensitivity analysis for the primary outcome re-infection rate of the index patient by excluding studies with attrition of greater than 20%. Two review authors independently assessed the risk of bias and extracted data. We contacted study authors for additional information.

Main results

We included 26 trials (17,578 participants, 9015 women and 8563 men). Five trials were conducted in developing countries. Only two trials were conducted among HIV-positive patients. There was potential for selection bias, owing to the methods of allocation used and of performance bias, owing to the lack of blinding in most included studies. Seven trials had attrition of greater than 20%, increasing the risk of bias.

The review found moderate-quality evidence that expedited partner therapy is better than simple patient referral for preventing reinfection of index patients when combining trials of STIs that caused urethritis or cervicitis (6 trials; RR 0.71, 95% CI 0.56 to 0.89, I² = 39%). When studies with attrition greater than 20% were excluded, the effect of expedited partner therapy was attenuated (2 trials; RR 0.8, 95% CI 0.62 to 1.04, I² = 0%). In trials restricted to index patients with chlamydia, the effect was attenuated (2 trials; RR 0.90, 95% CI 0.60 to 1.35, I² = 22%). Expedited partner therapy also increased the number of partners treated per index patient (three trials) when compared with simple patient referral in people with chlamydia or gonorrhoea (MD 0.43, 95% CI 0.28 to 0.58) or trichomonas (MD 0.51, 95% CI 0.35 to 0.67), and people with any STI syndrome (MD 0.5, 95% CI 0.34 to 0.67). Expedited partner therapy was not superior to enhanced patient referral in preventing re-infection (3 trials; RR 0.96, 95% CI 0.60 to 1.53, I² = 33%), low-quality evidence). Home sampling kits for partners (four trials) did not result in lower rates of re-infection in the index case (measured in one trial), or higher numbers of partners elicited (three trials), notified (two trials) or treated (one trial) when compared with simple patient referral. There was no consistent evidence for the relative effects of provider, contract or other patient referral methods. In one trial among men with non-gonococcal urethritis, more partners were treated with provider referral than with simple patient referral (MD 0.5, 95% CI 0.37 to 0.63). In one study among people with syphilis, contract referral elicited treatment of more partners than provider referral (MD 2.2, 95% CI 1.95 to 2.45), but the number of partners receiving treatment was the same in both groups. Where measured, there was no statistical evidence of differences in the incidence of adverse effects between PN strategies.

Authors' conclusions

The evidence assessed in this review does not identify a single optimal strategy for PN for any particular STI. When combining trials of STI causing urethritis or cervicitis, expedited partner therapy was more successful than simple patient referral for preventing re-infection of the index patient but was not superior to enhanced patient referral. Expedited partner therapy interventions should include all components that were part of the trial intervention package. There was insufficient evidence to determine the most effective components of an enhanced patient referral strategy. There are too few trials to allow consistent conclusions about the relative effects of provider, contract or other patient referral methods for different STIs. More high-quality RCTs of PN strategies for HIV and syphilis, using biological outcomes, are needed.

PLAIN LANGUAGE SUMMARY

Strategies for partner notification for sexually transmitted infections, including HIV.

Sexually transmitted infections (STI) are a major global cause of acute illness, infertility and death. Every year there are an estimated 499 million new cases of the most common curable STIs (trichomoniasis, chlamydia, syphilis and gonorrhoea), and between two and three million new cases of HIV. The presence of several STIs, including syphilis and herpes can increase the risk of acquiring or transmitting HIV.

Partner notification (PN) is a process whereby sexual partners of patients given a diagnosis of STI are informed of their exposure to infection and the need to receive treatment. PN for curable STI may prevent re-infection of the patient and reduce the risk of complications and further spread.

A review update of the research of the strategies of partner notification in people with STI, including human immunodeficiency virus (HIV) infection was conducted by researchers in the Cochrane Collaboration. After searching for all relevant studies, they found 26 studies. This review covers four main PN strategies: 1) Patient referral means that the patient tells their sexual partners that they need to be treated, either with (enhanced) or without (simple) additional support to enhance outcomes. 2) Expedited partner therapy means that the patient delivers medication or a prescription for medication to their partner(s) without the need for a medical examination of the partner. 3) Provider referral means that health service personnel notify the partners. 4) Contract referral means that the patient is encouraged to notify partners but health service personnel will contact them if they do not visit the health service by a certain date.

The 26 trials in this review included 17,578 participants. Five trials were conducted in developing countries and only two trials were performed among HIV-positive patients. Expedited partner therapy was more successful than simple patient referral in reducing repeat infection in patients with gonorrhoea, chlamydia or non-gonococcal urethritis (six trials). Expedited partner therapy and enhanced patient referral resulted in similar levels of repeat infection (three trials). Evidence about the effects of home sampling, where patients with chlamydia received a sample kit for the partner, was inconsistent (three trials). There were too few trials to allow consistent conclusions



about the relative effects of provider, contract or other patient referral methods for different STIs. More studies need to be performed on HIV and syphilis and harms need to be measured and reported.

SUMMARY OF FINDINGS

Summary of findings for the main comparison. Enhanced patient referral compared with simple patient referral for partner notification for STIs, including HIV

Enhanced patient referral compared with simple patient referral for partner notification for STIs, including HIV

Health problem: partner notification for STIs, including HIV

Settings: people in rural and urban areas, given a diagnosis of STI (clinically or by a laboratory) in health services

Intervention: enhanced patient referral

Comparison: simple patient referral

Outcomes	Illustrative comparative	risks* (95% CI)	Relative ef-	No of Partici- pants	Quality of the evidence	Comments
	Assumed risk	Corresponding risk	(95% CI)	(studies)	(GRADE)	
	Simple patient referral	Enhanced patient referral				
Re-infection in index patient - home sampling vs. simple	Study population		RR 2.14 (0.91 to 5.05)	220 (1 study)	⊕⊕⊝⊝ low 1,2	
patient referral Follow-up: 12 months	64 per 1000	136 per 1000 (58 to 321)	(0.31 (0 3.03)	(I Study)	(OW -)-	
	Moderate					
	64 per 1000	137 per 1000 (58 to 323)				
Re-infection in index patient - information booklet vs.	Study population		RR 0.55 (0.22 to 1.33)	942 (2 studies)	⊕⊕⊝⊝ low 3,4	
simple patient referral Follow-up: 8 weeks	180 per 1000	99 per 1000 (40 to 239)	(0.22 (0 1.33)	(2 300103)		
	Moderate					
	156 per 1000	86 per 1000 (34 to 207)				
Re-infection in index pa- tient - patient referral (DIS/	Study population		RR 0.35 - (0.01 to 8.51)	140 (1 study)	⊕⊕⊝⊝ low ⁵	
health advisor) vs. patient referral (nurse) Follow-up: 6 weeks	14 per 1000	5 per 1000 (0 to 118)		(I SUUY)	low ~	

Cochrane Library

disease-specific website vs. simple referal Follow-up: 1 weeks0 per 1000 (0 to 0)0 per 1000 (0 to 0) <th< th=""><th></th><th>14 per 1000</th><th>5 per 1000 (0 to 119)</th><th></th><th></th><th></th></th<>		14 per 1000	5 per 1000 (0 to 119)				
vs. simple referral Follow-up: 1 weeks 0 per 1000 0 per 1000 (0 to 0) 0 per 1000 (0 to 0) 58.73) Moderate 0 per 1000 0 per 1000 (0 to 0) 600	Re-infection in index patient - disease-specific website vs. simple referral Follow-up: 1 weeks	Study population					
Image: constraint of the state of		0 per 1000	•	•		low °	
Re-infection in index patient additional counselling vs. simple patient referral Follow-up: 6 months Study population RR 0.49 (0.27 to 0.89) 600 (1 study) 000 (1 study) 000 moderate 7 Moderate Moderate 101 per 1000 (27 to 90) 49 per 1000 (27 to 90) 101 per 1000 49 per 1000 (27 to 90) 101 per 1000 49 per 1000 (27 to 90) 101 per 1000 101 per 1		Moderate					
- additional counselling vs. simple patient referral Follow-up: 6 months Moderate 101 per 1000 101 per 1000 (27 to 90) Moderate 101 per 1000 (27 to 90) Moderate 101 per 1000 (27 to 90) Moderate (0.27 to 0.89) (1 study) moderate 7 Moderate (0.27 to 0.89) (1 study) moderate 7 (1 study) moderate 7 (1 study) (1		0 per 1000	•				
simple patient referral 101 per 1000 50 per 1000 Follow-up: 6 months Moderate Moderate 101 per 1000 101 per 1000 49 per 1000 (27 to 90)		Study population					
101 per 1000 (27 to 90)	simple patient referral			(0.21 (0 0.03)	(moderate	
(27 to 90)		Moderate					
		101 per 1000	•				
The corresponding risk (and its 95% confidence interval) is based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI: confidence interval; DIS: disease intervention specialist; RR: risk ratio; STI: sexually transmitted infection.					relative effect	of the intervention (and its 95%	

¹ Method of allocation concealment was not reported. 70% completed follow-up, some were lost to follow-up and some withdrew from the study, reasons for withdrawal were not reported. Study was not blinded.

² Assuming alpha of 0.05 and beta of 0.2. For relative risk reduction of 20% with best estimate of control event rate of 0.2 approximately 3000 participants were required. The total sample size was 220 and did not meet the optimal information size.

³ High attrition rate and no information given on method of allocation concealment in one of the studies. Different methods were used for outcome assessment

 4 I² = 76% (P value = 0.06) and minimal overlap of CIs.

⁵ Sample size less than 400, there were very few events and CIs around both relative and absolute estimates include both appreciable benefit and appreciable harm.

⁶ Sample size was very small and optimal information size was not met. There were very few events and CIs overlapped, therefore, no effect both for absolute and relative estimates.

ochrane. ibrary

Trusted evide Informed deci Better health. Summary of findings 2. Expedited partner therapy compared with simple patient referral for partner notification for STIs, including HIV

Expedited partner therapy compared with simple patient referral for partner notification for STIs, including HIV

Health problem: partner notification for STIs, including HIV

Settings: people in rural and urban areas, given a diagnosis of STI (clinically or by a laboratory) in health services

Intervention: expedited partner therapy

Comparison: simple patient referral

Outcomes	Illustrative comparative ris	sks* (95% CI)	Relative effect (95% CI)	No of Partici- pants	Quality of the evidence	Comments
	Assumed risk	Corresponding risk		(studies)	(GRADE)	
	Simple patient referral	EPT				
Re-infection in index patients Follow-up: 2-12 months	Study population		RR 0.71 (0.56 to 0.89)	6018 (6 studies)	⊕⊕⊕⊙ moderate ¹	
	110 per 1000	78 per 1000 (62 to 98)		(0 studies)		
	Moderate					
	84 per 1000	60 per 1000 (47 to 75)				
Re-infection in index patients - chlamydia	Study population		RR 0.9 (0.6 to 1.35)	2007 (2 studies)	⊕⊕⊕⊙ moderate ²	
Follow-up: 3-12 months	114 per 1000	102 per 1000 (68 to 154)	(moderate	
	Moderate					
	92 per 1000	83 per 1000 (55 to 124)				
Re-infection in index patients - tri- chomonas	Study population		RR 0.67 (0.34 to 1.28)	631 (2 studies)	⊕⊕⊝⊝ low ^{3,4}	
	67 per 1000	45 per 1000 (23 to 85)	(0.01101.20)		(OW -) -	
	Moderate					

Cochrane

	67 per 1000	45 per 1000 (23 to 86)				
Re-infection in index patients chlamydia or gonorrhoea	- Study population		RR 0.61 (0.39 to 0.94)	3380 (2 studies)	⊕⊕⊝⊝ low ^{5,6}	Lib
Follow-up: 4-18 weeks	116 per 1000	71 per 1000 (45 to 109)	(0.59 to 0.94)	(z studies)	low ^{3,0}	ibrary
	Moderate					망ㅋㅋ
	164 per 1000	100 per 1000 (64 to 154)				Better health. CI).
The corresponding risk (and its CI: confidence interval; RR: risk	95% confidence interval) is base ratio.	ed on the assumed risk in the co	mparison group and th	e relative effect (of the intervention (and its 95%	CI).
Very low quality: We are very u	ncertain about the estimate.					
 ¹ There was high attrition rate in t ² CI includes possibility of no effer ³ Method of sequence generation ⁴ Sample size was greater than 40 ⁵ There were no details on metho ⁶ l² = 74% Summary of findings 3. Exp.	ct (i.e. RR of 1.0). and allocation concealment not 0 but CI overlaps, therefore, no e d of sequence generation and all	reported in one of the studies. T effect (i.e. RR of 1.0). ocation concealment. One of the	here was high attrition e studies had a high attr	rate in one of the rition rate.	studies.	
 ² CI includes possibility of no effective of the sequence generation ³ Method of sequence generation ⁴ Sample size was greater than 40 ⁵ There were no details on metho ⁶ I² = 74% Summary of findings 3. Exp.	ct (i.e. RR of 1.0). and allocation concealment not 0 but CI overlaps, therefore, no e d of sequence generation and all	reported in one of the studies. T effect (i.e. RR of 1.0). ocation concealment. One of the pared with enhanced patier	here was high attrition e studies had a high attr at referral for partne	rate in one of the rition rate.	studies.	Cochra
 ² CI includes possibility of no effet ³ Method of sequence generation ⁴ Sample size was greater than 40 ⁵ There were no details on metho ⁶ l² = 74% Summary of findings 3. Exp Expedited partner therapy con Health problem: partner notified 	ct (i.e. RR of 1.0). and allocation concealment not 0 but CI overlaps, therefore, no e d of sequence generation and alle edited partner therapy comp mpared with enhanced patient cation for sexually transmitted in ban areas, given a diagnosis of S ^T r therapy	reported in one of the studies. T effect (i.e. RR of 1.0). ocation concealment. One of the pared with enhanced patier referral for partner notificatio fections, including HIV	here was high attrition e studies had a high attr nt referral for partne n for STIs, including H	rate in one of the rition rate.	studies.	Cochrane Database of S
 ² CI includes possibility of no effet ³ Method of sequence generation ⁴ Sample size was greater than 40 ⁵ There were no details on metho ⁶ l² = 74% Summary of findings 3. Exp Expedited partner therapy con Health problem: partner notific Settings: people in rural and ur Intervention: expedited partner 	ct (i.e. RR of 1.0). and allocation concealment not 0 but CI overlaps, therefore, no e d of sequence generation and alle edited partner therapy comp mpared with enhanced patient cation for sexually transmitted in ban areas, given a diagnosis of S ^T r therapy	reported in one of the studies. T effect (i.e. RR of 1.0). ocation concealment. One of the pared with enhanced patier referral for partner notificatio fections, including HIV TI (clinically or by a laboratory) i	here was high attrition e studies had a high attr nt referral for partne n for STIs, including H	rate in one of the rition rate.	studies.	Cochrane Database of Systematic Reviews

	Enhanced patient	t referral	EPT						
EPT vs. enhanced patie referral - re-infection ir		1		RR 0.96 (0.6 to 1.	1220 53) (3 stu		⊕⊕⊝⊝ low ^{1,2}		
dex patients Follow-up: 1-12 months	92 per 1000	92 per 1000 (55 to 140)				ules)			
	Moderate								
	86 per 1000		83 per 1000 (52 to 132)						
	(and its 95% confidence in E PT: expedited partner the			n the comparison grou	p and the relat	ive effect	of the interventior	n (and its 95% CI).	
High quality: Further research is very unlikely to change our confidence in the estimate of effect. Moderate quality: Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate. Low quality: Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate. Very low quality: We are very uncertain about the estimate. No details on method of sequence generation in one of the studies. One study had high attrition rate and one study used different methods for outcome assessment.									
ummary of findings 4	I includes appreciable ben I. Contract referral con ared with expedited part	mpared with	n expedited partner t	therapy for partner	notification				
				ratory) in health servio	es				
Outcomes	Illustrative comparativ	ve risks* (95%	CI)	Relative effection (95% CI)	t No of Pa pants	rtici-	Quality of the evidence	Comments	
	Assumed risk	Corres	ponding risk		(studies)	(GRADE)		
	ЕРТ	Contra	oct referral						
Re-infection in index patient	Study population			RR 2	322		$\oplus \oplus \odot \odot$		
				(0.7 to 5.72)	(1 study)		low 1,2		

Cochrane Library

Trusted evidence. Informed decisions. Better health.

Cochrane Database of Systematic Reviews

	(69 to 565)
loderate	
9 per 1000	198 per 1000 (69 to 566)

The **corresponding risk** (and its 95% confidence interval) is based on the assumed risk in the comparison group and the **relative effect** of the intervention (and its 95% CI). **CI:** confidence interval; **RR:** risk ratio.

GRADE Working Group grades of evidence

Ν

9

High quality: Further research is very unlikely to change our confidence in the estimate of effect.

Moderate quality: Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.

Low quality: Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate. Very low quality: We are very uncertain about the estimate.

¹ Method of sequence generation and allocation concealment not reported. The study had high attrition rate. No blinding. ² Imprecision owing to small sample size.



BACKGROUND

Description of the condition

Sexually transmitted infections (STI) have a negative impact on the social, health and economic well-being of a country. Every year an estimated 499 million new cases of the four most common curable STI, trichomoniasis, chlamydia, syphilis and gonorrhoea, are acquired (WHO 2012). Furthermore, two to three million new cases of human immunodeficiency virus (HIV) occur per year (UNAIDS 2010). Up to 4000 infants become blind annually due to eye infections attributable to underlying gonococcal and chlamydial infections in the mother (WHO 2007).

The term STI includes both infections that remain latent or asymptomatic and those that progress to a clinical manifestation (disease). In this update, we used the term STI instead of sexually transmitted diseases (STD), which was used in the original review. STI are more prevalent in countries and communities where socio-economic conditions are poor (Glasier 2006; Low 2006a). Curable STIs are often overshadowed by the burden of HIV, but are important causes of morbidity in their own right (Table 1).

Clinical symptoms of STIs can be non-specific and, where possible, the diagnosis needs to be confirmed by laboratory testing. In lower-income countries, laboratory testing is not always available and women and men reporting symptoms suggestive of an STI are often treated according to algorithms without confirmatory tests. For male urethritis and genital ulcers, this approach is effective but with vaginal discharge the risk of misdiagnosis is high. Syndromic management of STI can therefore lead to overtreatment and adverse social consequences such as stigma and intimate partner violence (Trollope-Kumar 2006). Women are more likely than men to suffer from reproductive tract complications of STIs such as chlamydia and gonorrhoea if the infection ascends to the upper genital tract; pelvic inflammatory disease (PID), ectopic pregnancies and infertility are the most commonly documented complications (Gerbase 1998). STIs are, however, often asymptomatic in both women and men (WHO 2007). As a result, disclosing a diagnosis of an STI to sexual partners and partner treatment play a critical part in the comprehensive management of STI. Willingness to disclose varies according to the STI and gender (Alam 2010). In one study among people with a diagnosis of HIV, 85% of people living with HIV were sexually active, but only 58% revealed their HIV status to recent sexual partners (Simbayi 2007). In a study in Connecticut, US, 25% of females with chlamydia intended not to notify their partners (Niccolai 2007) as most (46%) thought it unimportant and 43% were not willing to discuss the condition. In a study in India, the patient characteristics most likely to increase the odds of referring a partner were having a diagnosis of genital ulcer disease (odds ratio (OR) 2.78, 95% confidence interval (CI) 1.08 to 7.13, P value = 0.033) and having the intention to inform the regular partners (OR 16.9, 95% CI 3.29 to 86.70, P value = 0.001) (Sahasrabuddhe 2002).

Description of the intervention

"Partner notification is a process that includes informing sexual partners of infected people of their exposure, administering presumptive treatment, and providing advice about the prevention of future infection" (UNAIDS 1999). Partner notification (PN) is also known as contact tracing, partner management or partner information. A person with a newly diagnosed STI is often referred

to as an 'index case' or 'index patient'. The index patient has one or more sexual partners. The sexual partners of the index patient might have been the source of the infection in the index patient or they might have acquired the infection from the index patient.

A variety of approaches has been used to notify sexual partners and to ensure that they receive treatment. In principle, managing infection in people with more than one current sexual partner should have the greatest impact on the spread of STI (Fenton 1997). The use of different approaches depends partly on the STI for which they were originally intended. There are other influences at the country level, including cultural factors, the structure and financing of health systems, and clinical consensus. At the individual level, factors such as patient choice influence choice of PN strategies. Traditionally, three main approaches have been defined: patient referral, provider referral and contract (or conditional) referral. Definitions and explanations of these PN methods are given below.

Patient referral (patient-led referral) refers to an approach in which health service personnel encourage index patients to notify their own partners. In this review, we used the term simple patient referral to refer to spoken advice from health service personnel about the need for sexual partners to receive treatment. This can be seen as a minimum standard for a PN intervention. There is, however, no agreement about the content of a consultation for simple patient referral. Patient referral was developed in the 1970s when rates of gonorrhoea in the US were very high and the capacity of specialist PN personnel was exceeded. Patient referral has since become the preferred method of PN for gonorrhoea and subsequently chlamydia in many countries. There has been great interest in developing methods to support index patients so that the outcomes of patient referral can be improved or enhanced (Trelle 2007). Patient referral can, therefore, be split into two categories (simple and enhanced), according to the level of support given to the patient. Expedited partner therapy (EPT) has developed in the US since the late 1990s as a new patient-led strategy to help index patients to get their partners treated more quickly.

Enhanced patient referral refers to a group of strategies that supplement the spoken advice with the aim of improving patient referral success, including educational material such as videos viewed in waiting rooms, written disease-specific information for index patients to give to their partners, home sampling kits for partners, disease-specific websites, theory-based counselling and reminders by telephone or other means (Trelle 2007).

EPT is a group of strategies to enhance the success of patient referral by increasing the numbers of partners treated and speeding up the time to treatment (CDC 2006). The EPT strategies include: patient-delivered partner medication (PDPM) or patient-delivered partner therapy (PDPT), where the index patient receives antibiotics (often in a package with condoms and written information) to give to their partner without the need for a medical examination of the partner (Golden 2005); or additional prescriptions given to index patients for their partner(s). EPT can reduce loss to follow-up of index cases (Young 2007), and reduce the risk of repeated infection in the index case (Golden 2005). There are, however, disadvantages, including the risk of adverse drug reactions, other underlying disease remaining undetected and a missed opportunity for counselling and testing for other STIs including HIV (Golden 2005). In some countries, such as the UK, EPT



is not legal unless the partner is assessed before receiving antibiotic treatment (ECDC 2013).

Provider referral (provider-led referral) uses third parties (usually specialist health service personnel) to notify partners. The name of these health professionals differs between countries, for example; 'disease intervention specialists' (DIS) in the US; 'health advisers' in the UK and 'Kurators' in Sweden. Provider referral originated in Scandinavia and the UK as a method to trace and refer the sexual partners of people with syphilis when treatment first became available. More recently, it has been used for other clinically severe STIs such as HIV infection and hepatitis B. It can also be used for other STIs such as gonorrhoea and chlamydia when the index patient is unable to notify partners by themselves. Provider referral should only be done with the explicit consent of the index patient. In some countries, for example France, provider referral does not occur because it is seen as an invasion of privacy (ECDC 2013).

Contract referral (conditional referral) refers to an approach in which there is an agreement (contract) between the patient and the health professional. Health service personnel encourage index patients to notify their partners, with the understanding that health service personnel will notify those partners who do not visit the health service by an agreed date. Contract referral is, in practice, difficult to define as a separate PN approach. It can be difficult to distinguish from provider referral if the time window for patient referral is very short (two or three days) (Peterman 1997). In contrast, contract referral is often used as an extension to simple patient referral, rather than a separate strategy, if the index patient has not been able to inform their partner(s) when they are followed up.

How the intervention might work

There are different aims of PN, depending on the level at which it is targeted and the infection (Low 2006a). At the level of the index patient with a curable STI the aim is to provide concurrent antibiotic treatment to the sexual partner(s) so that infection can be eradicated in both people and re-infection prevented in the index patient, which is a clinical goal. For the sexual partner(s) the aim is to identify and treat infection that might have been the source of infection in the index patient, or might have been acquired from the index patient. At the level of sexual networks and populations, the aim is to interrupt chains of transmission and reduce the spread of STIs, which is a public health goal. For viral STIs, the aim is to identify previously undiagnosed infections, which can provide early access for sexual partners to treatment and prevent onward transmission through behavioural change by the infected person.

To succeed, PN strategies need to first elicit from the index patient details of all sexual partners from whom he/she may have acquired the infection, or whom he/she might have subsequently infected. Identifying partners in the latent period of infection (usually three months for primary syphilis and one month for acute urethritis) (Toomey 1996), should identify those from whom infection was acquired, while identifying partners after the onset of symptoms will identify those who were likely to have been infected by the index case. The time period for identifying partners differs between countries for different STIs.

For most PN strategies, eliciting partner information from infected people is a prerequisite to notifying sexual partners. For example, when health service personnel notify partners, they rely on the index patient to count, name and provide details to enable all his/ her partners to be traced. Once partners have been elicited, PN strategies need to provide either the index patient or the health service personnel with the necessary knowledge, skills or resources to enable them to locate, notify, medically evaluate and test or treat these partners.

Communication between partners, during which the index patient encourages them to consider screening or treatment, has been identified as a critical point in effective PN strategies (Young 2007). The communication usually requires the index patient to disclose their STI diagnosis. Disclosure can lead to benefits other than successful partner treatment, such as emotional support and protecting the health of others. Disclosure can also lead to stigma, rejection, physical abuse and discrimination (Arnold 2008).

Why it is important to do this review

PN has been practised as a measure to control STIs since the early 1900s (ECDC 2013), but there is limited evidence of its public health impact. Many evaluations have not been conducted as randomised controlled trials (RCTs) and many were conducted in developed countries before the HIV/acquired immunodeficiency syndrome (AIDS) pandemic. It is not known whether interventions developed for high-income countries are applicable to resource-limited settings.

There are several published systematic reviews of PN. The first included only studies conducted in developed countries (Oxman 1994). Another included only published studies conducted in the US after 1980 (Macke 1999). The original Cochrane Review by Mathews et al. was assessed as up to date in July 2001 (Mathews 2001). Trelle et al. systematically reviewed studies of enhanced methods of patient referral, including EPT, to improve the effectiveness of simple patient referral (Trelle 2007). The latest systematic review only studied curable STIs in developing countries (Alam 2010). Considering the ongoing developments in this field, the Cochrane Review was updated in line with recommendations of the *Cochrane Handbook for Systematic Reviews of Interventions* (Higgins 2011).

OBJECTIVES

To assess the effects of alternative PN strategies.

METHODS

Criteria for considering studies for this review

Types of studies

We included RCTs that compared at least two PN strategies.

Types of participants

People in rural and urban areas, given a diagnosis of STI (clinically or by a laboratory) in health services with any of the following STI: gonorrhoea (*Neisseria gonorrhoeae*), chlamydia (*Chlamydia trachomatis*), trichomoniasis (*Trichomonas vaginalis*), syphilis (*Treponema pallidum*), chancroid (*Haemophilus ducreyi*), genital herpes, hepatitis B and HIV. We also included diagnoses of the following STI syndromes: genital ulcer syndrome - non-vesicular or vesicular, urethral discharge syndrome, vaginal discharge syndrome and lower abdominal pain in women. Studies conducted in any type of health service were included.



Types of interventions

Strategies directed at patients (patient-led) or health workers (provider-led) were included. The following types of strategies were included:

- strategies to enhance the effectiveness of patient referral through, for example, health education and counselling, health education materials (such as pamphlets, posters, video and audio productions), patient assistance strategies directed at facilitating patient referral (such as referral cards, incentives, reminders, video and audio productions). EPT was included as a specific type of enhanced patient referral;
- contract referral strategies;
- provider referral strategies;
- · combinations of the above.

Types of outcome measures

Primary outcomes

Number of index patients with curable STIs given a clinical or laboratory diagnosis of re-infection. Re-infection implies reinfection of the index patient with the same STI from an untreated sexual partner. In practice, the outcome measured is repeated detection of the STI at some time interval after the index case has been treated. Repeated detection of an STI could also result from a new infection in the index case acquired from a new sexual partner, or treatment failure due to antibiotic resistance or subtherapeutic dosing. These causes cannot be reliably distinguished and the term re-infection is used to include repeated detection from any cause.

Secondary outcomes

Numbers of partners elicited (sexual partners that the health professional obtains from the index patient for the recall period in question), located (sexual partners that the index patient was able to find; this number is likely to be a subset of partners elicited), notified (sexual partners that the index patient informed of their possible exposure to an STI; this number is likely to be a subset of partners located), presenting for care, testing positive or treated per index case; delay in partners presenting for care; incidence of STIs; changes in the index patient's or partner's behaviour with regard to condom use, abstinence in the presence of symptomatic infections, the number of partners, the number of concurrent partners; emotional impact on the index patient or partner in their relationship; harm to the patient or partners, such as domestic violence, abuse or suicide; ethical outcomes (patient autonomy vs. beneficence).

Search methods for identification of studies

Electronic searches

Search method for original review (Mathews 2001)

The original review authors searched MEDLINE (1966 to 24 July 2001), EMBASE (1974 to 24 July 2001), Psychological Abstracts (1967 to 24 July 2001) and Sociological Abstracts (1963 to 24 July 2001). The Cochrane Controlled Trials register was searched with the text words 'sexual partners', 'partner notification', 'contact-tracing' and 'contact tracing'. The Effective Practice and Organisation of Care (EPOC) register of studies was searched, as was the register of the HIV and AIDS Cochrane Review Group.

Search method for the review update

We searched three electronic databases, MEDLINE, EMBASE and CENTRAL, from 5 January 2001 to 31 August 2012. Search strategies are shown in Appendix 1, Appendix 2 and Appendix 3.

Searching other resources

Original Cochrane review (Mathews 2001)

The original review authors handsearched the Proceedings of the International AIDS Conferences (1996 to 24 July 2001) and the International Society for STD Research meetings (ISSTDR) (1991 to 24 July 2001). Bibliographies of studies and previous reviews were examined for references to other trials. Experts in the field were contacted.

Review update

We searched all reference lists of potential studies and previous reviews for relevant RCTs and contacted experts in the field. We searched the International Clinical Trials Registry Platform (ICTRP) from 18 March 2011 to 31 August 2012 to identify ongoing studies (www.who.int/ictrp/en/). We searched the ICTRP for the protocols of the 16 new studies. Trial registries were not searched for the protocols of the original included studies because these were all published before 1998.

Data collection and analysis

Selection of studies

Two review authors (Cathy Mathews, CM and Riabatu Abdullah, RA (original review); and Adel Ferreira, AF and Taryn Young, TY or CM or Moleen Zunza, MLZ (update)) independently screened titles and abstracts of the electronic search results. We obtained all the eligible abstracts of comparative studies in full-text format, and two review authors (CM and RA original review and AF and TY or CM update) independently reviewed them for inclusion using prespecified eligibility criteria. We included all studies that reported random allocation. We assessed the risk of bias in the methods of sequence generation and allocation, as described in the section 'Assessment of risk of bias in included studies' and considered risk of bias interpreting the strength of evidence for each intervention.

Data extraction and management

Two review authors (CM and Nicol Coetzee, NC or Merrick Zwarenstein, MZ (original review) and AF and TY or CM or MLZ (update)) independently abstracted study characteristics and outcomes including information on: social context (developing (World Bank classification: countries with low or middle levels of gross national product (GNP) per capita as well as five highincome developing economies - Hong Kong (China), Israel, Kuwait, Singapore and the United Arab Emirates. These five economies are classified as developing despite their high per-capita income because of their economic structure or the official opinion of their governments. Several countries with transition economies are sometimes grouped with developing countries based on their low or middle levels of per-capita income, and sometimes with developed countries based on their high industrialisation (World Bank 2012)) or developed country); access to health services; legislative context (permissive or proscriptive public health legislation); methodological quality of study; type of health facility; type of provider (for example, nurse, physician, DIS);



participants; type of interventions; outcome measure; results and correspondence required using a data extraction form.

We resolved disagreements by discussion. We summarised data from included studies in the Characteristics of included studies table and data from excluded studies in the Characteristics of excluded studies table. We summarised studies with insufficient information in the Characteristics of studies awaiting classification table. Where there were missing data, we attempted to contact study authors by email.

Assessment of risk of bias in included studies

Two review authors (AF and CM or MLZ) independently evaluated the risk of bias using The Cochrane Collaboration's tool (Higgins 2011a). We made judgements about the presence of bias by selecting one of three categories of risk of bias: low risk, high risk and unclear risk of bias. We resolved disagreements by discussion. If we could not reach consensus, we involved a third independent review author (TY). We contacted trial authors if there were any unclear issues and, if we received no response, we made a judgement of 'unclear risk of bias'.

We assessed and summarised the following main items in the 'Risk of bias' table: sequence generation, allocation concealment, blinding of participant and personnel, blinding of outcome assessment, whether incomplete outcome data were adequately addressed, selective reporting and any other bias. We searched the ICTRP for protocols of the 16 additional studies to assess selective reporting bias. Figure 1 and Figure 2 show the 'Risk of bias' graphs, which illustrate the proportions of studies with low, high and unclear risk of bias. In the 10 studies of the original review, the ICTRP was not searched; instead, the methods and result sections were compared to evaluate if the same outcomes were reported in these two sections. If the protocol was not available, the methods and results sections were compared to assess selective reporting bias.



Figure 1. Risk of bias summary: review authors' judgements about each risk of bias item for each included study.





Figure 1. (Continued)

Potterat 1977	•	?	•	•	?	•	•
Schillinger 2003	?	•	•	•	•		•
Schwebke 2010	?	?	•	•	•	•	?
Solomon 1988	?	?	•	•	?	•	•
Tomnay 2006	•	•	•	•	•	•	?
Trent 2010	•	?	•	•	•	•	?
Wilson 2009	•	?	•	•	•	•	•

Figure 2. Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies.



Measures of treatment effect

The review authors prepared tables summarising the results of each study for each comparison.

We defined re-infection rate in index patients as the percentage of index patients with a repeated diagnosis of the same STI divided by the number of index patients retested.

Partners elicited, notified, presenting for care, tested, treated or harmed: we assumed that the number of units of each outcome per index patient was a random variable following a Poisson distribution. We assumed that the index patients from the groups within a study had similar distributions for exposure time to partners, for time to notify their partners, and that the same assumption held for partners with respect to the time taken to present to the health service. The value of the mean and the variance of a Poisson distribution are the same.

To calculate a CI for the difference in relevant outcomes, we used the normal approximation to the Poisson distribution since only summarised data from the included RCTs were available. The approximate 95% CI for the rate difference is given by:

(Lamda1 - Lamda2) \pm 1.96 $\sqrt{(lamda1/n1 + lamda2/n2)}$,

where lamda1 and lamda2 are the rates of partners per index patient in two groups, and n1 and n2 the number of index patients.

To calculate the standard error (SE) the formula used was:

(upper limit of 95% CI - lower limit of 95% CI)/3.92.

To calculate the standard deviation (SD) the formula used was:

SE/ $\sqrt{(1/Nexp+1/Ncont)}$,

where Nexp is the number of index patients randomised to the experimental group and Ncont is the number of index patients randomised to the control group

For continuous outcomes (number of partners elicited, notified, presenting for care, tested, treated or harmed), we recorded the mean (in number of partners per index patient randomised), SE and sample size. Where the exact numbers of partners were not



available, we contacted study authors. If authors did not respond or could not provide the exact numbers, the mean difference (MD) could not be calculated and we reported the study findings descriptively. In studies where the rate of partners elicited per index patient was not reported, we used the number of contact cards given to the index patient as a proxy indicator.

We described the delay in partners presenting for care as the mean or median number of days after index patient enrolment.

Unit of analysis issues

We dealt with studies with multiple intervention groups as recommended in the *Cochrane Handbook for Systematic Intervention Reviews* (Higgins 2011b). We compared each intervention arm with another.

Where this resulted in shared intervention groups, we did not perform a meta-analysis to prevent 'double-counts' of participants. In these studies, we described the results in narrative form (Ellison undated; Montesinos 1990). We did not include any cluster randomised trials and, therefore, no adjustments were necessary.

Dealing with missing data

Where there were missing data, we attempted to obtain the data by contacting study authors by email. We contacted the authors of eight trials and authors provided requested data for five of the eight trials.

Assessment of heterogeneity

We assessed sources of clinical and methodological heterogeneity by looking at characteristics of studies, evaluating similarity between type of participants, intervention used and outcomes. We calculated the Chi² test for heterogeneity (Deeks 2011), and the I² statistic to evaluate statistical heterogeneity. Values of the I² statistic were interpreted as follows (Deeks 2011): 0% to 40%: might not be important; 30% to 60%: might represent moderate heterogeneity; 50% to 90%: might represent substantial heterogeneity; 75% to 100%: might represent considerable heterogeneity.

Assessment of reporting biases

We did not find a sufficient number of studies to produce funnel plots to investigate publication bias for specific comparisons.

Data synthesis

We analysed data according to paired partner referral strategies (Table 2). We organised the comparisons first according to the four main PN strategies (1. enhanced patient referral, 2. EPT, 3. contract referral, 4. provider referral). Each main strategy was compared with simple patient referral and then with each other, if trials were available. We compared each enhanced patient referral with another enhanced patient referral. This resulted in 10 comparisons (Table 2).

The largest group of trials (Table 2; comparison 1, enhanced patient referral versus simple patient referral) included several different interventions to enhance the outcomes of patient referral. We grouped these into six categories: (1) patient referral with DIS or health adviser, (2) postal testing kit, (3) information booklet, (4) disease-specific website, (5) additional counselling or (6) showing a videotape.

We performed meta-analyses where appropriate using randomeffects models to report the pooled MD (for continuous outcomes) or risk ratio (RR for dichotomous outcomes) with 95% CI. When there was a moderate or low level of heterogeneity ($l^2 \le 50\%$), we pooled results. If there was more substantial evidence of heterogeneity ($l^2 > 50\%$), we pooled the results of individual studies if appropriate or described in the narrative. We reported results of tests for heterogeneity (Tau², Chi² test with number of degrees of freedom (df), P value and l^2 statistic).

Subgroup analysis and investigation of heterogeneity

We used subgroup analyses to explore possible sources of heterogeneity. These included: age of participant, gender, specific STIs investigated, setting (developed vs. developing country) and category of healthcare worker.

Sensitivity analysis

We performed a sensitivity analysis on the primary outcome, re-infection rate of index patient with curable STIs. Given the limited numbers of trials and meta-analyses, the sensitivity analysis examined only the effect of attrition bias. We repeated meta-analyses excluding trials with more than 20% attrition and compared results with the primary analysis.

'Summary of findings' table

We interpreted results using a 'Summary of findings' table, which provided key information about the quality of evidence for the studies included in a comparison, the magnitude of effect of the interventions examined and the sum of available data on the primary outcome. We imported data from Review Manager 5 (RevMan 2011), using the GRADE profiler (GRADE 2004). We selected the primary outcome of re-infection in the index case for the 'Summary of findings' table.

RESULTS

Description of studies

Results of the search

The initial search (1966 to 24 July 2001; Mathews 2001) identified 11 RCTs, including 8041 participants. The updated search (5 January 2001 to 31 August 2012) identified an additional 16 RCTs (9597 participants; 6841 women and 2756 men). One study was listed as awaiting classification (Characteristics of studies awaiting classification). In the original review, Levy 1998 (with 60 participants) was listed as under 'Included studies' but, in this update, it was placed under 'Characteristics of studies awaiting classification' because no results were available. We found four ongoing studies in trial registers (Characteristics of ongoing studies).

Included studies

Twenty-six RCTs (Figure 3) were included in the review including 17,578 participants (Characteristics of included studies). Most of the trials (14) were conducted in the US, four in the UK, two in Denmark, and one each in Australia, Malawi, South Africa, Uganda, Zambia and Zimbabwe. Most trials (21) were based in public health clinics. One was conducted in a large academic medical centre (Trent 2010), three in general practice (Andersen 1998; Low 2006b;



Ostergaard 2003), and one on a university campus (Montesinos 1990).






Figure 3. (Continued)

26 included studies

Participants

Trials were conducted among patients with gonorrhoea (three trials, Cleveland undated; Potterat 1977; Solomon 1988); gonorrhoea or non-gonococcal urethritis (one trial, Montesinos 1990); non-gonococcal urethritis only (one trial, Katz 1988); chlamydia (six trials, Andersen 1998; Apoola 2009; Cameron 2009; Low 2006b; Ostergaard 2003; Schillinger 2003); syphilis (one trial, Peterman 1997); HIV (two trials, Brown 2011; Landis 1992); chlamydia or gonorrhoea, or both (four trials, Golden 2005; Kerani 2011; Kissinger 2005; Wilson 2009); trichomonas (two trials, Kissinger 2006; Schwebke 2010); PID (one trial, Trent 2010); and chlamydia or non-gonococcal urethritis (one trial, Tomnay 2006). Four trials in developing countries where syndromic diagnoses are made included patients with any STI syndrome (Ellison undated; Faxelid 1996; Moyo 2002; Nuwaha 2001). In six studies, STI diagnoses were made clinically, based on symptoms or clinic tests (Ellison undated; Faxelid 1996; Katz 1988; Moyo 2002; Nuwaha 2001; Trent 2010). In the other 20 trials, STI diagnoses (other than non-gonococcal urethritis) were confirmed with laboratory testing. There were no RCTs among patients with laboratory-diagnosed hepatitis B, genital herpes or chancroid.

Six trials included male patients only, or reported over 90% male index patients (Cleveland undated; Katz 1988; Kerani 2011; Kissinger 2005; Potterat 1977; Solomon 1988). Seven trials included female index patients only (Andersen 1998; Apoola 2009; Cameron 2009; Kissinger 2006; Schillinger 2003; Schwebke 2010; Trent 2010).The remaining trials included male and female index patients. Two trials included men who had sex with men (Kerani 2011; Landis 1992) and one included male and female injecting-drug users (Landis 1992).

Types of interventions

Included studies investigated the effects of various PN strategies (Table 2; Table 3):

- Enhanced patient referral versus simple patient referral;
- Enhanced patient referral versus other enhanced patient referral method;
- EPT versus simple patient referral;
- EPT versus enhanced patient referral;
- EPT and enhanced patient referral versus simple patient referral;
- contract referral versus simple patient referral;
- contract referral versus enhanced patient referral;
- contract referral versus EPT;
- provider referral versus simple patient referral;
- choice between provider or simple patient referral versus simple patient referral;
- provider referral versus enhanced patient referral;
- provider referral versus contract referral.

Outcomes

Outcomes assessed are reported in Table 3. The comprehensive details of included studies can be seen in the Characteristics of included studies table.

One study from the original review was classified as a study awaiting assessment because there were no results available (Levy 1998) (Characteristics of studies awaiting classification).

Four ongoing studies were identified from the trial register (Characteristics of ongoing studies).

Excluded studies

We excluded 11 studies (see Characteristics of excluded studies for details).

Risk of bias in included studies

The risk of bias for each study is presented in the 'Risk of bias' table in the section Characteristics of included studies. Figure 1 and Figure 2 illustrate the summary of risk of bias in all the studies.

Allocation

Random sequence generation

Eleven trials reported adequate generation of the random allocation sequence (Apoola 2009; Brown 2011; Cameron 2009; Faxelid 1996; Kissinger 2005; Kissinger 2006; Low 2006b; Nuwaha 2001; Tomnay 2006; Trent 2010; Wilson 2009). Of these trials, eight used blocked randomisation (Apoola 2009; Brown 2011; Cameron 2009; Kissinger 2005; Kissinger 2006; Low 2006b; Tomnay 2006; Wilson 2009), two trials used computer-generated random numbers tables (Nuwaha 2001; Trent 2010), and, in one study, lots were drawn by index patient (Faxelid 1996). Sequence generation was adequate in six of nine trials reporting the primary outcome of re-infection with a bacterial STI (Cameron 2009; Kissinger 2005; Kissinger 2005; Kissinger 2006; Low 2006b; Tomnay 2006; Wilson 2009).

In 13 trials, random sequence generation was unclear (Cleveland undated; Ellison undated; Golden 2005; Katz 1988; Kerani 2011; Landis 1992; Montesinos 1990; Moyo 2002; Ostergaard 2003; Peterman 1997; Schillinger 2003; Schwebke 2010; Solomon 1988) and two trials reported methods used that can introduce a high risk of bias (Andersen 1998; Potterat 1977). In Andersen 1998, the date of birth of index patient was used and, in Potterat 1977, assignment of index patient was performed alternately to specific intervention arms. Both of these trials reported secondary outcomes only.

Allocation concealment

Five trials reported adequate allocation concealment (Apoola 2009; Brown 2011; Low 2006b; Schillinger 2003; Tomnay 2006). Of these, four trials reported the use of sealed, opaque, sequentially numbered envelopes (Apoola 2009; Brown 2011; Schillinger 2003; Tomnay 2006), and one trial reported the use of a centralised telephone service (Low 2006b). In 18 trials, the methods used for allocation concealment were not adequately described (Andersen



1998; Cameron 2009; Cleveland undated; Faxelid 1996; Golden 2005; Katz 1988; Kerani 2011; Kissinger 2005; Kissinger 2006; Landis 1992; Moyo 2002; Nuwaha 2001; Ostergaard 2003; Potterat 1977; Schwebke 2010; Solomon 1988; Trent 2010; Wilson 2009). Allocation concealment was adequate in three of nine trials reporting the primary outcome of re-infection with a bacterial STI.

Three studies reported methods that could introduce a high risk of bias (Ellison undated; Montesinos 1990; Peterman 1997). In Ellison et al., the interventions were allocated in turn to each consecutive patient according to a printed schedule, which could have influenced enrolment or exclusion and hence the intervention received by the index patients (Ellison undated). In Montesinos et al., the protocol used in the intervention was colour coded and the counsellor removed the protocol for the next index patient from a randomly ordered set (Montesinos 1990). Peterman et al. reported that the assignment was known to the interviewer before contact with index patients and sequentially adapted (Peterman 1997).

Blinding

Blinding of participants and personnel (performance bias)

Twenty-five trials did not have blinding of the participants or the personnel (Andersen 1998; Apoola 2009; Brown 2011; Cameron 2009; Cleveland undated; Ellison undated; Faxelid 1996; Golden 2005; Katz 1988; Kerani 2011; Kissinger 2005; Kissinger 2006; Landis 1992; Low 2006b; Montesinos 1990; Moyo 2002; Nuwaha 2001; Peterman 1997; Potterat 1977; Schillinger 2003; Schwebke 2010; Solomon 1988; Tomnay 2006; Trent 2010; Wilson 2009). In one trial, the index patient received identical specimen collection kits to be given to their partners, and was, therefore, blinded to the intervention in which they were taking part (Ostergaard 2003).

Blinding of outcome assessment (detection bias)

Eleven trials did not report blinding of the outcome assessors (Apoola 2009; Faxelid 1996; Katz 1988; Kerani 2011; Kissinger 2005; Kissinger 2006; Montesinos 1990; Moyo 2002; Nuwaha 2001; Peterman 1997; Potterat 1977). In five trials, the outcome assessors were blinded (Cleveland undated; Ellison undated; Low 2006b; Solomon 1988; Wilson 2009). Cameron et al. reported that the laboratory personnel (primary outcome) were blinded but not the interviewers (Cameron 2009). We judged the risk of bias as low. In six studies, the blinding of outcome assessors was unclear (Andersen 1998; Landis 1992; Ostergaard 2003; Schwebke 2010; Tomnay 2006; Trent 2010). In the remaining three studies, the outcome assessor was not blinded but we judged the risk of bias as low because the primary outcome was objectively assessed (Brown 2011; Golden 2005; Schillinger 2003).

Incomplete outcome data

Seven trials had a high (> 20%) attrition rate (Cameron 2009; Golden 2005; Kerani 2011; Kissinger 2005; Moyo 2002; Schwebke 2010; Trent 2010), including four of nine trials reporting re-infection with a bacterial STI as an outcome. In Cameron 2009, 65% of index patients submitted at least one urine sample in 12 months, while in Golden 2005, 68% of index patients completed the study. In Kerani 2011, 71% of index patients completed baseline and follow-up interviews. In Kissinger 2005, 79% of index patients had a follow-up interview but only 37.5% were retested, and in Moyo 2002, only 50% of index patients had a follow-up interview. In Schwebke 2010,

40% of index patients completed the study. In Trent 2010, 62% of index patients had a follow-up interview.

Selective reporting

We compared the trial protocols with published trial results sections to assess reporting bias. If the trial protocol was not available, we compared the methods and results sections of the trial. We searched three trial registries for the protocols of the 16 additional studies included in this update. Protocols were available for five of these studies (Apoola 2009; Kissinger 2006; Low 2006b; Schwebke 2010; Wilson 2009).

We judged 21 trials to have a low risk of reporting bias either because the primary outcome stated in the protocol was reported in the trial result sections (Apoola 2009; Schwebke 2010), or the outcomes stated in the method sections were reported in the result sections (Andersen 1998; Brown 2011; Cameron 2009; Cleveland undated; Ellison undated; Faxelid 1996; Katz 1988; Kerani 2011; Landis 1992; Montesinos 1990; Moyo 2002; Nuwaha 2001; Ostergaard 2003; Peterman 1997; Potterat 1977; Schillinger 2003; Schwebke 2010; Solomon 1988; Tomnay 2006; Trent 2010).

We considered four trials to have an unclear risk of reporting bias because the outcomes reported in the results sections differed from those stated in the method sections (Golden 2005; Kissinger 2005), or protocols (Kissinger 2006; Low 2006b). In Kissinger 2006, the protocol had primary and secondary outcomes whereas in the trial report outcomes were not divided into primary and secondary. Furthermore, additional sexual and behavioural outcomes were reported. Low et al. reported some outcomes in the published paper that differed from the protocol (Low 2006b).

We assessed one trial as being at high risk of reporting bias. In Wilson 2009, the primary outcomes stated in the protocol differed from those stated in trial report; in the protocol there were also three intervention arms described but only two were reported in the trial publication.

Other potential sources of bias

One study had a high potential for other bias (Peterman 1997). The authors of the study reported contamination between the three groups caused by overlap of partners common to index patients. In eight studies, it was unclear if there was any other potential source of bias (Andersen 1998; Cleveland undated; Golden 2005; Kerani 2011; Landis 1992; Nuwaha 2001; Potterat 1977; Solomon 1988). Of these seven studies, in five no comparisons of baseline characteristics between study arms were given (Andersen 1998; Cleveland undated; Landis 1992; Potterat 1977; Solomon 1988). In Golden 2005, selective reporting of subgroups might have introduced bias and in Nuwaha 2001, partners of the patient referral group could have been treated elsewhere leading to misclassification bias. In the remainder of the studies, the risk for potential sources of bias was low.

Effects of interventions

See: Summary of findings for the main comparison Enhanced patient referral compared with simple patient referral for partner notification for STIs, including HIV; Summary of findings 2 Expedited partner therapy compared with simple patient referral for partner notification for STIs, including HIV; Summary of findings 3 Expedited partner therapy compared with enhanced



patient referral for partner notification for STIs, including HIV; **Summary of findings 4** Contract referral compared with expedited partner therapy for partner notification for STIs, including HIV

Enhanced patient referral

1. Enhanced patient referral versus simple patient referral

Sixteen studies looked at different types of enhanced patient referral compared with simple patient referral among patients with gonorrhoea (Cleveland undated; Solomon 1988), chlamydia (Andersen 1998; Apoola 2009; Cameron 2009; Low 2006b; Ostergaard 2003), non-gonococcal urethritis (Katz 1988), gonorrhoea or chlamydia (Kerani 2011; Kissinger 2005; Wilson 2009), trichomoniasis (Kissinger 2006), chlamydia or non-gonococcal urethritis (Tomnay 2006), PID (Trent 2010), or any STI syndrome (Ellison undated; Moyo 2002).

There were seven different types of enhanced patient referral interventions for patients or partners: 1) an additional counselling session (Cleveland undated; Ellison undated; Moyo 2002; Wilson 2009); 2) a home testing kit for the partners to use and send back to a laboratory (Andersen 1998; Cameron 2009; Ostergaard 2003), or for the partners to bring back to the clinic (Apoola 2009); 3) an additional information booklet to be given to the partner (Kissinger 2005; Kissinger 2006); 4) a videotape shown to the index

patient (Solomon 1988; Trent 2010); 5) a disease-specific website was available to the partner (Kerani 2011; Tomnay 2006); 6) health education messages for the index case (Ellison undated); and 7) health education plus counselling for the index patient (Ellison undated). In addition, two studies compared patient referral performed by a contact tracer (DIS or health adviser) with patient referral performed by a nurse (Katz 1988; Low 2006b).

Primary outcome

Six studies (2007 participants) assessed the index patient reinfection rate (Cameron 2009; Kissinger 2005; Kissinger 2006; Low 2006b; Tomnay 2006; Wilson 2009) (Figure 4). Owing to substantial heterogeneity (Tau² = 0.38; Chi² = 16.86, df = 5 (P value = 0.005); l² = 70%), the results of individual studies were not pooled. In one comparison, the risk of re-infection in the index patients was 51% lower in the enhanced patient referral (additional counselling) compared with the simple patient referral group (RR 0.49, 95% CI 0.27 to 0.89) (Wilson 2009). In two smaller studies, the risk of re-infection was higher in index patients receiving the enhanced patient referral strategy but CIs included the possibility of no difference (Cameron 2009; Tomnay 2006). In the other three studies, there was no statistical evidence of a difference between enhanced and simple patient referral (Table 4).

	Enhance	d PR	Simple	PR		Risk Ratio	Risk Ratio
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Random, 95% Cl	M-H, Random, 95% Cl
1.1.1 Home sampling	j vs. simple	e patien	t referral				
Cameron 2009	15	110	7	110	100.0%	2.14 [0.91, 5.05]	
Subtotal (95% Cl)		110		110	100.0%	2.14 [0.91, 5.05]	
Fotal events	15		7				
Heterogeneity: Not ap	plicable						
Fest for overall effect:	Z=1.74 (P	² = 0.08))				
1.1.2 Information boo	oklet vs. sir	nple pa	ntient refe	erral			
<issinger 2005<="" td=""><td>30</td><td>348</td><td>67</td><td>285</td><td>57.0%</td><td>0.37 [0.25, 0.55]</td><td></td></issinger>	30	348	67	285	57.0%	0.37 [0.25, 0.55]	
<issinger 2006<="" td=""><td>11</td><td>154</td><td>12</td><td>155</td><td>43.0%</td><td>0.92 [0.42, 2.03]</td><td>_</td></issinger>	11	154	12	155	43.0%	0.92 [0.42, 2.03]	_
Subtotal (95% CI)		502		440	100.0%	0.55 [0.22, 1.33]	
Fotal events	41		79				
Heterogeneity: Tau ² =	: 0.32; Chi ^z	= 4.19,	df = 1 (P :	= 0.04)	; i² = 76%		
Fest for overall effect:	•	•					
1.1.3 Patient referral	(DIS/healtl	n advis	or) vs. pa	tient re	eferral (nu	ırse)	
_ow 2006b	0	68	1	72	100.0%	0.35 [0.01, 8.51]	•
Subtotal (95% CI)	-	68			100.0%	0.35 [0.01, 8.51]	
Fotal events	0		1				
Heterogeneity: Not ap	plicable						
Fest for overall effect:		⁹ = 0.52))				
I.1.4 Disease-specif	ic website	vs. sim	ple refer	ral			
Fomnav 2006	3	73	0	32	100.0%	3.12 [0.17, 58.73]	←
Subtotal (95% CI)	-	73	-	32		3.12 [0.17, 58.73]	
Fotal events	3		0				
Heterogeneity: Not ag	plicable		-				
Fest for overall effect:		⁹ = 0.45)				
1.1.5 Additional coun	selling vs.	simple	patient r	eferral			
Vilson 2009	15	304	30		100.0%	0.49 [0.27, 0.89]	
Subtotal (95% CI)		304		296		0.49 [0.27, 0.89]	
Fotal events	15		30				
Heterogeneity: Not ag	plicable						
Fest for overall effect:	•	$P = 0.02^{\circ}$)				
			,				
							0.2 0.5 1 2

Figure 4. Forest plot: 1 Enhanced patient referral versus simple patient referral, outcome: 1.1 Re-infection in index patient, by STI.

Test for subgroup differences: $Chi^2 = 9.37$, df = 4 (P = 0.05), $l^2 = 57.3\%$

We judged the quality of evidence for the primary outcome, using the GRADE approach, as low for four of the five enhanced patient referral interventions. We judged additional counselling to provide moderate evidence of a beneficial effect when compared with simple patient referral but there was only one trial in this group (Wilson 2009) (Summary of findings for the main comparison).

Secondary outcomes

Twelve studies (6045 participants) used five different comparisons and assessed the number of partners elicited (Andersen 1998; Apoola 2009; Cameron 2009; Cleveland undated; Ellison undated; Katz 1988; Kerani 2011; Kissinger 2005; Low 2006b; Moyo 2002; Solomon 1988; Tomnay 2006). There was no evidence of clinically relevant differences between enhanced and simple patient referral strategies (Table 5). When simple patient referral delivered by a nurse was compared with specialist contact tracer (DIS or health adviser) (Katz 1988; Low 2006b), the number of partners elicited was slightly higher in the simple patient referral (nurse) group. We conducted a sensitivity analysis, removing the trial by Andersen 1998 (high risk of bias in random sequence generation), but there was no appreciable difference in the results.

In Ellison et al. there were four intervention arms comparing three different enhanced patient referral methods with simple patient referral: (1) patient referral with a health education message, (2) patient referral with counselling and (3) patient referral with health education message and counselling (Ellison undated). Small increases in the number or partners elicited per index patient were observed in the enhanced patient referral strategy with a health education message (MD 0.25, 95% CI 0.10 to 0.39) and health education message plus counselling (MD 0.6, 95% CI 0.45 to 0.76). In Solomon et al. the authors reported that there was no evidence of differences between enhanced patient referral (videotape) and

simple patient referral group for number of partners elicited (Solomon 1988).

Six studies (1885 participants) assessed number of partners notified (Cameron 2009; Moyo 2002; Ostergaard 2003; Tomnay 2006; Trent 2010; Wilson 2009). In Trent 2010 and Wilson 2009, the exact number of partners notified was not reported so we could not calculate the MD. In three studies (Table 6), there was no evidence of a difference in the number of partners notified per index patient between the groups (Cameron 2009; Ostergaard 2003; Tomnay 2006). In Moyo et al. additional counselling resulted in slightly more partners being notified (Moyo 2002).

Five studies (2684 participants) assessed the number of partners who presented for care (Andersen 1998; Apoola 2009; Cameron 2009; Cleveland undated; Solomon 1988). Data were only available for four studies (Andersen 1998; Apoola 2009; Cameron 2009; Cleveland undated). There was no evidence that one group resulted in more partners who presented for care compared with another (MD 0.1, 95% CI -0.08 to 0.28; heterogeneity: Tau² = 0.02; Chi² = 12.59, df = 3 (P value = 0.006); I² = 76%). In Solomon 1988), the authors reported no difference in number of partners presenting for care when a videotape was used.

Five studies (2601 participant) assessed the number of partners who tested positive (Andersen 1998; Cameron 2009; Cleveland undated; Katz 1988; Ostergaard 2003). There was no evidence that there were more partners testing positive in one group than the other (MD 0.04, 95% Cl -0.01 to 0.09; heterogeneity: Tau² = 0.00; Chi² = 8.49, df = 4 (P value = 0.08); l² = 53%).

Six studies (3275 participants) assessed the number of partners treated (Table 7) (Apoola 2009; Ellison undated; Katz 1988; Kissinger 2005; Low 2006b; Trent 2010). In Trent 2010, the exact number of partners treated was not reported so we could not calculate the MD. The enhanced group receiving the information booklet had slightly more partners treated compared with simple patient referral (Kissinger 2005). The combination of a health education message and counselling also resulted in slightly more partners treated (Ellison undated) (MD 0.08, 95% CI 0.01 to 0.14). There was no evidence of a difference in partners treated with the other enhanced patient referral strategies.

In one study (902 participants), 14.5% of partners in the simple patient referral group and 3.3% in the enhanced group (videotape) attended the clinic eight or more days after the index patient (Solomon 1988).

Five studies (1138 participants) assessed the number of harmful events reported (Kerani 2011; Moyo 2002; Tomnay 2006; Trent 2010; Wilson 2009). In two of these, no harms were reported (Kerani 2011; Tomnay 2006). In Wilson et al., no evidence of a difference of the amount of harm (argument, fight or physical violence) was found in the group receiving the enhancement (additional counselling) compared with simple patient referral group (Wilson 2009). In the fourth trial, complications due to medicine or symptoms worsening were equally distributed between two groups (Trent 2010). The fifth study did not specify the number of harms (physical and verbal abuse) reported but stated that it was not associated with the study arm assignment (Moyo 2002).

No information was available for incidence of STI, changes in behaviour emotional impact and ethical outcomes.

2. Enhanced patient referral versus other enhanced patient referral method

Two studies (1351 participants) compared one enhanced patient referral method with another enhanced patient referral method among patients with any STI syndrome (Ellison undated) and gonorrhoea or non-gonococcal urethritis (Montesinos 1990).

Secondary outcomes

Both studies assessed the number of partners elicited. In Ellison et al., a health education message plus counselling elicited a slightly higher number of partners compared with counselling alone (MD 0.48, 95% CI 0.32 to 0.64) or to a health education message alone (MD 0.35, 95% CI 0.19 to 0.52) (Ellison undated). There was no difference between the groups receiving health education messages alone (MD -0.12, 95% CI -0.27 to 0.03). In Montesinos 1990, there was no evidence of differences in the number of partners elicited when counselling was compared with a combination of counselling plus incentive plus contact cards, and with counselling plus no incentive plus follow-up call.

One study (65 participants) assessed the number of partners who presented for care (Montesinos 1990), and found no difference between groups when index patients received counselling plus follow-up call plus no incentive plus contact cards compared with counselling alone or counselling plus incentive plus contact cards.

One study (1286 participants) assessed number of partners treated (Ellison undated). There was no difference between the groups receiving counselling plus health education message compared with health message alone (MD 0.05, 95% CI -0.01 to 0.12) or with counselling alone (MD 0.03, 95% CI -0.03 to 0.1). No evidence of a difference between groups receiving health message alone compared with counselling alone was found (MD 0.02, 95% CI -0.04 to 0.08).

No information was available for index patient re-infection rate, partners notified, delay in partners presented for care, partners testing positive, incidence of STI, changes in behaviour, emotional impact, harms or ethical outcomes.

Expedited partner therapy

3. Expedited partner therapy versus simple patient referral

Eight studies compared EPT versus simple patient referral among patients with chlamydia (Cameron 2009; Schillinger 2003), trichomoniasis (Kissinger 2006; Schwebke 2010), gonorrhoea or chlamydia (Golden 2005; Kerani 2011; Kissinger 2005) and any STI syndrome (Nuwaha 2001).

Primary outcome

Six studies (6018 participants) assessed the index patient reinfection rate (Cameron 2009; Golden 2005; Kissinger 2005; Kissinger 2006; Schillinger 2003; Schwebke 2010). Index patients in the EPT group had a 29% lower risk of being re-infected compared with index patients in simple patient referral group (RR 0.71, 95% CI 0.56 to 0.89; heterogeneity: Tau² = 0.03; Chi² = 8.15, df = 5 (P value = 0.15), l² = 39%) (Figure 5). When a sensitivity analysis was performed and only studies with attrition less than 20% were included (Kissinger 2006; Schillinger 2003), the effect of EPT

was attenuated and CIs were wider (RR 0.8, 95% CI 0.62 to 1.04; heterogeneity: Tau² = 0.00; Chi² = 18, df = 1 (P value = 0.67), $I^2 = 0\%$).

Figure 5. Forest plot: 3 Expedited partner therapy versus simple patient referral, outcome 3.1 Re-infection in index patients, by STI.

	EPT		Simple	PR		Risk Ratio	Risk Ratio
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Random, 95% Cl	M-H, Random, 95% Cl
3.1.1 Chlamydia							
Cameron 2009	10	110	7	110	5.6%	1.43 [0.56, 3.62]	
Schillinger 2003	87	887	108	900	29.9%	0.82 [0.63, 1.07]	
Subtotal (95% CI)		997		1010	35.6%	0.90 [0.60, 1.35]	-
Total events	97		115				
Heterogeneity: Tau ² =	0.03; Chi	i ^z = 1.28	8, df = 1 (P = 0.2	6); I² = 22	%	
Test for overall effect:	Z = 0.51 ((P = 0.8	61)				
3.1.2 Trichomonas							
Kissinger 2006	8	154	12	155	6.4%	0.67 [0.28, 1.60]	
Schwebke 2010	6	162	9	160	4.9%	0.66 [0.24, 1.81]	
Subtotal (95% CI)		316		315	11.2 %	0.67 [0.34, 1.28]	
Total events	14		21				
Heterogeneity: Tau ² =	0.00; Chi	i ^z = 0.01	0, df = 1 (P = 0.9	8); I² = 0%	6	
Test for overall effect:	Z = 1.21 ((P = 0.2	23)				
3.1.3 Chlamydia or go	norrhoe	а					
Golden 2005		1375	124	1376	30.6%	0.74 [0.57, 0.96]	
Kissinger 2005	32	344	68	285	22.6%	0.48 [0.33, 0.68]	
Subtotal (95% CI)		1719	00	1661	53.2%	0.61 [0.39, 0.94]	
Total events	131		192		001270		
Heterogeneity: Tau ² =		i≊ – 3 8;		P - n n	5): IZ – 74	٥٢	
Test for overall effect:	•			0.0	5),1 - 74	70	
restion overall effect.	2 - 2.20	(i = 0.0	,2,				
Total (95% CI)		3032		2986	100.0%	0.71 [0.56, 0.89]	◆
Total events	242		328				
Heterogeneity: Tau ² =	0.03; Chi	i ^z = 8.1:	5, df = 5 (P = 0.1	5); I ^z = 39	%	0.5 0.7 1 1.5 2
Test for overall effect:							0.5 0.7 1 1.5 2 Favours EPT Favours simple
reation overall effect.							

The GRADE quality of the overall evidence for six studies reporting the primary outcome of re-infection was moderate. We downgraded the quality of the evidence because of the serious risk of bias resulting from attrition and from inadequately described methods in several of the studies. When stratified according to type of STI (two studies each), there was low-quality evidence suggesting no difference between EPT and simple patient referral for chlamydia, and low-quality evidence favouring EPT for trichomonas and a combined outcome of either chlamydia or gonorrhoea (Summary of findings 2).

Secondary outcomes

Six studies (4339 participants) assessed the number of partners elicited (Cameron 2009; Golden 2005; Kerani 2011; Kissinger 2005; Nuwaha 2001; Schwebke 2010). There was no evidence of a difference between the two groups (MD -0.02, 95% -0.09 to 0.04; heterogeneity: Tau² = 0.00; Chi² = 1.05, df = 5 (P value = 0.96); l² = 0% (Figure 6).

Figure 6. Forest plot: 3 Expedited partner therapy versus simple patient referral, outcome 3.2 Number of partners elicited.

		EPT		Sin	nple Pl	R		Mean Difference	Mean Difference
Study or Subgroup	Mean	SD	Total	Mean	SD	Total	Weight	IV, Random, 95% C	I IV, Random, 95% Cl
Cameron 2009	1.14	1.09	110	1.22	1.09	110	4.8%	-0.08 [-0.37, 0.21] ←
Golden 2005	0.99	1	1375	1.02	1	1376	71.3%	-0.03 [-0.10, 0.04	
Kerani 2011	2.75	1.6	16	2.33	1.6	18	0.3%	0.42 [-0.66, 1.50	ŋ ← ►
Kissinger 2005	2.05	1.43	344	2.03	1.43	285	7.9%	0.02 [-0.20, 0.24	.] ← →
Nuwaha 2001	1.23	1.11	192	1.23	1.11	191	8.1%	0.00 [-0.22, 0.22	2] ←
Schwebke 2010	1.1	1.05	162	1.12	1.05	160	7.6%	-0.02 [-0.25, 0.21] ←
Total (95% CI)			2199			2140	100.0%	-0.02 [-0.09, 0.04	
Heterogeneity: Tau ² =	Heterogeneity: Tau ² = 0.00; Chi ² = 1.02, df = 5 (P = 0.96); l ² = 0%								
Test for overall effect:	Z=0.74	(P = (0.46)						-0.1 -0.05 0 0.05 0.1 Favours simple PR Favours EPT

In one small study of men who have sex with men (75 men, Kerani 2011), a slightly higher number of partners was elicited when the index patient received EPT compared with simple patient referral (MD 0.42, 95% CI 0.05 to 0.79).

Three studies (3600 participants) assessed number of partners notified (Cameron 2009; Golden 2005; Kissinger 2005). These three studies showed inconsistent results (heterogeneity: $Tau^2 = 0.07$;

Chi² = 29.71, df = 2 (P value < 0.001); l² = 93%) (Figure 7). Heterogeneity was explored by setting, STI and gender, and it could not be explained by subgroup analysis. In one study, slightly more partners of index patients in the EPT group were notified (MD 0.45, 95% CI 0.28 to 0.62) (Kissinger 2005). In two studies, there was no significant difference (Cameron 2009: MD 0.13, 95% CI -0.06 to 0.32; Golden 2005: MD -0.05, 95% CI -0.12 to 0.01).

Figure 7. Forest plot: 3 Expedited partner therapy versus simple patient referral, outcome 3.3 Number of partners notified.

		EPT		Sin	iple Pl	R	Mean Difference	Mean Difference
Study or Subgroup	Mean	SD	Total	Mean	SD	Total	IV, Random, 95% Cl	IV, Random, 95% Cl
Cameron 2009	0.59	0.73	110	0.46	0.73	110	0.13 [-0.06, 0.32]	
Golden 2005	0.75	0.88	1375	0.8	0.88	1376	-0.05 [-0.12, 0.02]	-++
Kissinger 2005	1.44	1.1	344	1	1.1	285	0.44 [0.27, 0.61]	→
								-0.5-0.25 0 0.25 0.5 Favours simple PR Favours EPT

One study (220 participants) found no evidence of a difference in the number of partners who presented for care between the groups (MD 0.05, 95% CI -0.12 to 0.23) (Cameron 2009).

Four studies (4085 participants) assessed the number of partners treated (Golden 2005; Kissinger 2005; Nuwaha 2001; Schwebke 2010). The studies showed results in the same direction but were very heterogeneous (heterogeneity: Tau² = 0.07; Chi² = 59.57, df =

3 (P value < 0.001); I² = 95%) (Figure 8). Subgroup analysis (setting, STI, gender) did not explain the heterogeneity. In three of the four trials, there was a moderate difference favouring EPT (Kissinger 2005: MD 0.43, 95% Cl 0.28 to 0.58; Nuwaha 2001: MD 0.50, 95% Cl 0.34 to 0.67; Schwebke 2010: MD 0.51, 95% Cl 0.35 to 0.67). The difference between groups was very small in the fourth trial (Golden 2005: MD 0.06, 95% Cl 0.01 to 0.12).



		EPT		Sin	nple Pl	R	Mean Difference	Mean Difference
Study or Subgroup	Mean	SD	Total	Mean	SD	Total	IV, Random, 95% Cl	IV, Random, 95% Cl
3.5.1 Chlamydia or g	onorrho	ea						
Golden 2005	0.59	0.75	1375	0.53	0.75	1376	0.06 [0.00, 0.12]	-+-
Kissinger 2005	1.14	0.95	344	0.71	0.95	285	0.43 [0.28, 0.58]	
3.5.2 Trichomonas								
Schwebke 2010	0.79	0.73	162	0.28	0.73	160	0.51 [0.35, 0.67]	-+
3.5.3 Any STI syndro	me							
Nuwaha 2001	0.91	0.81	192	0.41	0.81	191	0.50 [0.34, 0.66]	-+
							F	-0.5 -0.25 0 0.25 0.5 avours simple PR Favours EPT

Figure 8. Forest plot: 3. Expedited partner therapy versus simple patient referral, outcome 3.5 Number of partners treated.

Kissinger 2005) trichomoniasis (Kissinger 2006) or chlamyd

One of the studies included a measure of harm (Nuwaha 2001). This study (383 participants) found no statistical evidence of a difference in harm between simple patient referral and EPT (MD 0.06, 95% CI 0.0 to 0.12). The index patients in the EPT group reported 23 incidents of quarrelling compared with 11 incidents of quarrelling reported in simple patient referral group. Side effects were reported by index patients in 20 partners in the EPT group and in 10 partners in the simple patient referral group.

No information was available for: partners testing positive, changes in behaviour, emotional impact, ethical outcomes, delay in partners presenting for care or incidence of STI.

4. Expedited partner therapy versus enhanced patient referral

Four studies compared EPT versus enhanced patient referral among patients with gonorrhoea or chlamydia (Kerani 2011;

Kissinger 2005), trichomoniasis (Kissinger 2006) or chlamydia (Cameron 2009).

Primary outcome

Three studies (1220) assessed the index patient re-infection rate (Cameron 2009; Kissinger 2005; Kissinger 2006). There was no evidence of a difference between the two groups (RR 0.96, 95% CI 0.6 to 1.53; heterogeneity: Tau² = 0.06; Chi² = 2.99, df = 2 (P value = 0.22); I² = 33%) (Figure 9). Sensitivity analysis including only studies with attrition less than 20% (Kissinger 2006) also found no evidence of a difference between the two groups (RR 0.73, 95% CI 0.30 to 1.76).

Figure 9. Forest plot: 4 Expedited partner therapy versus enhanced patient referral, outcome: 4.1 Re-infection in index patients.

	EP1	Г	Enhance	d PR		Risk Ratio	Risk Ratio
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Random, 95% Cl	M-H, Random, 95% Cl
4.1.1 Re-infection in	index pat	ients					
Cameron 2009	10	110	15	110	27.5%	0.67 [0.31, 1.42]	
Kissinger 2005	39	344	30	348	50.7%	1.32 [0.84, 2.07]	
Kissinger 2006	8	154	11	154	21.8%	0.73 [0.30, 1.76]	
Subtotal (95% CI)		608		612	100.0%	0.96 [0.60, 1.53]	•
Total events	57		56				
Heterogeneity: Tau ² :	= 0.06; Ch	i ^z = 2.9	9, df = 2 (P	= 0.22)); I z = 33%	, b	
Test for overall effect	:Z=0.18	(P = 0.8)	36)				
							0.01 0.1 1 10 1

The GRADE assessment suggests low-quality evidence that there was no difference between EPT and enhanced patient referral for preventing re-infection in patients with curable STI (three studies). The evidence was downgraded because of the risk of bias in the methods and imprecision in the effect estimate (Summary of findings 3).

Secondary outcomes

Three studies (945 participants) assessed the number of partners elicited (Cameron 2009; Kerani 2011; Kissinger 2005). There was no evidence of a difference between the two groups (MD 0.07, 95% CI -0.180 to 0.32; heterogeneity: Tau² = 0.02; Chi² = 3.33, df = 2 (P = 0.19); $I^2 = 40\%$) (Figure 10).

EPT Enhanced PR

Figure 10. Forest plot: 4 Expedited partner therapy versus enhanced patient referral: 4.2 Secondary outcomes.

Study or Subgroup Mean SD Total 4.2.1 Number of partners elicited 1.0 110 Cameron 2009 1.14 1.06 110 Kerani 2011 2.75 1.51 16 Kissinger 2005 2.05 1.43 344 Subtotal (95% CI) 470 470 Heterogeneity: Tau ² = 0.02; Chi ² = 3.34, df = 2 (P = 1) 4.2.2 Number of partners notified	Mean SD 1.13 1.06 1.76 1.51 2.03 1.43 0.19); I² = 40% 0.48	i 110 17 348 4 75	Weight 41.5% 5.6% 52.8% 100.0% 100.0%	N, Random, 95% Cl 0.01 [-0.27, 0.29] 0.99 [-0.04, 2.02] 0.02 [-0.19, 0.23] 0.07 [-0.18, 0.32] 0.11 [-0.08, 0.30] 0.11 [-0.08, 0.30]	IV, Random, 95% Cl
Cameron 2009 1.14 1.06 110 Kerani 2011 2.75 1.51 16 Kissinger 2005 2.05 1.43 344 Subtotal (95% CI) 470 Heterogeneity: Tau ² = 0.02; Chi ² = 3.34, df = 2 (P = 0) Test for overall effect: Z = 0.55 (P = 0.59) 4.2.2 Number of partners notified Cameron 2009 0.59 0.73 110 Subtotal (95% CI) 110 Heterogeneity: Not applicable Test for overall effect: Z = 1.12 (P = 0.26) 4.2.3 Number of partners presenting for care Cameron 2009 0.47 0.09 110 Subtotal (95% CI) 110	1.76 1.51 2.03 1.43 0.19); I≇= 40%	17 348 475 110	5.6% 52.8% 100.0% 100.0%	0.99 [-0.04, 2.02] 0.02 [-0.19, 0.23] 0.07 [-0.18, 0.32] 0.11 [-0.08, 0.30]	
Kerani 2011 2.75 1.51 16 Kissinger 2005 2.05 1.43 344 Subtotal (95% CI) 470 Heterogeneity: Tau ² = 0.02; Chi ² = 3.34, df = 2 (P = 1) Test for overall effect: $Z = 0.55$ (P = 0.59) 4.2.2 Number of partners notified Cameron 2009 0.59 0.73 110 Subtotal (95% CI) 110 Heterogeneity: Not applicable Test for overall effect: $Z = 1.12$ (P = 0.26) 4.2.3 Number of partners presenting for care Cameron 2009 0.47 0.09 110 Subtotal (95% CI) 110	1.76 1.51 2.03 1.43 0.19); I≇= 40%	17 348 475 110	5.6% 52.8% 100.0% 100.0%	0.99 [-0.04, 2.02] 0.02 [-0.19, 0.23] 0.07 [-0.18, 0.32] 0.11 [-0.08, 0.30]	
Kissinger 2005 2.05 1.43 344 Subtotal (95% CI) 470 Heterogeneity: Tau ² = 0.02; Chi ² = 3.34, df = 2 (P = 1) Test for overall effect: $Z = 0.55$ (P = 0.59) 4.2.2 Number of partners notified Cameron 2009 0.59 0.73 110 Subtotal (95% CI) 110 Heterogeneity: Not applicable Test for overall effect: $Z = 1.12$ (P = 0.26) 4.2.3 Number of partners presenting for care Cameron 2009 0.47 0.09 110 Subtotal (95% CI) 110	2.03 1.43 0.19); I² = 40%	348 475	52.8% 100.0 % 100.0%	0.02 [-0.19, 0.23] 0.07 [-0.18, 0.32] 0.11 [-0.08, 0.30]	
Subtotal (95% CI) 470 Heterogeneity: Tau ² = 0.02; Chi ² = 3.34, df = 2 (P = 1) Test for overall effect: Z = 0.55 (P = 0.59) 4.2.2 Number of partners notified Cameron 2009 0.59 0.73 110 Subtotal (95% CI) 110 110 Heterogeneity: Not applicable Test for overall effect: Z = 1.12 (P = 0.26) 4.2.3 Number of partners presenting for care Cameron 2009 0.47 0.09 110 Subtotal (95% CI) 110 110	0.19); i² = 40%	475 110	100.0%	0.07 (-0.18, 0.32) 0.11 (-0.08, 0.30)	
Test for overall effect: Z = 0.55 (P = 0.59) 4.2.2 Number of partners notified Cameron 2009 0.59 0.73 110 Subtotal (95% CI) 110 110 Heterogeneity: Not applicable 1.12 (P = 0.26) 1.12 (P = 0.26) 4.2.3 Number of partners presenting for care Cameron 2009 0.47 0.09 110 Subtotal (95% CI) 110 110 110 110 110					
Test for overall effect: Z = 0.55 (P = 0.59) 4.2.2 Number of partners notified Cameron 2009 0.59 0.73 110 Subtotal (95% CI) 110 110 Heterogeneity: Not applicable 1.12 (P = 0.26) 1.12 (P = 0.26) 4.2.3 Number of partners presenting for care Cameron 2009 0.47 0.09 110 Subtotal (95% CI) 110 110 110 110 110					-
Cameron 2009 0.59 0.73 110 Subtotal (95% Cl) 110 110 Heterogeneity: Not applicable 110 110 Test for overall effect: Z = 1.12 (P = 0.26) 4.2.3 Number of partners presenting for care 110 Cameron 2009 0.47 0.09 110 Subtotal (95% Cl) 110 110	0.48 0.73				-
Subtotal (95% CI) 110 Heterogeneity: Not applicable 110 Test for overall effect: Z = 1.12 (P = 0.26) 110 4.2.3 Number of partners presenting for care 110 Cameron 2009 0.47 0.09 110 Subtotal (95% CI) 110	0.48 0.73				
Test for overall effect: Z = 1.12 (P = 0.26) 4.2.3 Number of partners presenting for care Cameron 2009 0.47 0.09 110 Subtotal (95% CI) 110					
4.2.3 Number of partners presenting for care Cameron 2009 0.47 0.09 110 Subtotal (95% CI) 110					
Cameron 2009 0.47 0.09 110 Subtotal (95% CI) 110					
Subtotal (95% CI) 110					
Heterogeneity: Not applicable	0.46 0.09	110 110	100.0% 100.0 %	0.01 [-0.01, 0.03] 0.01 [-0.01, 0.03]	
					-
Test for overall effect: Z = 0.82 (P = 0.41)					
4.2.4 Number of partners treated					_
Kissinger 2005 1.142442 0.07733 344 Subtotal (95% CI) 344	0.925287 0.07733	348 348	100.0% 100.0 %	0.22 [0.21, 0.23] 0.22 [0.21, 0.23]	📮
Heterogeneity: Not applicable					
Test for overall effect: Z = 36.93 (P < 0.00001)					
				-	-0.2 -0.1 0 0.1 0.2

Favours enhanced PR Favours EPT

One study (220 participants) measured the number of partners notified and found no evidence of a difference between the groups (MD 0.11, 95% CI -0.08 to 0.3) (Cameron 2009).

One study (220 participants) measured the effect on number of partners presenting for care. There was no evidence of a difference between groups (MD 0.01, 95% Cl -0.02 to 0.03) (Cameron 2009).

One study (692 participants) found a small increase in the number of partners treated per index patient randomised to the EPT group compared with the enhanced patient referral group (MD 0.22, 95% CI 0.21 to 0.23) (Kissinger 2005).

No information was available for delay in partners presenting for care, partners testing positive, changes in behaviour, emotional impact, harms, ethical outcomes and incidence of STI.

One study compared EPT plus enhanced patient referral or simple patient referral among men who have sex with men with chlamydia or gonorrhoea (Kerani 2011). A website, 'inSPOT' was used to enhance the patient referral intervention. The primary outcome assessed was the number of partners treated or notified. In the comparison of EPT and inSPOT (41 participants), a moderately higher number of partners was elicited in the combination group compared with inSPOT alone (MD 1.15, 95% CI 0.22 to 2.08). There was no evidence of differences in the number of partners treated or notified for the comparisons of EPT and inSPOT versus EPT alone (40 participants; MD 0.17, 95% CI -0.89 to 1.23); or EPT and inSPOT versus simple patient referral (42 participants, MD 0.58, 95% CI -0.4 to 1.57).

No information was available for index patient re-infection rate, incidence of STI, partners notified, partners presenting for care, number of partners tested, number of partners testing positive, partners treated, delay in partners presented for care, changes in behaviour, emotional impact, harms or ethical outcomes.

Contract referral

5. Contract referral versus simple patient referral

Five trials compared contract referral versus simple patient referral among patients with HIV (Brown 2011; Landis 1992), gonorrhoea (Cleveland undated; Potterat 1977) or trichomoniasis (Schwebke 2010).

Primary outcome

The index patient re-infection rate was assessed in one trial (322 participants) among women with trichomoniasis (Schwebke 2010). There was no statistical evidence of a difference in the risk of re-infection in the women receiving contract referral or simple patient referral at either one month (RR 1.65, 95% CI 0.74 to 3.65) or three months (RR 1.65, 95% CI 0.4 to 6.77).

The GRADE level of evidence was very low because the findings were from one small trial with a serious risk of bias in the methods (Summary of findings 4).

Secondary outcomes

All five studies (2006 participants) assessed the number of partners elicited per index patient. Slightly fewer partners were elicited in the contract referral than the simple patient referral group (MD -0.22, 95% CI -0.37 to -0.06; heterogeneity: Tau² = 0.01; Chi² = 5.27,

YBetter health.

df = 4 (P value = 0.26); $I^2 = 24\%$) (Figure 11). We conducted a sensitivity analysis, removing the trial by Potterat et al. (high risk of

bias in random sequence generation), but there was no appreciable difference in the results.

Figure 11. Forest plot: 5 Contract referral versus simple patient referral, outcome: 5.1 Number of partners elicited.

		CR		Sin	nple Pl	R		Mean Difference	Mean Difference
Study or Subgroup	Mean	SD	Total	Mean	SD	Total	Weight	IV, Random, 95% Cl	IV, Random, 95% Cl
Brown 2011	1.15	1.09	82	1.21	1.09	77	17.0%	-0.06 [-0.40, 0.28]	← ■
Cleveland undated	2.9	1.76	632	3.3	1.76	632	37.2%	-0.40 [-0.59, -0.21]	←──
Landis 1992	4.03	2.05	39	4.37	2.05	35	2.7%	-0.34 [-1.28, 0.60]	←→
Potterat 1977	2.04	1.44	94	2.13	1.44	93	12.2%	-0.09 [-0.50, 0.32]	←
Schwebke 2010	0.99	1.03	162	1.12	1.03	160	31.0%	-0.13 [-0.36, 0.10]	
Total (95% CI)			1009			997	100.0%	-0.22 [-0.37, -0.06]	
Heterogeneity: Tau ² =	= 0.01; C	hi² = 5							
Test for overall effect	: Z = 2.77	' (P = ().006)						-0.2 -0.1 0 0.1 0.2
		· ·	,					1	Favours simple PR Favours CR

One study (74 participants) assessed the number of partners notified per index patient among patients with HIV (Landis 1992). There were more partners notified per index patient in the contract referral group than those that were asked to refer partners themselves (MD 1.71, 95% CI 1.24 to 2.19).

Three studies (1610 participants) assessed the number of partners who presented for care (Brown 2011; Cleveland undated; Potterat 1977). Contract referral resulted in slightly more partners presenting for care (MD 0.25, 95% CI 0.18 to 0.32; heterogeneity: Tau² = 0.00; Chi² = 0.85, df = 2 (P value = 0.65); l² = 0%). We conducted a sensitivity analysis, removing the trial by Potterat 1977 (high risk of bias in random sequence generation), but there was no appreciable difference in the results.

Two studies (481 participants) assessed the time delay between enrolment of the index patient and presentation of the partner for care (Brown 2011; Schwebke 2010). In both studies, authors reported that the partner presented sooner in the simple patient referral than the contract referral group. In one study, the median time between enrolment of the index patient and partner presentation was 3 days (interquartile range (IQR) 2 to 7 days) in the simple patient referral group compared with 7 days (IQR 3 to 11 days) in the contract referral group (Brown 2011), and, in the other trial, the mean time was 5 days in the simple patient referral group and 7.25 days in the contract referral group (P value = 0.19) (Schwebke 2010).

Four studies (1684 participants) assessed the number of partners who tested positive (Brown 2011; Cleveland undated; Landis 1992; Potterat 1977). Contract referral resulted in slightly more partners who tested positive (MD 0.12, 95% CI 0.07 to 0.17; Heterogeneity: Tau² = 0.00; Chi² = 2.73, df = 3 (P value = 0.44); l² = 0%). We conducted a sensitivity analysis, removing the trial by Potterat 1977 (high risk of bias in random sequence generation), but there was no appreciable difference in the results.

Two studies (509 participants) assessed the number of partners treated (Potterat 1977; Schwebke 2010). In one study, slightly more partners of women with trichomoniasis were treated in contract referral than in the simple patient referral group (MD 0.28, 95% Cl 0.14 to 0.42) (Schwebke 2010). In the trial of men with gonorrhoea (Potterat 1977), there was no evidence of a difference between groups (MD 0, 95% Cl -0.04 to 0.03). These two studies were not summarised in a meta-analysis (heterogeneity: Tau² = 0.04; Chi² =

14.61, df = 1 (P value = 0.0001); I^2 = 93%). These two studies were both performed in the US but in different gender groups reporting different STI.

One study (159 participants) reported on harms with one event in each group (Brown 2011). One episode of abandonment was reported in the simple patient referral group and the police were contacted to placate the partner of one index patient in the contract referral group.

No information was available for incidence of STI, changes in behaviour and emotional impact.

6. Contract referral versus enhanced patient referral

One study (1266 participants) compared contract referral versus enhanced patient referral (counselling) among patients with gonorrhoea (Cleveland undated).

Secondary outcomes

The number of partners elicited per index patient randomised was moderately lower in contract referral group than the enhanced patient referral (counselling) group (MD -0.40, 95% CI -0.59 to -0.21).

The number of partners who presented for care per index patient (MD 0.25, 95% CI 0.17 to 0.33) and the number of partners who tested positive per index patient (MD 0.11, 95% CI 0.05 to 0.18) were slightly higher in the contract referral group than the enhanced patient referral (counselling) group.

7. Contract referral versus expedited partner therapy

One study (324 participants) compared contract referral with EPT among patients with trichomoniasis (Schwebke 2010).

Primary outcome

There was no statistical evidence of a difference in index patient re-infection rate at one or three months after treatment comparing EPT with contract referral (one month: RR 0.40, 95% CI 0.16 to 1.01 and three months: RR 2.0, 95% CI 0.7 to 5.72).

Secondary outcomes

There was no statistical evidence of a difference between the two groups in the number of partners elicited per index patient (MD 0.11,95% CI -0.11 to 0.33). The number of partners treated per index



patient was slightly higher in the EPT group compared with the contract referral group (MD 0.23, 95% CI 0.05 to 0.41).

No information was available for incidence of STI, changes in behaviour, emotional impact, harms, ethical outcomes, partners notified, partners presented for care, delay in partners presented for care or partners testing positive.

Provider referral

8. Provider referral versus simple patient referral

Two studies compared provider referral versus simple patient referral among patients with HIV (Brown 2011), and nongonococcal urethritis (Katz 1988). One study compared a choice between simple patient or provider referral with counselling versus simple patient referral among patients with STI syndromes (Faxelid 1996). None of these studies rinvestigated the primary outcome.

Secondary outcomes

Both studies comparing provider referral with simple patient referral (Brown 2011; Katz 1988) (596 participants) assessed the number of partners elicited per index patient. The results of these two studies showed effects in the opposite direction (heterogeneity: Tau² = 0.14; Chi² = 7.76, df = 1 (P value = 0.005); l² = 87%). Subgroup analysis showed that these two studies included index patients with different STI, different settings and participants, and these studies were reported individually. Among women and men with HIV infection (Brown 2011), there was no evidence of a difference in the number of partners elicited per index patient (MD 0.21, 95% CI -0.15 to 0.57). Among men with non-gonococcal urethritis (Katz 1988), those receiving provider referral reported fewer partners (MD -0.36, 95% CI -0.55 to -0.17).

In one study (158 participants), the time delay in partners presenting for care was measured (Brown 2011). Partners presented sooner for care in the simple patient referral group (median time from index patient enrolment to partners presenting for care 3 days (IQR 2 to 7 days)) compared with the provider referral group (median time 4 days (IQR 2 to 8 days)).

In both trials, there was a small increase in the number of partners testing positive per index patient in the provider group compared with the simple patient referral group (MD 0.06, 95% Cl 0.02 to 0.11; heterogeneity: Tau² = 0.00; Chi² = 0.35, df = 1 (P value = 0.55); l² = 0%).

Among men with non-gonococcal urethritis (438 participants) there was a moderate increase in the number of partners treated per index patient in the provider referral group compared with the simple patient referral group (MD 0.5, 95% CI 0.37 to 0.63) (Katz 1988).

One trial (158 participants) reported harms among patients with HIV infection (Brown 2011). In the provider referral group, no harms were reported and in the simple patient referral group one episode of abandonment was reported.

No information was available for index patient re-infection rate, partners notified, partners presenting for care, incidence of STI, changes in behaviour, emotional impact or ethical outcomes.

In the study that compareda choice between simple patient or provider referral with counselling versus simple patient referral (Faxelid 1996) (396 participants), there was evidence of a difference between the two groups in the number of partners elicited (MD -0.03, 95% CI -0.3 to 0.23).

The number of partners notified per index patient (MD 0.41, 95% CI 0.18 to 0.64) and the number of partners who presented for care per index patient (MD 0.46, 95% CI 0.24 to 0.69) were moderately higher in those given a choice than the simple patient referral group. The number of harms reported per male index patient randomised was slightly higher in choice option compared with patient referral option (MD 0.15, 95% CI 0.06 to 0.25). The trial authors did not report individual data but stated that there was no difference between the two groups in the number of harms reported.

No information was available for delay in partners presenting for care, partners testing positive, partners treated, changes in behaviour, emotional impact or ethical outcomes.

9. Provider referral versus enhanced patient referral

One study (461 participants) compared provider referral versus enhanced patient referral (contact tracer (DIS)) among men with non-gonococcal urethritis (Katz 1988). This study did not investigate the primary outcome.

Secondary outcomes

No evidence of a difference was found in the two groups when comparing the number of partners elicited per index patient (MD -0.05, 95% CI -0.21 to 0.11). The number of partners who tested positive per index patient (MD -0.06, 95% CI -0.11 to -0.02) and number of partners treated per index patient (MD -0.54, 95% CI -0.66 to -0.42) were slightly lower in the provider referral group than the enhanced patient referral (contact tracer) group.

No information was available for index patient re-infection rate, partners notified, partners presented for care, delay in partners presented for care, incidence of STI, changes in behaviour, emotional impact, harms or ethical outcomes.

10. Provider referral versus contract referral

Two studies (1491 participants) compared provider referral versus contract referral among patients with HIV (Brown 2011), and syphilis (Peterman 1997). Peterman et al. also compared a strategy of enhanced provider referral (field testing) with contract referral (1224 participants) and with provider referral alone (1380 participants). Neither of these studies investigated the primary outcome.

Secondary outcomes

Both studies that compared provider referral with contract referral (Brown 2011; Peterman 1997) assessed the number of partners elicited. The results were inconsistent (heterogeneity: $Tau^2 = 3.03$; $Chi^2 = 127.21$, df = 1 (P value < 0.001); $I^2 = 100\%$). Subgroup analysis (setting, STI, gender) could not explain heterogeneity. Brown et al. (163 participants) found no evidence of a difference between the two groups in patients with HIV infection (MD -0.27, 95% CI -0.62 to 0.07). The other study (1328 participants) found that the number of partners elicited per index patient with syphilis was higher in the contract referral group than the provider referral group (MD 2.2 95% CI 1.95 to 2.45) (Peterman 1997).

Both studies (1491 participants) assessed the number of partners located. No evidence of a difference between the two groups was found (MD 0.10, 95% CI -0.01 to 0.2; heterogeneity: Tau² = 0.00; Chi² = 0.05, df = 1 (P value = 0.82); I² = 0%).

One of these studies (163 participants) compared the number of partners who presented for care and found no evidence of a difference between the two groups (MD 0.03, 95% CI -0.19 to 0.25) (Brown 2011).

Peterman et al. (1328 participants) assessed the number of partners tested per index patient and found no evidence of a difference between two groups (MD 0.05, 95% CI -0.05 to 0.15) (Peterman 1997).

Both studies (1491 participants) compared the number of partners testing positive (Brown 2011; Peterman 1997). No evidence was found of a difference between two groups (MD 0.02, 95% CI -0.03 to 0.06; heterogeneity: Tau² = 0.00; Chi² = 0.07, df = 1 (P value = 0.79); $l^2 = 0\%$).

Peterman et al. (1328 participants) compared the number of partners treated per index patient and found no evidence of a difference between the two groups (MD 0.06, 95% CI -0.03 to 0.15) (Peterman 1997).

One of these studies (163 participants) reported on harms (Brown 2011). The study reported no harms reported in the provider referral arm and one episode of abandonment reported in the contract referral arm (MD 0.01, 95% CI -0.01 to 0.04).

One study (163 participants) assessed the time delay in partners presented for care after enrolment of index patient (Brown 2011). The study found that the partners of the index patient in the provider referral arm presented sooner for care (median time between enrolment of index patient and partner presenting 4 days (IQR 2 to 8 days) compared with the contract referral arm (median time between enrolment of index patient and partner presenting for care 7 days (IQR 3 to 11 days).

No information was available for ethical outcomes, index patient re-infection rate, partners presenting for care, incidence of STI, changes in behaviour or emotional impact.

In Peterman et al., the number of partners elicited per index patient was moderately higher in the enhanced provider (field testing) referral group compared with the contract referral group (MD 0.5, 95% CI 0.21 to 0.79) and much higher than in the group receiving provider referral alone (MD 2.7, 95% CI 2.45 to 2.95) (Peterman 1997).

There was no evidence of a difference between enhanced provider (field testing) referral group compared with contract referral or provider referral alone in the number of partners located per index patient (contract referral: MD -0.10, 95% CI -0.22 to 0.02; provider referral: MD 0.0, 95% CI -0.11 to 0.11), in the number of partners who were tested (contract referral: MD -0.06, 95% CI -0.17 to 0.05; provider referral: MD -0.01, 95% CI -0.11 to 0.09), in the number of partners testing positive (contract referral: MD -0.02 95% CI -0.07 to 0.03; provider referral: MD 0.0; 95% -0.05 to 0.04) or in the number of partners receiving treatment (contract referral: MD -0.05, 95% CI -0.14 to 0.04; provider referral: MD 0.01, 95% CI -0.07 to 0.09).

No information was available for incidence of STI, partners notified, index patient re-infection rate, partners presenting for care, delay in partners presenting for care, changes in behaviour, emotional impact, harms, and ethical outcomes.

DISCUSSION

Summary of main results

Twenty-six RCTs including 17,578 participants (9015 women and 8563 men) conducted in 10 countries were included in this systematic review.

Summary of evidence according to type of partner notification strategy

EPT for index patients, in trials including those with gonorrhoea, chlamydia, gonorrhoea or chlamydia, or trichomonas (six trials) was better than simple patient referral for the prevention of reinfection of the index patient. EPT also increased the number of partners treated per index patient (four trials). The re-infection rate after EPT was similar to that with enhanced patient referral (three trials) but EPT resulted in more partners treated (one trial). When contract referral was compared with EPT (one trial), there was no difference in re-infection rates among index patients but EPT resulted in more partners being treated. There was insufficient evidence to determine the most effective components of an enhanced patient referral intervention.

We found some evidence that more partners were treated with provider referral (one trial of non-gonococcal urethritis) compared with simple patient referral. In patients with syphilis (one trial), contract referral elicited more partners than provider referral but the number of partners presenting for care and receiving treatment was the same in the two groups. There was no consistent evidence for the relative effects of provider, contract or patient referral for other STI.

The results of four trials comparing home sampling kits for partners with simple patient referral found no evidence of a reduction in reinfection rates in index cases or higher numbers of partners elicited, notified or treated. We found no studies evaluating provider training. Only seven trials assessed potential harms; we could not combine the results but there was no evidence of differences in the incidence of adverse effects in any of the individual trials.

Summary of evidence, by infection

There were 11 different categories of STI included in the review. Fifteen studies assessed strategies for PN in individual STI and 11 studies assessed combinations of STI or syndromic diagnoses. There were no RCTs among patients with laboratory-diagnosed hepatitis B, genital herpes or chancroid.

ΗIV

Only two studies evaluated PN strategies among patients with HIV (314 participants) (Brown 2011; Landis 1992). Both contract referral and provider referral resulted in more partners presenting for care and testing positive than simple patient referral.

Chlamydia

There was no evidence of a difference in index patient re-infection rates in two trials that compared EPT with simple patient referral (2007 participants) (Cameron 2009; Schillinger 2003). Four studies



compared home sampling kits for partners with simple patient referral (1058 participants) (Andersen 1998; Apoola 2009; Cameron 2009; Ostergaard 2003). One study found no reduction in reinfection in index patients (Cameron 2009). There was no difference between groups in numbers of partners elicited, notified or treated.

Gonorrhoea

There was no evidence about index patient re-infection rates. Three studies were performed among patients with gonorrhoea (Cleveland undated; Potterat 1977; Solomon 1988). One study compared simple patient referral versus contract referral (Potterat 1977), another study compared simple patient referral versus enhanced patient referral (videotape) (Solomon 1988), and the third study compared simple patient referral versus contract referral versus enhanced patient referral (additional counselling) (Cleveland undated). Simple patient referral elicited a slightly higher number of partners if compared with contract referral (Cleveland undated; Potterat 1977). The authors of one study using the enhanced patient referral (videotape) did not report results (Solomon 1988).

Chlamydia or gonorrhoea

In trials that included index patients with either chlamydia or gonorrhoea, there was evidence that EPT reduced the index patient re-infection rate compared with simple patient referral (3380 participants) (Golden 2005; Kissinger 2005). There was also evidence from one trial (600 participants) that index patient re-infection rates were reduced by patient referral enhanced by additional counselling compared with simple patient referral (Wilson 2009). In one trial among men who had sex with men, more partners were elicited when a combination of EPT and enhanced patient referral (inSPOT website) was used compared with enhanced patient referral (inSPOT website) alone (Kerani 2011).

Trichomonas

There was no statistical evidence that EPT resulted in a lower re-infection rate in female index patients in comparisons of: EPT versus patient-booklet enhanced patient referral versus simple patient referral (463 participants) (Kissinger 2006); or EPT versus contract referral versus simple patient referral (484 participants) (Schwebke 2010). Slightly more partners were treated when EPT was used compared with contract referral (Schwebke 2010).

Non-gonococcal urethritis

One study (678 participants) compared simple patient referral delivered by a nurse versus enhanced patient referral delivered by a DIS versus provider referral (Katz 1988). Provider referral resulted in slightly more partners who tested positive and who received treatment when compared with simple patient referral delivered by a nurse. Simple patient referral by a nurse was superior to enhanced patient referral in the number of partners elicited, but there was no evidence of a difference between groups in number of partners who tested positive.

Non-gonococcal urethritis or gonorrhoea

There was no evidence about index patient re-infection rates. One study (65 participants) compared patient referral enhanced by additional counselling alone, counselling with incentives and counselling with a follow-up telephone call (Montesinos 1990). There was no evidence of superiority of any of the different method assessed in eliciting partners or increasing the number of partners who presented for care.

Non-gonococcal urethritis or chlamydia

In one study (105 participants), there was no evidence that the use of a website reduced index patient re-infection rates, or increased the number of partners elicited or notified (Tomnay 2006).

Syphilis

One study (1966 participants) was performed among patients with syphilis (Peterman 1997). This study compared contract referral versus provider referral versus enhanced provider referral (with field testing). Contract referral elicited more partners than provider referral. There was no difference between the numbers of partners who were tested, who tested positive or who received treatment between the contract and provider referral group.

Pelvic inflammatory disease

There was no evidence about index patient re-infection rates. One study (126 participants) was included on PID, but exact numbers of partners notified were not available from trial authors (Trent 2010).

Any sexually transmitted infections syndrome

Four studies (2770 participants) in developing countries in Africa were performed among patients with a syndromic diagnosis of a STI (Ellison undated; Faxelid 1996; Moyo 2002; Nuwaha 2001). One study (396 participants) found that index patients given a choice between patient and provider referral, compared with simple patient referral resulted in slightly more partners notified and presenting for treatment (Faxelid 1996). One study (383 participants) found that EPT resulted in slightly more partners treated (Nuwaha 2001). In two studies (1991 participants), simple patient referral was compared with enhanced patient referral with additional counselling (Ellison undated; Moyo 2002). In one study (858 participants), a combination of giving additional counselling and health education messages compared with simple patient referral resulted in slightly more partners elicited and treated (Ellison undated).

Overall completeness and applicability of evidence

We identified 16 new trials in the update in addition to the 11 in the first Cochrane review (Mathews 2001). We found studies on the four most common curable STIs: chlamydia (six trials), gonorrhoea (three trials), chlamydia or gonorrhoea (four trials), trichomoniasis (two trials) and syphilis (one trial). We included only two trials among people with HIV and we identified no studies on chancroid, genital herpes or hepatitis B. Only five of the 26 trials were conducted in developing countries. Only one trial included in this review enrolled men who had sex with men who were infected with chlamydia or gonorrhoea (Kerani 2011). One of the trials among people with HIV infection included men who had sex with men (Landis 1992). We added EPT as a new strategy to enhance the effectiveness of patient referral in this update. In addition, we separated patient referral interventions into those that added components such as counselling, written information, websites and specimen testing kits (enhanced patient referral), and those restricted to spoken advice about the need for partners to receive treatment (simple patient referral). We found no studies on provider training. Nine studies reported index patient re-infection rate, the primary outcome for curable STIs. Few of the



studies assessed the proportion of partners who were infected, but both studies of patients with HIV infection reported this outcome. Instead, most studies relied on surrogate outcomes such as partners presenting for medical evaluation, or reports by index patients of partners presenting. Secondary outcomes reported on infrequently or not at all included delays in partners presenting for care, incidence of STIs, changes in behaviour, emotional impact and ethical outcomes.

Quality of the evidence

In every study, there were risks to the validity of the findings and assessment of risk of bias was hampered by incomplete reporting in more than half of the included studies. Sequence generation was adequate in 11 studies while allocation concealment was only adequate in five studies. Inadequate methods of allocation concealment are an important source of potential bias for RCTs of PN interventions, where those enrolling participants might preferentially allocate selected patients to one particular intervention. Blinding of investigators and patients was not feasible for the types of interventions studied and only six studies reported blinding of outcome assessors. Where outcomes can be subjective, for example judging patient-reported outcomes, unblinded outcome assessment could introduce bias. Re-infection is an objective biological outcome, so lack of blinding of outcome assessors would be less important. Seven studies reported loss to follow-up of more than 20%. Most studies had a low risk of selective outcome reporting. In addition, methods and sensitivity of tests used to diagnose STIs varied across studies.

When the body of evidence about PN strategies was considered, there were only four comparisons reporting the primary outcome of re-infection of index patients with curable STI. EPT compared with simple patient referral was the comparison with the largest number of trials, showing moderate-quality evidence that EPT reduces re-infection more than simple patient referral when we pooled results from trials of all curable STIs. We downgraded the quality of evidence because of the risk of bias resulting from attrition and inadequately described methods. There was also low-quality evidence (limited by the small number of studies and attrition bias), that effect size might differ for different STI. There was also low-quality evidence from three trials that the effect of EPT was similar to that of enhanced patient referral strategies. Comparisons of enhanced versus simple patient referral were limited to one or two trials for each strategy. There was moderate-quality evidence that additional counselling reduced re-infection more than simple patient referral. There was low-quality evidence from one trial that the effect of contract referral was similar to patient referral.

Potential biases in the review process

We conducted an extensive and comprehensive search strategy with no language restrictions of electronic databases to identify all published and unpublished trials. We contacted experts in the field and searched trial registries to identify ongoing studies. We contacted trial authors, where necessary, to obtain missing data. To minimise bias in the review process, two review authors independently performed all study selection, eligibility assessment, data extraction and assessment of risk of bias. If consensus could not be reached, we consulted a third review author. We used standardised eligibility and data extraction forms.

Agreements and disagreements with other studies or reviews

Our findings were consistent with the findings of the two most recently published systematic reviews (Alam 2010; Trelle 2007). The first found that counselling increased partner referral and was reasonable for developing countries where it was well received by index patient, easily integrated and cost effective (Alam 2010). It also found that EPT resulted in more partners treated compared with simple patient referral alone. Barriers to partner referral were mainly cultural and psychosocial (fear of rejection and abuse). The second review also found that EPT resulted in fewer reinfections of the index patient and more partners treated than simple patient referral and that the outcomes of EPT were similar to those with enhanced patient referral (Trelle 2007). Consistent with this update, both Trelle 2007 and Alam 2010 reported the inappropriateness of summarising the evidence in a meta-analysis due to the differences in PN methods used and the way outcomes were reported. Two observational studies reported on adverse effects, 9% of index patients reported physical violence (Kissinger 2003), and 44% reported negative emotional reactions by partners (Rosenthal 1995). In Trelle et al., the authors suggested that labourintensive methods, such as provider and contract referral, could be considered for more serious conditions, such as HIV and syphilis, even though evidence for their superiority was inconsistent (Trelle 2007).

Furthermore, Trelle et al. argued for more studies on the use of EPT in chlamydia and gonorrhoea, as well as large RCTs on PN and HIV and syphilis, and that adverse effects need to be reported specifically (Trelle 2007).

AUTHORS' CONCLUSIONS

Implications for practice

The evidence assessed in this systematic review does not identify a single optimal strategy for partner notification (PN) for any particular sexually transmitted infection (STI). Few studies evaluated syphilis and human immunodeficiency virus (HIV), most were conducted in developed countries for STIs acquired heterosexually and few studies assessed adverse events.

It is important that expedited partner therapy (EPT) interventions include all the components that were part of the EPT package in trials to achieve the outcomes expected. The EPT interventions in the trials in this review included condoms, details of STI clinics, and written information for patients and partners in addition to treatment with antibiotics. In practice, many physicians report giving additional courses of antibiotics or prescriptions to index patients, but it is not clear whether they also give additional support (CDC 2006). EPT is more successful than simple patient referral in preventing re-infection of the index patient and resulted in more partners treated when compared with simple patient referral and contract referral. The effect of EPT was attenuated when we excluded studies with high attrition (> 20%) from the analysis. In addition, in many countries, EPT is not legal and, therefore, not an available option at present. Provider referral and contract referral identified slightly more new infections in partners of patients with HIV compared with simple patient referral. These strategies are more labour and cost intensive than simple patient referral but are considered worthwhile for serious conditions such as HIV and syphilis (Trelle 2007).

When considering the use of enhanced patient referral in chlamydia, gonorrhoea or trichomonas infections or nongonococcal urethritis, most methods were only investigated in one trial and there was no strong evidence of differences in specific outcomes when compared with simple patient referral. The most effective components in the enhanced patient referral strategy could not be identified.

Implications for research

There is a need for more evaluations of interventions combining provider training and patient education, and for evaluations conducted in developing countries. The use of syndromic diagnosis in trials needs to be discouraged especially where vaginal discharge is the concern. Self sampling and self testing need to be evaluated in low-income communities relying heavily on syndromic management. Evaluations of interventions to improve the training in delivering PN for healthcare providers and interventions combining both training and patient education would be valuable.

Large randomised controlled trials (RCTs) for PN in syphilis and HIV are needed and could compare the outcomes of provider referral with methods of enhanced patient referral. Trials conducted in the future should strongly consider using biological outcomes, such as re-infection of the index patient for curable STI and numbers of infected partners identified for HIV. The effect of PN strategies on changes in the behaviour of index patients or partners should also be assessed, particularly for HIV patients. Furthermore, they need to consider measuring to what extent strategies are successful at reaching partners who have a high potential for onward transmission of STI as opposed to monogamous partners. The acceptability of various PN strategies to index patients and partners needs to be assessed, and the costs and potential harms of PN need to be measured and compared. A proposed question for primary research is: "In patients given a diagnosis of HIV in developing countries, will provider referral when compared with enhanced patient referral increase the number of infected partners identified?"

ACKNOWLEDGEMENTS

We would like to thank Rabiatu Abdullah for her general assistance and for reviewing abstracts and developing the data extraction form for the original review. In addition, we are grateful to Elizabeth Pienaar, Joy Olivier, Susan Hansen, Miguel Diaz Ortega and Gail Kennedy for their assistance with the search for trials. Authors of the original review: Catherine Mathews, Nicol Coetzee, Merrick Zwarenstein, Carl Lombard, Sally Guttmacher, Andrew D Oxman, George Schmid. For statistical support Carl Lombard and Tonya Esterhuizen.

The Medical Research Council and the Public Health Department of the University of Cape Town supported and funded the original review. The update was supported by funding from the Effective Health Care Research Consortium, which is funded by UK Aid from the Department for International Development.

Part of the text of this review contributed to a project supported by the National Institute for Health Research (NIHR) Health Technology Assessment programme (project number 07/42/02). The project will be published in full in the *Health Technology Assessment* journal series. Visit the HTA programme website for more details (www.hta.ac.uk/1722). The views and opinions expressed herein are those of the authors and do not necessarily reflect those of the Department of Health.

REFERENCES

References to studies included in this review

Andersen 1998 {published data only}

Andersen B, Ostergaard L, Moller JK, Olesen F. Home sampling versus conventional contact tracing for detecting Chlamydia trachomatis infection in male partners of infected women: randomised study. *BMJ* 1998;**316**:350-1.

Apoola 2009 {published data only}

Apoola A, Beardsley J. Does the addition of a urine testing kit to use of contact slips increase the partner notification rates for genital chlamydial infection. *International Journal of STD & AIDS* 2009;**20**:775-7.

Brown 2011 {published data only}

Brown LB, Miller WC, Kamanga G, Nyirenda N, Mmodzi P, Pettifor A, et al. HIV partner notification is effective and feasible in sub-Saharan Africa: opportunities for HIV treatment and prevention. *Journal of Acquired Immune Deficiency Syndromes* 2011;**56**(5):437-42.

Cameron 2009 {published data only}

Cameron ST, Glasier A, Scott G, Young, Melvin L, Johnstone A, et al. Novel interventions to reduce re-infection in women with chlamydia: a randomized controlled trial. *Human Reproduction* 2009;**24**(4):888-95.

Melvin L, Cameron ST, Glasier A, Scott G, Johnstone A, Elton R. Preferred strategies of men and women for managing chlamydial infection. *BJOG* 2009;**116**:357-65.

Cleveland undated {unpublished data only}

Cleveland JQ. A cost-effective study of alternate methods for gonorrhea contact referral and rescreening. Data on file.

Ellison undated {unpublished data only}

Ellison GTH, Moniez V, Stein J. Improving partner notification for sexually transmitted disease using a standardised health message and patient-centred counselling. Data on file.

Faxelid 1996 {published data only}

Faxelid E, Tembo G, Ndulo J, Krantz I. Individual counselling of patients with sexually transmitted diseases: a way to improve partner notification in a Zambian setting?. *Sexually Transmitted Diseases* 1996;**23**:289-92.

Golden 2005 {published data only}

Golden MR, Whittington WLH, Handsfield HH, Clark A, Malinski C, Helmers JR, et al. Failure of family-planning referral and high interest in advanced provision emergency contraception among women contacted for STD partner notification. *Contraception* 2004;**69**:241-6.

Golden MR, Whittington WLH, Handsfield HH, Hughes JP, Stamm WE, Hogben M, et al. Effect of expedited treatment of sex partners on recurrent or persistent gonorrhea or chlamydial infection. *New England Journal of Medicine* 2005;**352**:676-85.

Golden MR, Whittington WLH, Handsfield HH, Malinski C, Clark A, Hughes JP, et al. Partner management for gonococcal and chlamydial infection expansion of public health services to the private sector and expedited sex partner treatment through a partnership with commercial pharmacies. *Sexually Transmitted Disease* 2001;**28**(11):658-65.

Shiely F, Hayes K, Thomas KK, Kerani RP, Hughes JP, Whittington WLH, et al. Expedited partner therapy: a robust intervention. *Sexually Transmitted Diseases* 2010;**37**(10):602-7.

Katz 1988 {published data only}

Katz BP, Danos CS. Efficiency and cost-effectiveness of field follow-up for patients with chlamydia trachomatis infection in a sexually transmitted disease clinic. *Sexually Transmitted Diseases* 1988;**15**(1):11-6.

Kerani 2011 {published data only}

Kerani RP, Fleming M, DeYoung B, Golden MR. A randomized, controlled trial of inSPOT and patient-delivered partner therapy for gonorrhea and chlamydial infection among men who have sex with men. *Sexually Transmitted Diseases* 2011;**38**(10):941-6.

Kissinger 2005 {published data only}

Kissinger P, Mohammed H, Richardson-Alston G, Leichliter JS, Taylor SN, Martin DH, et al. Patient-delivered partner treatment for male urethritis: a randomized, controlled trial. *Clinical Infectious Diseases* 2005;**41**:623-9.

Mohammed H, Leichliter JS, Schmidt N, Kissinger P. Does patient-delivered partner treatment improve disclosure for treatable sexually transmitted diseases?. *AIDS Patient Care and STDs* 2010;**24**(3):183-8.

Kissinger 2006 {published data only}

Kissinger P, Schmidt N, Mohammed H, Leichliter JS, Gift TL, Meadors B, et al. Patient-delivered partner treatment for *Trichomonas vaginalis* infection: a randomized controlled trial. *Sexually Transmitted Diseases* 2006;**33**(7):445-50.

Landis 1992 {published data only}

Landis SE, Schoenbach VJ. Results of a randomized trial of partner notification in cases of HIV infection in North Carolina. *New England Journal of Medicine* 1992;**326**(2):101-6.

Low 2006b {published data only}

Low N, McCarthy A, Macleod J, Salisbury C, Campbell R, Roberts TE, et al. Epidemiological, social, diagnostic and economic evaluation of population screening for genital chlamydial infection (executive summary). *Health Technology Assessment* 2007;**11**(8):1-165.

Low N, McCarthy A, Macleod J, Salisbury C, Horner PJ, Roberts TE, et al. The chlamydia screening studies: rationale and design. *Sexually Transmitted Infections* 2004;**80**:342-8.

* Low N, McCarthy A, Roberts TE, Huengsberg M, Sanford E, Sterne JAC, et al. Partner notification of chlamydia infection in primary care: randomised controlled trial and analysis of resource use. *BMJ* 2006;**332**:14-9.



Montesinos 1990 {published data only}

Montesinos L, Frisch LE, Greene BF, Hamilton M. An analysis of and intervention in the sexual transmission of disease. *Journal of Applied Behavior Analysis* 1990;**23**(3):275-84.

Moyo 2002 {published data only}

Moyo W, Chirenje ZM, Mandel J, Schwarcz SK, Klausner J, Rutherford G, et al. Impact of a single session of counseling on partner referral for sexually transmitted disease treatment, Harare, Zimbabwe. *AIDS and Behavior* 2002;**6**(3):237-43.

Nuwaha 2001 {published data only}

Nuwaha F, Kambugu F, Nsubuga PSJ, Hojer B, Faxelid E. Efficacy of patient-delivered partner medication in the treatment of sexual partners in Uganda. *Sexually Transmitted Diseases* 2001;**28**:105-10.

Ostergaard 2003 {published data only}

Ostergaard L, Andersen B, Moller JK, Olesen F, Worm AM. Managing partners of people diagnosed with *Chlamydia trachomatis*: a comparison of two partner testing methods. *Sexually Transmitted Infections* 2003;**79**:358-62.

Peterman 1997 {published data only}

Peterman TA, Toomey KE, Dicker LW, Zaidi AA, Wroten JE, Carolina J. Partner notification for syphilis: a randomised controlled trial of three approaches. *Sexually Transmitted Diseases* 1997;**24**(9):511-18.

Potterat 1977 {published data only}

Potterat JJ, Rothenberg RR. The case-finding effectiveness of a self-referral system for gonorrhea: a preliminary report. *American Journal of Public Health* 1977;**67**(2):174-6.

Schillinger 2003 {published data only}

Magnus M, Schillinger JA, Fortenberry JD, Berman SM, Kissinger P. Partner age not associated with recurrent *Chlamydia trachomatis* infection, condom use, or partner treatment and referral among adolescent women. *Journal of Adolescent Health* 2006;**39**:396-403.

Schillinger JA, Kissinger P, Calvet H, Whittington WLH, Ransom RL, Sternberg MR, et al. Patient-delivered partner treatment with azithromycin to prevent repeated *Chlamydia trachomatis* infection among women. *Sexually Transmitted Diseases* 2003;**30**:49-56.

Schwebke 2010 {published data only}

Schwebke JR, Desmond RA. A randomized controlled trial of partner notification methods for prevention of trichomoniasis in women. *Sexually Transmitted Diseases* 2010;**37**(6):392-6. [DOI: 10.1097/OLQ.0b013e3181dd1691]

Solomon 1988 {published data only}

Solomon MZ, DeJong W. The impact of a clinic-based educational videotape on knowledge and treatment behavior of men with gonorrhea. *Sexually Transmitted Diseases* 1988;**15**:127-32.

Tomnay 2006 {published data only}

Tomnay JE, Pitts MK, Kuo TC, Fairley CK. Does the Internet assist clients to carry out contact tracing? A randomized controlled trial using web-based information. *International Journal of STD & AIDS* 2006;**17**(6):391.

Trent 2010 {published data only}

Trent M, Chung S, Burke M, Walker A, Ellen J. Results of a randomized controlled trial of a brief behavioral intervention for pelvic inflammatory disease in adolescents. *Journal of Pediatric and Adolescent Gynecology* 2010;**23**:96-101.

Wilson 2009 {published data only}

Hoffman S, Beckford Jarrett ST, Keivin EA, Wailace SA, Augenbraun M, Hogben M, et al. HIV and sexually transmitted infection risk behaviors and beliefs among black West Indian immigrants and US-born blacks. *American Journal of Public Health* 2008;**98**:2042-50.

Wilson TE, Hogben M, Malka ES, Liddon N, McCormack WM, Rubin SR, et al. A randomized controlled trial for reducing risks for sexually transmitted infections through enhanced patientbased partner notification. *American Journal of Public Health* 2009;**99**(S1):S104-10.

References to studies excluded from this review

Colvin 2006 {published data only}

Colvin M, Bachmann MO, Homan RK, Nsibande D, Nkwanyana NM, Connolly C, et al. Effectiveness and cost effectiveness of syndromic sexually transmitted infection packages in South African primary care: cluster randomised trial. *Sexually Transmitted Infections* 2006;**82**:290-4.

Garcia 2003 {published data only}

Garcia P, Hughes J, Carcamo C, Holmes KK. Training pharmacy workers in recognition, management, and prevention of STDs: district randomised control trial. *Bulletin of the World Health Organization* 2003;**81**(11):806-14.

Hogben 2005 {published data only}

Hogben M, Madico G. The Participant Agreement for Contact Tracing (PACT) study: enhancing partner notification services. clinicaltrials.gov/show/NCT00207493 (accessed 17 June 2013).

Marion 2009 {published data only}

Marion LN, Finnegan L, Campbell RT, Szalacha LA. The Well Woman Program: a community-based randomized trial to prevent sexually transmitted infections in low-income African American women. *Research in Nursing & Health* 2009;**32**:274-85.

Okonofua 2003 {published data only}

Okonofua FE, Coplan P, Collins S, Oronsaye F, Ogunsaki D, Ogonor JT, et al. Impact of an intervention to improve treatment-seeking behavior and prevent sexually transmitted diseases among Nigerian youths. *International Journal of Infectious Diseases* 2003;**7**:61-73.

Richens 2010 {*published data only*}

Richens J, Copas A, Sadiq ST, Kingori P, McCarthy O, Jones V, et al. A randomised controlled trial of computer-assisted



interviewing in sexual health clinics. *Sexually Transmitted Infections* 2010;**86**(4):310-37.

Shain 2004 {published data only}

Shain RN, Piper JM, Holden AEC, Champion JD, Perdue ST, Korte JE, et al. Prevention of gonorrhea and chlamydia through behavioral intervention results of a two-year controlled randomized trial in minority women. *Sexually Transmitted Diseases* 2004;**31**(7):401-8.

Sherman 2005 {published data only}

Sherman C, Hogben M. Computer-assisted STD partner notification. clinicaltrials.gov/ct2/show/NCT00207571 (accessed 17 June 2013).

Thurman 2008 {published data only}

Thurman AS, Holden AEC, Shain R, Perdue S, Piper J. Partner notification of sexually transmitted infections among pregnant women. *International Journal of STD & AIDS* 2008;**19**:309-15.

Wu 2009 {published data only}

Wu Z, Yen W. A randomized community intervention trial on reducing HIV infection among drug users attending methadone maintenance treatment (MMT) and preventing secondary transmission from HIV positive clients to their sexual partners in China. http://clinicaltrials.gov/show/NCT01108614 (Accessed 14 September 2013).

Young 2007 {published data only}

Young IT, de Kock A, Jones, Altini L, Ferguson T, Van der Wijgert J. A comparison of two methods of partner notification for sexually transmitted infections in South Africa: patient-delivered partner medication and patient-based partner referral. *International Journal of STD & AIDS* 2007;**18**:338-40.

References to studies awaiting assessment

Levy 1998 {published data only}

Levy JA, Fox SE. The Outreach-Assisted Model of partner notification with IDUs. *Public Health Reports* 1998;**113 Suppl 1**:160-9.

References to ongoing studies

Cassell 2010 {published data only}

Different Approaches to Partner Notification in Primary Care. Ongoing study 1 May 2010.

Falk 2012 {published data only}

Home-Sampling in Partner Notification of Chlamydia. Ongoing study November 2006.

Farquhar 2012 {published data only}

Assisted-Partner Notification Services. Ongoing study June 2012.

Golden 2012 {published data only}

Washington State Community Expedited Partner Treatment (EPT) Trial. Ongoing study July 2007.

Additional references

Alam 2010

Alam N, Chamot E, Vermund SH, Streatfield K, Kristensen S. Partner notification for sexually transmitted infections in developing countries: a systematic review. *BioMed Central Public Health* 2010;**10**(19):1-11. [DOI: 10.1186/1471-2458-10-19]

Arnold 2008

Arnold EM, Rice E, Flannery D, Rotherham-Borus MJ. HIV disclosure among adults living with HIV. *Aids Care* 2008;**20**(1):80-92.

CDC 2006

Centers for Disease Control and Prevention. Expedited partner therapy in the management of sexually transmitted diseases. US Department of Health and Human Services 2006.

Deeks 2011

Deeks JJ, Higgins JPT, Altman DG. Chapter 9: Analysing data and undertaking meta-analysis. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0. [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochranehandbook.org.

ECDC 2013

European Centre for Disease Prevention and Control. Public health benefits of partnernotification for sexually transmitted infections and HIV, 2013. http://optimisation.ecdc.europa.eu/ en/publications/publications/partner-notification-for-hiv-stijune-2013.pdf.. Stockholm: ECDC, (accessed 16 September 2013).

Fenton 1997

Fenton KA, Peterman TA. HIV partner notification: taking a new look. *AIDS* 1997;**11**:1535-46.

Gerbase 1998

Gerbase AC, Rowley JT, Heymann DHL, Berkley SFB, Piot P. Global prevalence and incidence estimate of selected curable STDs. *Sexually Transmitted Infections* 1998;**74 Suppl 1**:S12-6.

Glasier 2006

Glasier A, Gűlmezoglu AM, Schmid GP, Moreno CG, Van Look PFA. Sexual and reproductive health: a matter of life and death. *Lancet* 2006;**368**:1595. [DOI: 10.1016/ S0140-6736(06)69478-6)]

GRADE 2004 [Computer program]

Brozek J, Oxman A, Schunemann H. GRADEpro. Version 3.2 for Windows. 2008.

Higgins 2011

Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org.



Higgins 2011a

Higgins JPT, Altman DG. Chapter 8: Assessing risk of bias in included studies. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org.

Higgins 2011b

Higgins JPT, Deeks JJ, Altman DG. Chapter 16: Special topics in statistics. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org.

Kissinger 2003

Kissinger PJ, Niccolai LM, Magnus M. Partner notification for HIV and syphilis: effects on sexual behaviors and relationship stability. *Sexually Transmitted Diseases* 2003;**30**:75-82.

Low 2006a

Low N, Broutet N, Adu-Sarkodie Y, Barton P, Hassain M, Hawkes S. Global control of sexually transmitted infections. *Lancet* 2006;**368**(9551):2001-16.

Macke 1999

Macke BA, Maher JE. Partner notification in the United States: an evidence-based review. *American Journal of Preventive Medicine* 1999;**17**(3):230-42.

Mathews 2001

Mathews C, Coetzee N, Zwarenstein M, Lombard C, Guttmacher S, Oxman AD, et al. Strategies for partner notification for sexually transmitted diseases. *Cochrane Database of Systematic Reviews* 2001, Issue 4. [DOI: 10.1002/14651858.CD002843]

Niccolai 2007

Niccolai L, Livingston K, Teng F, Pettigrew M. Behavioral intentions in sexual partnerships following a diagnosis of *Chlamydia trachomatis*. *Preventive Medicine* 2007;**46**(2008):170-6.

Oxman 1994

Oxman AD, Scott EAF, Sellors JW, Clarke JH, Millson ME, Rasooly I, et al. Partner notification for sexually transmitted diseases: an overview of the evidence. *Canadian Journal of Public Health* 1994;**85**:127-32.

RevMan 2011 [Computer program]

The Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager (RevMan). Version 5.1. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2011.

Rosenthal 1995

Rosenthal SL, Baker JG, Biro FM. Secondary prevention of STD transmission during adolescence: partner notification. *Adolescent & Pediatric Gynecology* 1995;**8**:183-7.

Sahasrabuddhe 2002

Sahasrabuddhe VV, Gholap TA, Jethava YS, Joglekar NS, Brahme RG, Gaikwad BA, et al. Patient-led partner referral in Cochrane Database of Systematic Reviews

a district hospital based STD clinic. *Journal of Postgraduate Medicine* 2002;**48**(2):105-8.

Simbayi 2007

Simbayi L, Strebel A, Cloete A, Henda N, Mqeketo A, Kalichman SC. HIV status disclosure to sex partners and sexual risk behaviours among HIV-positive men and women in Cape Town, South Africa. *Sexually Transmitted Infections* 2007;**83**:29-34.

Toomey 1996

Toomey KE, Latif AS, Steen RC. Partner management. In: Dallabetta GA, Laga M, Lamptey PR editor(s). Control of Sexually Transmitted Diseases. A Handbook for the Design and Management of Programs. Arlington, VA: Family Health International, AIDS Control and Prevention Project, 1996:211-224.

Trelle 2007

Trelle S, Shang A, Nartey L, Cassell JA, Low N. Improved effectiveness of partner notification for patients with sexually transmitted infections: systematic review. *BMJ* 2007;**334**(7589):354-60. [10.1136/bmj.39079.460741.7C]

Trollope-Kumar 2006

Trollope-Kumar K, Guyatt G. Syndromic approach for treatment of STIs: time for a change. *Lancet* 2006;**367**:1380-1.

UNAIDS 1999

UNAIDS/World Health Organization. Sexually transmitted diseases: policies and principles for prevention and care, 1999. www.who.int/hiv/pub/sti/pubstiprevcare/en/index.html (accessed 17 June 2013).

UNAIDS 2010

UNAIDS. UNAIDS report on the global AIDS epidemic, 2010. www.unaids.org/globalreport/global_report.htm (accessed 17 June 2013).

WHO 2004

World Health Organization. Global burden of disease, 2004. www.who.org (accessed 17 June 2013).

WHO 2007

World Health Organization. Global strategy for the prevention and control of sexually transmitted infections: 2006-2015: breaking the chain of transmission. www.who.int/ reproductivehealth/publications/rtis/9789241563475/en/ (accessed 17 June 2013).

WHO 2012

World Health Organization. Global incidence and prevalence of selected curable sexually transmitted infections - 2008. www.who.int/reproductivehealth/publications/rtis/ stisestimates/en/ (accessed 17 June 2013).

World Bank 2012

World Bank. World Bank Data, 2012. http://data.worldbank.org/ income-level/MIC (accessed 14 September 2013).

* Indicates the major publication for the study

CHARACTERISTICS OF STUDIES

Characteristics of included studies [ordered by study ID]

Methods	Setting: general practic	ces in Aarhus, Denmark		
	<u>Enrolment</u> : women who tested positive for <i>Chlamydia trachomatis</i> were randomised - no specific date given			
	Follow-up: no follow-u	p was recorded		
Participants	96 women with C. track	<i>nomatis</i> were randomised		
	Inclusion criteria			
	 Women <i>C. trachomatis</i> positive 			
	Exclusion criteria			
	Not specified			
Interventions	Patient referral with h	nome sampling (n = 45)		
	Index patients were given a questionnaire about numbers of sexual partners. Index patients were given an envelope with a urine sample home test kit for each partner. The sample was to be sent by the part- ner to the study laboratory in the provided prepaid envelope			
	Patient referral with office sampling (n = 51)			
	Not stated if index patients completed questionnaire. Index patients were given an envelope contain- ing a contact slip and a request to partner to visit his doctor to request sampling by urethral swab. The doctor was to send a sample in a prepaid envelope to the study laboratory			
Outcomes	• Partners contacted (partners receiving a urine sample test kit or contact slip delivered by index pa-			
	tient) Partners tested (review of laboratory records) 			
	Partners testing positive for chlamydia (review of laboratory records)			
	Time until testing (clinical records			
Notes	It is not known how many of the partners who tested positive were treated			
	Ethical approval was obtained but no details given			
	Unclear whether consent was obtained			
Risk of bias				
Bias	Authors' judgement Support for judgement			
Random sequence genera- tion (selection bias)	High risk	Used date of birth "Ninety six women with <i>C trachomatis</i> infection seen in gen- eral practices in Aarhus County, Denmark, were randomly divided according to their date of birth into an intervention group (45 patients) and a control group (51 patients)"		
Allocation concealment (selection bias)	Unclear risk	Envelopes used for both groups but not stated if they appeared identical. Envelopes for the intervention group contained a 10 mL container that may be palpable		

Andersen 1998 (Continued)

Incomplete outcome data (attrition bias) All outcomes	Low risk	Test outcome for each partner of every index patient who was randomised was available
Selective reporting (re- porting bias)	Low risk	Outcomes reported in methods section were reported in results section. Trial registries were not searched
Other bias	Unclear risk	No comparison of baseline characteristics between study arms
Blinding of participants and personnel (perfor- mance bias) All outcomes	High risk	Participants and personnel were not blinded
Blinding of outcome as- sessment (detection bias) All outcomes	Unclear risk	Samples were sent to the laboratory in provided envelopes. It is not stated whether the laboratory personnel knew which procedure was allocated to which group. For urine sample a PCR was performed, for urethral swab en- zyme immune assay and if inconclusive a PCR to confirm

Methods	<u>Setting</u> : STI clinic at a single study site in Derbyshire, UK
	Enrolment: participants recruited by health adviser - recruitment period not given
	Follow-up: no follow-up of index patient
Participants	200 index patients with a diagnosis of genital chlamydia were randomised
	Inclusion criteria
	Diagnosis of genital chlamydiaFemale
	Exclusion criteria
	Not specified
Interventions	Patient referral with swab testing (clinic) (n = 100)
	Index patients were seen by a health adviser and details of contacts recorded. Contact slips coded wit the diagnosis were given to the index patient to give to the male partners, who were to bring this to the clinic for testing by urethral swab and treatment
	Patient referral with home sampling urine kit (n = 100)
	Index patients were seen by health advisers and details of contacts recorded. Contact slips coded with the diagnosis and a urine sampling kit, for the partner, with instructions, on collecting a first pass urine sample at home, were given to the index patient. Sampling kits included directions to clinic where the samples would be tested and partners would be treated if they tested positive
Outcomes	Primary outcome:
	Number of partners treated per index case (clinic records)
	Secondary outcomes:
	 Number of partners identified per index (recorded by health adviser) Number of traceable partners (contact slips)



Apoola 2009 (Continued)		treated within 28 days (clinic records) atients with at least 1 partner treated within 28 days per index case (%, clinic	
Notes	Ethical approval was obtained from the Derbyshire Research Ethics Committee When the study was originally designed, the PN rate at the study site was 0.3 contacts per index case of chlamydia and the study was powered to detect a difference of 0.2 contacts per index case. However, during the study period, the PN rates improved significantly making it more difficult to detect 0.2 con- tacts per case difference		
	Authors were contacted regarding blinding, consent and exact numbers reported. Authors reported that investigators were not blinded, oral consent was obtained and they gave the number of partners elicited		
Risk of bias			
Bias	Authors' judgement	Support for judgement	
Random sequence genera- tion (selection bias)	Low risk	Blocked randomisation based on random numbers	

tion (selection bias)	Low HSK	
Allocation concealment (selection bias)	Low risk	Allocated group concealed in sealed opaque numbered envelopes opened se- quentially
Incomplete outcome data (attrition bias) All outcomes	Low risk	Outcome for each partner of every index patient who was randomised was available
Selective reporting (re- porting bias)	Low risk	Protocol was available from trial registry. Only primary outcome was stated in protocol, no secondary outcomes were stated. Primary outcome in protocol same as in trial. Outcomes in method section of trial are the same outcomes reported
Other bias	Low risk	No other bias identified
Blinding of participants and personnel (perfor- mance bias) All outcomes	High risk	No blinding of participants or personnel (health adviser)
Blinding of outcome as- sessment (detection bias) All outcomes	High risk	Investigators were not blinded. Nucleic acid amplification tests with high specificity and sensitivity were used on urine specimens. Test used for urethral swab not specified. Details on blinding not given but obtained from authors di- rectly who advised that investigators were not blinded

Brown 2011	
Methods	Setting: 2 hospitals in Malawi, outpatient STI clinics
	Enrolment: participants enrolled from 2 October 2008 to 2 September 2009
	<u>Follow up</u> : 2 weeks after initial diagnosis follow-up was scheduled but authors did not report number of index patients returning for follow-up
Participants	240 newly diagnosed HIV-positive men (n = 100) and women (n = 140) from 2 Malawian hospitals were randomised



Trusted evidence. Informed decisions. Better health.

Brown 2011 (Continued)	Inclusion criteria		
	-		
	Exclusion criteria		
	Previously diagnose	ed with HIV	
Interventions	All index patients were provided with referral cards, all counselled on importance of safe sex behaviour, staged according to WHO, blood drawn for CD4 count		
	Simple patient referra	al (n = 77)	
	Index patients notify pa	artners themselves	
	Contract referral (n =	82)	
		ren 7 days to notify their partners after which a healthcare provider contacted reported to the clinic, for counselling and testing	
	Provider referral (n = 81)		
	Notification of partners within 48 hours by community outreach workers who were trained HIV testing counsellors or nurses		
Outcomes	Primary outcome		
	• Partner visit to the clinic during the 30 days after index enrolment (identified as partners if they pre- sented a partner referral card or their name was on the log of named partners)		
	Secondary outcomes		
	 Harms - abandonment (reported by index patient (2 weeks after enrolment) and partners (at clinic visit)) 		
	Partners testing pos	itive (clinic records)	
Notes	Authors did not report the number of index patients who came for 2-week follow-up. A tacted but data from Malawi on 2-week follow-up were not available		
	Ethics approval from Institutional Review Board at the University of North Carolina, Chapel Hill and the National Health Sciences Research Committee in Malawi		
	Power was set at 85% to detect an absolute difference of 25% between passive referral and the 2 ac- tive referral study arms - therefore need 80 index patients in each arm - respective arms had 77, 82, 81 therefore sufficient		
Risk of bias			
Bias	Authors' judgement	Support for judgement	
Random sequence genera- tion (selection bias)	Low risk	Randomised using a permuted block design with randomly allocated block sizes of 6, 9 and 12 stratified by sex and study site	
Allocation concealment (selection bias)	Low risk	Was concealed in a sealed envelope until the end of the enrolment visit (after all partner data and locator information had been collected)	

Brown 2011 (Continued)

Incomplete outcome data (attrition bias) All outcomes	Low risk	Clinic visit and test outcome data were available for each partner of every in- dex patient who was randomised Harms - number of index patients returning for 2-week follow-up was not giv- en, therefore, loss to follow-up cannot be calculated
Selective reporting (re- porting bias)	Low risk	Outcome for each partner of every index patient who was randomised was available. Protocol not available in 3 trial registries
Other bias	Low risk	No other bias identified
Blinding of participants and personnel (perfor- mance bias) All outcomes	High risk	Blinding of participants not possible
Blinding of outcome as- sessment (detection bias) All outcomes	Low risk	Personnel not blinded to which group index patient or partner belonged - part- ner identified if presented with a patient referral card or if their name was found on the log. Index patient returned 2 weeks after enrolment and were asked if partners were notified, how they were notified and what their behav- iour was like (harms). HIV antibody-negative or antibody-indeterminate spec- imens were tested for the presence of HIV RNA using the ultrasensitive Roche Amplicor Monitor HIV RNA assay. Primary outcome low risk

Cameron 2009

Methods	Setting: city centre FPC, GUM or a hospital termination of pregnancy in Edinburgh, UK
	Enrolment: participants enrolled from May 2004 to December 2006
	Follow-up: index patients agreed to submit a urine sample at 3-monthly intervals over 12 months
Participants	330 index patients who tested positive for Chlamydia trachomatis were randomised in Edinburgh
	Inclusion criteria
	Positive for Chlamydia trachomatis (uncomplicated)
	• Woman
	• 16-45 years old
	Index patient who have at least 1 sexual partner not been treated and able to be contacted
	Planning to be resident in Lothian (Edinburgh and surrounding area) for 12 months after recruitmen
	Able to give written consent
	Exclusion criteria
	Women with partners who had known or suspected allergies to azithromycin
	 Women with partners with significant illnesses (to address concern about safety of administering azithromycin)
Interventions	All index patients received written and verbal information about chlamydia and the importance of part
	ner treatment
	Simple patient referral (n = 110)
	Index patients provided details of partners of past 6 months. Index patients contacted partners them- selves and were given standard contact slips to be given to partners. Index patients also received in- formation leaflet about chlamydia with details of GUMs. After 4 weeks, index patient was contacted by study personnel to check if partners were successfully contacted



Cameron 2009 (Continued)

Trusted evidence. Informed decisions. Better health.

Random sequence genera-	Low risk	Computer-generated randomisation numbers in blocks, stratified for each re-	
Bias	Authors' judgement	Support for judgement	
Risk of bias			
Notes		ned from the Lothian Research Ethics Committee. Approval was also obtained h and Developmental Department and the Chief Pharmacist of the Responsible	
	Partner testing/treatment rates (laboratory and clinic databases were checked)		
	Secondary outcomes		
	asked to post a urine sa	atient (all index patients received a postal testing kit for themselves, and were ample to laboratory for re-testing at 3 months' post-treatment, further postal o index patient at 6, 9 and 12 months for repeat testing)	
Outcomes	Primary outcome		
	to give to each partner. the study with contact tails of GUMs they coul contained a 'tear-off' sl postage paid envelope	details of partners of past 6 months. Index patient was given 1 treatment pack . The treatment pack contained azithromycin 1 g, an information leaflet about details for study nurse, information about chlamydia, drug safety leaflet and de- d attend for testing/treatment if they preferred. The study information leaflet lip that the partner was asked to complete and return (in a pre-addressed) to confirm that they had taken the medication. There was also an 'objection' pleted and returned, if the partner objected to treatment in this way	
	EPT (n = 110)		
	Index patient provided details of partners of past 6 months. Index patient received 1 postal testing kit to deliver to each partner to collect a urine sample in. Postal testing kit consisted of a universal container for the urine sample, laboratory form with preferred contact method, an instruction leaflet and a postage paid pre-addressed envelope to send sample to laboratory. The kit also included a leaflet about chlamydia, information about the study and contact details of study nurse if further information required.		

Patient referral with postal testing urine kit (n = 110)

Random sequence genera- tion (selection bias)	Low risk	Computer-generated randomisation numbers in blocks, stratified for each re- cruitment site
Allocation concealment (selection bias)	Unclear risk	Sealed opaque envelopes, not clear if sequentially numbered
Incomplete outcome data (attrition bias) All outcomes	High risk	Primary outcome: 215/303 participants submitted at least 1 urine sample in the 12-month follow-up (70%) period - 13 woman informed the study person- nel that they did not want to take part anymore (reasons not given), other 75 loss to follow-up no details given. No details given on ITT
		For secondary outcomes the partners of every index patient who was ran- domised had an outcome
Selective reporting (re- porting bias)	Low risk	Outcomes reported in methods section were reported in results section. Pro- tocol not available in 3 trial registries
Other bias	Low risk	No other bias detected
Blinding of participants and personnel (perfor- mance bias) All outcomes	High risk	There was no blinding

Cameron 2009 (Continued)		
Blinding of outcome as- sessment (detection bias) All outcomes	Low risk	The research nurse and doctor were not blinded. They were involved in the baseline interview and did the 6-month follow-up call to record whether part- ners were notified - to validate treatment and testing rates the laboratory, FPC and GUM clinic databases were checked
		Primary outcome assessment was blinded. The postal testing kit samples of the participating woman were labelled with non-identifying subject study codes so the laboratory staff who reported the results did not know to which intervention the woman belonged
		The COBAS Amplicor CT test was used on urine samples
		Partner treatment/test rates: outcome assessment not blinded but validated by records

Methods	Setting: Dade County Department of Public Health, Georgia, US			
	Enrolment: once the study criteria were met, participants were enrolled - details not given			
	<u>Follow-up</u> : a test of cure was performed 3-5 days after treatment. A re-screening interview was per- formed 28 days after treatment			
Participants	1898 index patients with gonorrhoea were randomised, 1786 men and 112 women			
	Inclusion criteria			
	 Gonorrhoea positive by routine screening Diagnosis confirmed by positive smear (males only) or culture Treated according to US Public Health Service recommendations 			
	Exclusion criteria			
	 Identified as a contact Identified as a transient person Concomitant syphilis infection Infected with gonorrhoea during the previous 6 weeks 			
Interventions	Patient referral with pamphlet and health worker interview (n = 634)			
	Index patient received an informational pamphlet. A health worker used the pamphlet to explain asymptomatic partners, re-infection and complications. The patient was also encouraged to ask ques tions. Index patient was advised to refer his partners of the previous 30 days to the clinic. Index patien was offered 4 referral cards to be given to partners and where asked if he/she needed more or less. Th number of cards taken was recorded			
	Contract referral with interview from health worker (n = 632)			
	Index patient received a standard interview to offer medical information, allow rapport building and to elicit contact details of partners. Index patient was advised to refer his partners of the previous 30 days to the clinic and was told that if partners did not present at the health service after 3 days, then the health worker would contact them			
	Simple patient referral standard message (n = 632) Index patient only received a message to say that he/she had been diagnosed with gonorrhoea, that it was contracted sexually and that sexual partners of the previous 3-4 weeks needed examination and treatment. Index patient was offered 4 referral cards to be given to partners and where asked if he/she needed more. No contact details of partners recorded			

Cleveland undated (Continued)

Outcomes	 Partners presented to health service (clinic records, contact cards returned) Partners testing positive (laboratory records) Cost effectiveness (clinic records) 	
Notes	No details on ethics app	proval or consent from participants
Risk of bias		
Bias	Authors' judgement	Support for judgement
Random sequence genera- tion (selection bias)	Unclear risk	Patients were assigned through random selection to an intervention - no spe- cific details given
Allocation concealment (selection bias)	Unclear risk	No details given
Incomplete outcome data (attrition bias) All outcomes	Low risk	Test outcome available for all partners of every index patient who was ran- domised
Selective reporting (re- porting bias)	Low risk	Outcomes reported in methods section were reported in results section. Trial registries not searched
Other bias	Unclear risk	Baseline comparability not reported
Blinding of participants and personnel (perfor- mance bias) All outcomes	High risk	Participants and personnel not blinded
Blinding of outcome as- sessment (detection bias) All outcomes	Low risk	Clinic worker showed partner a referral card and asked them whether they have seen one of these, it was coded to what mode of interview was used orig- inally

Methods	<u>Setting</u> : Alexandra Health Centre and University Clinic, a community health clinic and principle provider of health care to the township of Alexandra, South Africa
	Enrolment: participants enrolled from 23 June to 12 September 1997
	Follow-up: no follow-up of index patient scheduled
Participants	1719 index patients, 811 men and 908 females, with any STI syndromically diagnosed were enrolled Inclusion criteria
	 Any outpatient aged 19-60 years Diagnosed with STI Not accompanied by partner Not enrolled in the study previously
	Exclusion criteriaNot specified



Trusted evidence. Informed decisions. Better health.

Ellison undated (Continued)			
Interventions	Simple patient referral (n = 433)		
	Index patient received be given to partner	a standard clinical consultation given by a nurse and received a contact card to	
	Patient referral and h	ealth education message (n = 431)	
	Index patient received education message giv	a standard clinical consultation, contact card and standardised verbal health ren by nurse	
	Patient referral and c	ounselling (n = 430)	
	Index patient received a standard clinical consultation, contact card and patient-centred counselling in a private room, conducted by trained lay-counsellors of same gender Patient referral with health education message and counselling (n = 425)		
	Index patient received a standard clinical consultation, contact card and both interventions (health ed- ucation by the nurse and counselling by lay-counsellors)		
Outcomes	 Partners presented for care with a notification slip at the health centre (clinical records) The time taken for notified partner to seek treatment at the health centre (clinical records) Contact cards issued and returned (recorded by nurse or lay-counsellor) 		
Notes	Ethical approval from Committee for Research on Human Subjects of the University of the Witwater- srand in Johannesburg		
Risk of bias			
Bias	Authors' judgement	Support for judgement	
Random sequence genera- tion (selection bias)	Unclear risk	Each consecutive patient received an anonymous consecutive number - no specific details on how these numbers were delivered	
Allocation concealment (selection bias)	High risk	Research nurse allocated alternate patients to 1 of 4 groups. Research nurse allocated alternate interventions to each consecutive patient according to a printed schedule (drawn up by project co-ordinator). Authors acknowledge	

		that research nurse could unwittingly or deliberately influence which patient received each intervention
Incomplete outcome data (attrition bias) All outcomes	Low risk	Low risk for main outcome, partner treated
Selective reporting (re- porting bias)	Low risk	Outcomes reported in methods section were reported in results section
Other bias	Low risk	No other risk of bias identified
Blinding of participants and personnel (perfor- mance bias) All outcomes	High risk	Personnel and participant not blinded
Blinding of outcome as- sessment (detection bias) All outcomes	Low risk	The research personnel at the pharmacy and casualty unit who collected the PN slips were masked to which intervention the participant received
All outcomes		Masked bivariate analysis, unmasked multivariate statistical analysis took

place



Faxelid 1996

Methods	<u>Setting</u> : urban health centre, Lusaka, Zambia		
	Enrolment: participants were enrolled from October 1992 to March 1993		
	Follow up: interview and follow-up 2 weeks after enrolment of index patient		
Participants	396 index patients (94 women, 302 men) with clinically or laboratory diagnosed STI were randomised		
	Inclusion criteria		
	Clinically or laboratory diagnosed STI		
	Exclusion		
	More than 1 diagnosis		
Interventions	Simple patient referral (n = 200)		
	Index patient received standard care, no contact cards were given		
	Choice between patient and provider referral with counselling (n = 196)		
	Index patient received individual counselling (10-20 minutes) from same-gender nurse (female) or clin ical officer (male). Index patient was given health education, information on importance of completing treatment, advise on abstinence and how to inform partners of previous 3 months of their exposure. Index patients received contact cards with the index patient's file number on to be given to partners. Names and address of partners taken. Provider referral offered if patient did not want to talk to partne		
Outcomes	 Partners elicited (names and addresses of the partners were recorded during initial interview) Partners notified (self report by index patient and contact cards filed at clinic) Partners treated (self report by index patient and contact cards filed at clinic) 		
	Harms - quarrels and partner refusal to go for treatment (self report by index patient)		
Notes	The policy at this health service was not to treat an index patient unless they bring a partner. This may affect the generalisability of the study to other settings		
	No details on ethical approval given		

Risk of bias

Bias	Authors' judgement	Support for judgement
Random sequence genera- tion (selection bias)	Low risk	Authors state that patients were randomised. Patients drew lots - in each box 4 cards with "intervention" and 4 cards with "non-intervention"
Allocation concealment (selection bias)	Unclear risk	No details given
Incomplete outcome data (attrition bias) All outcomes	Low risk	188/196 (96%) index patients in intervention group and 189/200 (94.5%) index patients in control group returned for follow-up
Selective reporting (re- porting bias)	Low risk	Same outcomes in methods as in results section. Trial registries were not searched
Other bias	Low risk	No other bias identified



axelid 1996 (Continued)			
Blinding of participants and personnel (perfor- mance bias) All outcomes	High risk	Participant and personnel not blinded	
Blinding of outcome as- sessment (detection bias) All outcomes	High risk	No blinding. Outcomes are subjective and therefore risk of detection bias	

Golden 2005				
Methods	<u>Setting</u> : participants were interviewed at the Public Health-Seattle and King County (PHSKC) STI clinic and one other PHSKC clinic in King County, Washington, US			
	<u>Enrolment</u> : patients who received a diagnosis of gonorrhoea or genital chlamydial infection between 29 September 1998 and 7 March 2003 were identified through laboratory reporting, case reports from healthcare providers and onsite case ascertainment were identified. Clinicians who made diagnosis were contacted to seek permission and potential participants were contacted for an interview			
	Follow-up: interview of index patient 10-18 weeks after treatment			
Participants	2751 index patients, 646 men and 2105 women, with either gonorrhoea or chlamydia or both infections were randomised			
	Inclusion criteria			
	• Women			
	Heterosexual men			
	Diagnosis of gonorrhoea or chlamydia			
	Exclusion criteria			
	 Patients who could not be contacted 14 days after treatment Patients with partners already treated 			
	Men who had sex with men			
	Non-English speaking people			
	Previously enrolled in the study			
	Homeless or institutionalised			
	Diagnosed in context of sexual assault			
	Less than 14 years of age			
	Unable to give informed consent			
	 Patients with partners who were jailed or institutionalised 			
	Patients with incomplete case reports			
	Patients enrolled in another PN study			
Interventions	Before randomisation, study personnel offered to contact partners who index patients were unable or unwilling to contact themselves			
	Simple patient referral (n = 1376)			
	Index patients were advised to tell their partners to seek care and that care was available at no cost at the STI clinic			
	EPT (n = 1375)			
	Index patients were offered medication to give to up to 3 partners, study staff members offered med- ication to partners they contacted themselves. Partner packages were distributed to patients or their			

ication to partners they contacted themselves. Partner packages were distributed to patients or their



Golden 2005 (Continued)	
	partners through commercial pharmacies, the PHSKC STI Clinic or direct mailing. Packets also con- tained condoms, information on medication, warning for adverse effects, telephone contact for study staff and brochure. Pharmacies were contacted 1 week after medication prescribed to determine whether it was picked up - if not picked up within 1 week patient received a telephone call reminder
Outcomes	Primary outcome
	 Persistent or recurrent gonorrhoea or chlamydial infection in index patient (urine testing at 10- to 18- week follow-up interview)
	Secondary outcome
	• Behavioural outcomes - PN, sexual interaction with untreated partner (self report by index patient)
Notes	Ethical approval obtained from the institutional review board of the University of Washington and Group Health Cooperative

Risk of bias

Bias	Authors' judgement	Support for judgement
Random sequence genera- tion (selection bias)	Unclear risk	At enrolment, 2751 patients reported having untreated partners they could contact and underwent randomisation. No details given
Allocation concealment (selection bias)	Unclear risk	No details given
Incomplete outcome data (attrition bias) All outcomes	High risk	Of 1375 assigned to the expedited treatment arm, 929 (68%) completed study. Of 1376 assigned to partner referral arm, 931 (68%) completed study. Only par- ticipants completing the study were included in the analysis
Selective reporting (re- porting bias)	Unclear risk	Persistent or recurrent gonorrhoea or chlamydia were the primary outcome stated in the methods section. Behavioural outcomes were reported in the outcome section. Adverse events were not reported and unclear whether no adverse events were reported or whether authors failed to record them. Proto- col was not available from 3 trial registries
Other bias	Unclear risk	Selective reporting of subgroups, this might have been a potential bias but there is insufficient information to assess whether an important risk of bias exist
Blinding of participants and personnel (perfor- mance bias) All outcomes	High risk	Participant and personnel not blinded
Blinding of outcome as- sessment (detection bias) All outcomes	Low risk	No blinding. Urine test use LCx (Abbott) ligase chain reaction used for primary outcome - objective. Self report on behavioural outcome - subjective

Katz 1988

Methods

<u>Setting:</u> public STI clinic, Indianapolis, Indiana, US <u>Enrolment</u>: male participants with NGU enrolled between July and December 1985 <u>Follow-up</u>: no follow-up stated for index patients

Katz 1988 (Continued)				
Participants	678 index patients with NGU were randomised to 1 of 3 interventions			
	Inclusion criteria			
	Heterosexual maleMicroscopically cont	firmed NGU		
	Exclusion criteria			
	No exclusion criteria	a specified		
Interventions	Simple patient referra	al with nurse (n = 217)		
	Nurse providing health	education and referral letters. No contact details of partners were requested		
	Patient referral with c	contact tracer (DIS) (n = 240)		
	Counselling with conta contact details elicited	ct tracer, partners names recorded but no referral letters given and no partner		
	Provider referral by co	ontact tracer (n = 221)		
	Interview with contact ters or visits	tracer, contact details of partners taken, attempt to contact by phone calls, let-		
Outcomes	 Cost-effectiveness (clinic records) Partners located (contact tracer telephoned partner, send letter via post or field visit) Partners treated (partners were matched to index patient by referral letter or by computerised database) 			
Notes	Ethical approval details not mentioned			
	The effectiveness of interventions 1 and 2 underestimated due to bias in outcome assessment: part- ners choosing to be treated at other health services were not counted for these groups			
Risk of bias				
Bias	Authors' judgement	Support for judgement		
Random sequence genera- tion (selection bias)	Unclear risk	Patients were randomised - no details given		
Allocation concealment (selection bias)	Unclear risk	Not stated		
Incomplete outcome data (attrition bias) All outcomes	Low risk	Outcome data for all partners of index patients randomised available		
Selective reporting (re- porting bias)	Low risk	Outcomes reported in methods section were reported in results section. Trial registries not searched		
Other bias	Low risk	No other bias identified		
Blinding of participants and personnel (perfor- mance bias) All outcomes	High risk	Participant and personnel not blinded		

Katz 1988 (Continued)

Blinding of outcome as-	High risk
sessment (detection bias)	
All outcomes	

No blinding. Partners were matched to the index patient by the referral letter or the clinic's computerised database in group 1 and 2. In group 3, the contact details were taken and partners were contacted by the provider

Methods	Setting: Public Health-Seattle & King County (PHSKC), Washington State, US			
	<u>Enrolment:</u> men who had sex with men who were given a diagnosis of gonorrhoea or chlamydia or both were enrolled at the time they were contacted to provide them with partner services between 1 July 2007 and 31 March 2009			
	Follow-up: index patients completed a follow-up interview approximately 2 weeks after enrolment			
Participants	75 men with gonorrhoea or chlamydia or both were randomised			
	Inclusion criteria			
	Men who had sex with men			
	Diagnosis of chlamydia or gonorrhoea or both			
	Exclusion criteria			
	Less than 18 years of age			
	Not able to speak English			
	If reported that all partners treated			
	 Not sexually active with another man in the 60 days prior to diagnosis 			
	 If case report was received more than 2 weeks after patient's treatment 			
	 If patient was diagnosed with HIV or syphilis in the 90 days before diagnosis with gonorrhoea o chlamydia 			
Interventions	Simple patient referral (n = 18)			
	Index patients notify partners themselves			
	Enhanced patient referral (n = 17)			
	Index patient used inSPOT (inspot.org), an Internet-based PN service. Index patients received a printed card with the site's Internet address or telephonic instructions if not present in STI clinic			
	EPT (n = 16)			
	Index patient received prepackaged medicine to give to 3 different partners. The package also included information on STI, importance of HIV testing, allergy warning to medication, condoms and a free vis- it to STI clinic. If not present in STI clinic, index patient was telephoned and informed to pick up similar packages at several local pharmacies			
	Combination of EPT and enhanced patient referral (n = 24)			
	Index patient received EPT and inSPOT			
Outcomes	Drimery outcome			
Outcomes	Primary outcome			
Outcomes	 Number of partners notified (data recorded by contract tracer from index patient or clinical records) Number of partners treated (data recorded by contract tracer from index patient or clinical records) 			
Outcomes	Number of partners notified (data recorded by contract tracer from index patient or clinical records)			



Kerani 2011 (Continued)

- Partner tested for HIV/syphilis (self report index patient)
- Adverse events (passive surveillance)

Notes

Ethical approval was received from University of Washington Institutional Review Board. Authors were contacted to clarify type of allocation concealment and whether protocol was available. Exact numbers of partners treated and notified per intervention arm were also requested and the type of adverse events. Authors failed to provide any of the above

Risk of bias

Bias	Authors' judgement	Support for judgement
Random sequence genera- tion (selection bias)	Unclear risk	A computer was used to randomly assign participants - no details given how this was performed
Allocation concealment (selection bias)	Unclear risk	Not stated
Incomplete outcome data (attrition bias) All outcomes	High risk	Only 53/75 (70.6%) participants completed the study. Only participants completing the study were included in the analysis
Selective reporting (re- porting bias)	Low risk	Primary outcomes reported in methods section were reported in results sec- tion. The protocol was not available from 3 trial registries
Other bias	Unclear risk	Baseline imbalances (race, type of STI) evident but insufficient to assess whether an important risk of bias existed. Early stopping due to low recruit- ment rate are not more likely to show extreme results and not considered to be prone to bias
Blinding of participants and personnel (perfor- mance bias) All outcomes	High risk	Participants and personnel not blinded
Blinding of outcome as- sessment (detection bias) All outcomes	High risk	Participants and personnel not blinded, outcomes subjective

Kissinger 2005	
Methods	Setting: public STI clinic in New Orleans, US
	Enrolment: participants enrolled from December 2001 to March 2004
	<u>Follow-up</u> : index patients were asked to return 4 weeks after the initial clinic visit (with a window of 2-8 weeks) for a follow-up interview and a urine specimen
Participants	977 index patients with diagnosis of urethritis were randomised
	Inclusion criteria
	• Male
	Diagnosis of urethritis
	Test positive for Chlamydia trachomatis or Neisseria gonorrhoeae
	16-44 years old
	At least 1 female sexual partner who did not accompany them to clinic

Kissinger 2005 (Continued)	Exclusion criteria		
	No criteria specified	1	
Interventions	Simple patient referral (n = 285)		
	Index patients were instructed to tell their partners that they needed to go to either the public STI clinic or the clinic of their choice for STI evaluation and treatment		
	Patient referral book	let enhanced (n = 348)	
	Index patients were given a wallet-sized booklet that contained 4 tear-out cards with information for the partner and treatment guidelines for professionals. If they had more than 4 partners they were given additional booklets		
	EPT (n = 344)		
	Index patients were given packages containing medication, written instructions about how to take medication, warning about adverse effects, 24-h nurse's pager number to call if any enquiries and asked to give package to each of their partners		
Outcomes	Primary outcome		
	• Proportion of partn	ers who received antibiotic treatment (self report by index patient)	
	Secondary outcome		
	 Recurrence of <i>C. trachomatis</i> and <i>N. gonorrhoeae</i> in index patient (urine sample or urethral swab collected at follow-up interview) 		
	 Behavioural outcome - partners treated (self report) Sexual outcome - unprotected sex before partner treatment, re-initiated sex with baseline partner, unprotected sex with any partner (self report) 		
Notes	Institutional review bo	ard approval was obtained from all participating institutions	
		d for statistical analysis (sample size calculations, power) details and exact num- hat sample size calculations were performed, but could not provide exact details	
Risk of bias			
Bias	Authors' judgement	Support for judgement	
Random sequence genera- tion (selection bias)	Low risk	Randomised by month in which they attended the clinic to 1 of 3 study arms. Randomisation of months was conducted using a blocked scheme of 3 to 6 units using Microsoft Excel software	
Allocation concealment (selection bias)	Unclear risk	No information given	
Incomplete outcome data (attrition bias) All outcomes	High risk	770/977 (79%) participants returned for follow-up interview but only 37.5% were retested. At follow-up interview, index patients were asked outcome questions for each partner. Outcome of interest was the response to the question: "Did baseline partner tell you that he or she took the medicine?"	
Selective reporting (re- porting bias)	Unclear risk	Same outcomes in the methods section (re-infection index patient and part- ners treated) were reported in the results section. With additional sexual out- comes (unprotected sex before partner treatment, re-initiated sex with base- line partner, unprotected sex with any partner) not stated in the methods sec- tion. Protocol not available from 3 trial registries	

Kissinger 2005 (Continued)		
Blinding of participants and personnel (perfor- mance bias) All outcomes	High risk	Participant and personnel not blinded
Blinding of outcome as- sessment (detection bias) All outcomes	High risk	The 1-month interview was performed either by computer-assisted self interview or study staff The outcomes were assessed by an interview either computer-assisted self interview (24.3%), telephonic (35.4%) or face-to-face (40.2%). The interviewer was not blinded. An in-person interview has the potential for information bias. No details given whether laboratory personnel were blinded but outcome measure was objective

Methods	Setting: the Orleans Women's Health Clinic in New Orleans, US			
	Enrolment: participants enrolled from December 2001 to August 2004			
	<u>Follow-up</u> : participants were asked to return 4 weeks after the initial visit (with a window of 2-8 weeks)			
Participants	463 index patients with a culture-confirmed diagnosis of Trichomonas vaginalis were randomised			
	Inclusion criteria			
	• Women			
	Culture-confirmed Trichomonas vaginalis diagnoses			
	Not in first trimester of pregnancy			
	No medical contraindication to take metronidazole or bringing metronidazole to partner			
	At least 1 male sexual partner in the last 60 days			
	Exclusion criteria			
	No criteria specified			
Interventions	Study staff counselled women in all study arms about <i>T. vaginalis</i> and the importance of partner treat- ment before randomisation			
	Simple patient referral (n = 155)			
	Index patients were instructed to tell their partners that they need to go to a clinic for STI evaluation and treatment			
	Booklet enhanced partner referral (n = 154)			
	Index patients were given a wallet-sized booklet containing tear-out cards with information for the partner and treatment guidelines for providers			
	EPT (n = 154)			
	Index patients were given packages for their partners, containing medicine, written instructions on how to take medicine, warnings about side effects and nurse's pager number for enquiries			
Outcomes	Re-infection rate of index patient (<i>T. vaginalis</i> culture)			
	 PN (self report index patient - interview) 			
	 Partner treatment (self report index patient) 			
	 Having unprotected sex before partner took medication (self report index patient) 			



Kissinger 2006 (Continued)	 Re-initiated sex with baseline partner (self report index patient) Unprotected sex with any partner (self report index patient) Cost effectiveness
Notes	Ethical approval from Institutional review board from Tulane University Health Sciences Center, CDC and the Louisiana Office of Public Health
	Author was contacted and provided details on consent (oral) and exact numbers of how many women returned for follow-up and testing. Details to what intervention arm the woman with re-infection be- longed to was also provided

Risk of bias

Bias	Authors' judgement	Support for judgement
Random sequence genera- tion (selection bias)	Low risk	Blocked scheme of 3 or 6 units using Microsoft Excel
Allocation concealment (selection bias)	Unclear risk	Previously prepared envelopes. Not specified if these were sealed or identical
Incomplete outcome data (attrition bias) All outcomes	Low risk	412/463 (89%) index patients were re-interviewed (some interviews done by telephone, and, therefore, no sample submitted) but only 376/463 (81%) index patients were retested and re-interviewed (data from author directly)
Selective reporting (re-	Unclear risk	Protocol available from trial registries
porting bias)		Outcomes stated in the protocol:
		Primary - Index patient report of partner taking medicine at 6-8 weeks
		Secondary - Index patient re-infection at 6-8 weeks, cost-effectiveness out- comes
		Outcome reported in actual study:
		Outcomes were not reported as primary and secondary. Additional sexual and behavioural outcomes reported Re-interview scheduled for 4 weeks after treatment (window of 2-8 weeks)
		Outcome in method section same as results section but differs from protocol
Other bias	Low risk	No other bias identified
Blinding of participants and personnel (perfor- mance bias) All outcomes	High risk	Participant and personnel not blinded
Blinding of outcome as-	High risk	No blinding
sessment (detection bias) All outcomes		Although some outcomes were subjective, the outcome of interest in the tele- phone interview was the response to this question: "Did partner tell you that he took the medicine?" Different methods were used for outcome assessment (i.e. telephone or computer-assisted self interview) that may have introduced detection bias, outcomes assessors were unlikely blinded
		Assessment of <i>T. vaginalis</i> culture result was not blinded but is an objective outcome



Landis 1992

Methods	Setting: 3 large county health departments in North Carolina, US		
	Enrolment: participants enrolled from 16 November 1988 to 30 June 1990		
	Follow up: no follow-up	of index patient reported	
Participants	74 HIV-infected men (51) and women (23) were randomised	
	Inclusion criteria		
	-	r their positive HIV result needle-sharing partners whose name they knew	
	Exclusion criteria		
	Only had partners thHad no needle-shari	sitive for HIV and had no new sexual or needle-sharing partners at they did not know name ng or sexual partners during the last year ctions of the 3 county health departments or whose partners did	
Interventions		r revealed diagnosis, provided standard counselling and explained study before nsent partner information was obtained	
	Simple patient referra	l (n = 35)	
	ceived coloured cards w	view with counsellor, discussing the process of notification. Index patient re- vith identification codes to be given to their partner. After 1 month, the counsel- any partner not yet contacted	
	Contract referral (n = 3	39)	
	coloured cards with ide	ose to notify some or all of their partners themselves. Index patient received ntification codes to be given to their partner. The remaining partners, as well as the health service after 2 weeks were contacted by the counsellors	
Outcomes	 PN (through location of partners by counsellors or partners arriving at the health department) Partner tested (clinic records) Partner tested positive (clinic records) 		
Notes	Ethical approval from the Ethics Committee on the protection of the rights of human subjects of the University of North Carolina School of Medicine		
Risk of bias			
Bias	Authors' judgement	Support for judgement	
Random sequence genera- tion (selection bias)	Unclear risk	Randomly assigned no specifications	
Allocation concealment (selection bias)	Unclear risk	No details given	
Incomplete outcome data (attrition bias) All outcomes	Low risk	Outcome for each partner of every index patient who was randomised was available	

Landis 1992 (Continued)

Selective reporting (re- porting bias)	Low risk	Outcomes reported in methods section were reported in results section. Trial registries were not searched
Other bias	Unclear risk	Baseline comparability unclear
Blinding of participants and personnel (perfor- mance bias) All outcomes	High risk	Participant and personnel not blinded
Blinding of outcome as- sessment (detection bias) All outcomes	Unclear risk	Coded cards were used but it is unclear if it was obvious to personnel whether they belonged to intervention or control group. Unclear who collected the cards and whether person had involvement in study findings

Methods	Setting: 27 general practices in Bristol and Birmingham, UK			
	Enrolment: participants enrolled from March 2001 to October 2002			
	Follow-up: 6 weeks after randomisation there was telephone follow-up of index patient			
Participants	140 index patients (92 woman and 48 men) with Chlamydia trachomatis were randomised			
	Inclusion criteria			
	Positive chlamydia test result received at their general practise			
	Exclusion criteria			
	No criteria specified			
Interventions	All participants received antibiotic treatment before randomisation			
	Simple patient referral with counselling from practice nurse (n = 72)			
	Nurses received 1 day of training about sexual history taking, management of chlamydia and PN. The index patient had a PN interview with the trained nurse. This interview involved taking of sexual history of the previous 6 months, patient referral using contact slips, abstinence and information about being screened for other STIs. Contact slips included details of the study GUM clinics and requested the treat- ment centre to return the slip to the study centre. Practise nurses did not follow-up the index patient			
	Referral to GUM clinic for partner referral from specialist health advisor (n = 68)			
	At randomisation, index patients were referred to GUM clinic. If clinic had not been contacted by tele- phone within 1 week by index patient, the health adviser made 2 attempts to contact them. PN was performed according to standardised protocols and contact slips were issued. The index patient was also offered a consultation for screening for other STIs. Follow-up was by telephone			
Outcomes	Primary outcome			
	 Proportion of index patient with at least 1 sexual partner treated (self report during telephone inter view with index patient, or a contact slip returned to the study centre or the partners was confirmed to have attended a local GUM clinic after the index patient received intervention) Number of partners treated per index patient 6 weeks after randomisation (clinic records) 			
	Secondary outcomes			

Copyright © 2013 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.



Low 2006b (Continued)	 Proportion of index patients with a positive chlamydia test result 6 weeks after randomisation (urine or vulval swab specimen available) Proportion of index patients with all sexual partners treated (clinic records)
Notes	Ethical approval South West multicentre research ethics committee
	Only 72 in nurse arm and 47 in clinic arm
	Study author was contacted to clarify clustering and replied. The author replied that the trial was indi- vidually randomised. However, there was often more than 1 participant from a single general practice (i.e. clustering), and it means that there are likely to be similarities between patients within the same practice

Risk of bias

Bias	Authors' judgement	Support for judgement
Random sequence genera- tion (selection bias)	Low risk	Computer-generated random numbers, permuted blocks, stratified by prac- tice
Allocation concealment (selection bias)	Low risk	Central computerised telephone system
Incomplete outcome data (attrition bias) All outcomes	Low risk	The PR (nurse) group had PN interview on same day. In PR (GUM) 21/68 (31%) did not attend PN interview. Authors used ITT analysis and assumed those lost to follow-up were not treated
Selective reporting (re- porting bias)	Unclear risk	Protocol available from trial registries. In protocol, adherence to advice to ab- stain from sexual intercourse until both partners completed treatment was stated as a secondary outcome but not reported in trial. Outcome "Cases with all partners treated" was not prespecified in study protocol but reported
Other bias	Low risk	No other bias identified
Blinding of participants and personnel (perfor- mance bias) All outcomes	High risk	Participant and personnel not blinded
Blinding of outcome as- sessment (detection bias) All outcomes	Low risk	A researcher not involved in the participant's PN did the follow-up

Montesinos 1990	
Methods	Setting: the health service of the Southern Illinois University, a large mid-western university, Illinois, US
	Enrolment: participants were enrolled from July 1984 to June 1985
	Follow-up: no follow-up recorded of index patients
Participants	65 index patients (48 men and 17 females) with gonorrhoea or NGU were randomised
	Inclusion criteria
	Diagnosis of gonorrhoea or NGUUniversity students



(selection bias)

Trusted evidence. Informed decisions. Better health.

Montesinos 1990 (Continued)			
		ers were university students rtner in the previous 6 weeks	
	Exclusion criteria		
	No criteria specified	I	
Interventions	Patient referral with	counselling (nurse of physician) (n = 27)	
	following a written pro tion on STI, obtained n	counselling from a physician (in his office) or a nurse (designated private area) otocol. Counsellor ascertained the reason for seeking treatment, gave informa- ames of sexual partners in previous 6 weeks, advise index patient to notify part- patient of confidentiality	
	Patient referral with	counselling, incentive and cards (n = 19)	
	following a written pro tion on STI, obtained n partner and assured in USD 3 charge, for index	counselling from a physician (in his office) or a nurse (designated private area) stocol. Counsellor ascertained the reason for seeking treatment, gave informa- names of sexual partners in previous 6 weeks, advised index patient to notify dex patient of confidentiality. In addition, counsellor advised index patient that a patient and partner, will be waived if partner successfully referred. A card with d advise to seek treatment given to index patient to give to partner	
	Patient referral with counselling, cards, follow-up call after 5 days, no incentive (n = 19) Index patient received counselling from a physician (in his office) or a nurse (designated private area) following a written protocol. Counsellor ascertained the reason for seeking treatment, gave informa- tion on STI, obtained names of sexual partners in previous 6 weeks, advised index patient to notify partner and assured index patient of confidentiality. A card naming specific STI and advise to seek treatment given to index patient to give to partner. Index patient did not receive any financial incen- tive. Counsellor told index patient that if partner failed to arrive at health service within 5 working days the index patient would be contacted by telephone		
Outcomes	Partners elicited (se	elf report by index patient)	
	 Partners presenting health service) 	g at health service (a list of partners identified in counselling session was kept at	
	Mean cost per partner traced (clinic records)		
Notes	Ethical approval from Southern Illinois University - Committee for Research involving Human Subjects		
	17 females vs. 48 males. 2 different time periods. Group 1 was interviewed from July and groups 2 and 3 received intervention in January to June 1985 - possibility that he role on who is available during that time		
Risk of bias			
Bias	Authors' judgement	Support for judgement	
Random sequence genera- tion (selection bias)	Unclear risk	No details given	
Allocation concealment	High risk	The protocol was colour coded. The counsellor removed the next protocol for	

Incomplete outcome data (attrition bias) All outcomes	Low risk	Outcome data for all partners of index patients available
Selective reporting (re- porting bias)	Low risk	Outcomes reported in methods section were reported in results section. Trial registries not searched

the next patient from a randomly ordered set



Montesinos 1990 (Continued)

Other bias	Low risk	No other bias identified
Blinding of participants and personnel (perfor- mance bias) All outcomes	High risk	Participant and personnel not blinded
Blinding of outcome as- sessment (detection bias) All outcomes	High risk	No blinding. Names of partners were recorded on the counselling protocols. A list for these identified partners were maintained for up to 1 month after index patient was seen to see if partners returned

Moyo 2002

loyo 2002			
Methods	<u>Setting</u> : 2 large public STI clinics in Harare, Zimbabwe		
	Enrolment: index patients were consecutively recruited from July to September 2000.		
	Follow-up: index patient was interviewed for 15 minutes at the routine 1-week clinic follow-up visit		
Participants	272 index patients (135 men and 137 women) with a syndromically diagnosed bacterial STI were ran- domised		
	Inclusion criteria		
	 Over the age of 18 years Syndromically diagnosed bacterial STI seen on their first visit for treatment 		
	Exclusion criteria		
	No criteria specified		
Interventions	All index patients completed a standard STI treatment and counselling consultation, a clinic nurse or doctor explained the objectives and procedure. The same gender counsellor explained the basic pro- cedure to all, then conducted the 30-minute baseline interview with each patient. All participants were given reminder cards to visit the study counsellor for a 15-minute follow-up interview when returning for routine 1-week clinic follow-up visit		
	Patient referral with additional counselling session (n = 131)		
	Counsellor conducted an additional individualised session with the index patient lasting approximate ly 30 minutes. Session included identification of likely sources and spread of STI, approaches to notifi- cation, role playing, motivating factors, barriers and domestic violence. Session also include health ed ucation. Index patients were also allocated coupons to give to partners for free treatment at the study clinic		
	Simple patient referral (n = 141)		
	Counsellor did a 30-minute baseline interview with index patient. No coupons were given for partners free treatment		
Outcomes	Primary outcome		
	 Notification and referral of partners for treatment (as reported by index patient at follow-up intervie 1 week after treatment) 		
	Secondary outcome		
	 Adverse events - physical and verbal abuse (as reported by index patient at follow-up interview 1 wee after treatment) 		

Moyo 2002 (Continued)

ochrane

.ibrarv

Notes

Ethics approved by the Committee on Human Research at the University of California, San Francisco, and by the Medical Research Council of Zimbabwe

Authors were contacted without success regarding discrepancies in numbers reported and distribution of harms in intervention arms

Risk of bias

Bias	Authors' judgement	Support for judgement
Random sequence genera- tion (selection bias)	Unclear risk	Randomisation process not described
Allocation concealment (selection bias)	Unclear risk	The nurse or doctor selected a sealed, opaque envelope from a box that ran- domly assigned the patient to intervention or control. Envelopes were con- structed prior to any recruitment. An equal number of the allocation slips with the words 'intervention' or 'control' were placed in the box and manual- ly mixed. All participants brought the envelope to the study counsellor, where- upon it was opened in the presence of both study counsellor and patient. Un- clear whether these envelopes were sequentially numbered
Incomplete outcome data (attrition bias) All outcomes	High risk	Self reported notification and referral of partners to treatment were assessed at follow-up interview. 137/272 (50%) participants completed the follow-up in- terview. ITT analyses were performed. However, the high loss to follow-up is potentially a source of bias
Selective reporting (re- porting bias)	Low risk	Outcomes reported in methods section were reported in results section. No protocol available from trial registries
Other bias	Low risk	No other bias identified
		The randomisation scheme produced approximately equivalent numbers in the intervention and control groups for men and women. Of note, people ran- domly allocated to the intervention arm were slightly older, more likely to be working in the formal economy, and more likely to be currently married or co- habiting. These findings may indicate a problem with randomisation
		It may also be due to the small sample size that baseline differences occurred by chance
Blinding of participants and personnel (perfor- mance bias) All outcomes	High risk	Blinding was not possible
Blinding of outcome as-	High risk	No blinding. Index patient reports about PN can introduce bias
sessment (detection bias) All outcomes		The same study counsellor who did the counselling session did the 1-week fol- low-up interview - this might have introduced detection bias

Nuwaha 2001

 Methods
 Setting: Mulago Hospital STI clinic in Kampala, Uganda treats patients free of charge. Clinic is the main STI reference centre, mainly serves as a walk-in primary care STI treatment centre

 Enrolment:
 consecutive patients with STI symptoms enrolled between November 1999 and January 2000



luwaha 2001 (Continued)	Follow-up: index patier	nts were asked to return to the clinic within 2 weeks		
Participants	383 index patients (196 men, 187 women) with STI symptoms were randomised			
	Inclusion criteria:			
	Sexual intercourse iFemale patients wit	ented for the first time n previous 3 months or for the period with STI symptoms h vaginal discharge were included, if on examination with speculum cervical di or if they had vaginal discharge associated with genital ulcer or with <i>Trichomonc</i>		
	Exclusion criteria			
		d treatment Ir to be reached within 1 month re diagnosed with only candida infections or bacterial vaginosis		
Interventions		given information, education and communication for 5-10 minutes. Trained re- rmed interviews using a pre-tested questionnaire		
	Simple patient referra	al (n = 191)		
	Index patients were given contact slips to take to sexual partners. Index patient asked to return 2 weeks later			
	EPT (n = 192)			
	Index patients were given medications to take to sexual partners. Index patient were asked to return af- ter 2 weeks. Index patients were request to return medication if their partners refused them or if they could not trace the partner			
Outcomes	 Partners (regular and casual) treated (contact slips returned, all patients attending the clinic were asked if they were referred, index patients records were reviewed to link partners to index patients, at 2-week follow-up index patient was asked if partners were treated) 			
	Partners (regular and casual) elicited (self report by index patient)			
	 Index patient 2-week post-treatment return (clinic records) Adverse reactions such as quarrelling, fighting and refusal of sexual intercourse (index patient report 			
	at 2-week interview)			
	Side effects of drugs (index patient report at 2-week interview)			
Notes	Ethics approval by Mbarara University, the Faculty of Medicine Research Committee, the Uganda AIDS Committee, the Uganda National Council for Science and Technology, and the Ethics Research Com- mittee at Karolinska Institute (Stockholm, Sweden). Permission to conduct the study was obtained from the Mulago Hospital administration			
Risk of bias				
Bias	Authors' judgement	Support for judgement		
Random sequence genera- tion (selection bias)	Low risk	Computer-generated random number between 0 and 999; even numbers to EPT group, and odd numbers were assigned to the patient-based partner re- ferral group. Stratified randomisation according to the sex of the index patien was used		
Allocation concealment (selection bias)	Unclear risk	No detail of allocation concealment given		
Incomplete outcome data (attrition bias)	Low risk	ITT analysis was used. In EPT, 187/192 (97%) index patients returned after 2 weeks and in simple patient referral 117/191 (61%) returned. On return, par-		



Nuwaha 2001 (Continued) All outcomes		ticipants reported on partner treatment and partner reaction. Attrition bias in the simple patient referral arm
Selective reporting (re- porting bias)	Low risk	Outcomes reported in methods section were reported in results section. Pro- tocol not available from 3 trial registries
Other bias	Unclear risk	Partners of participants in simple patient referral group could have been treat- ed elsewhere leading to misclassification bias
Blinding of participants and personnel (perfor- mance bias) All outcomes	High risk	Blinding not possible
Blinding of outcome as- sessment (detection bias) All outcomes	High risk	Partners in simple patient referral group returned coded slips. Clinic workers checked clinic records for all patients who said they had been referred by a partner to attempt to link them to an index patient. In addition, they collected reports from index patients on partner referral (not analysed in this review) In the EPT participants, the outcome was index patient reports whether part-
		ner took medication. This can introduce detection bias

Ostergaard 2003 Methods	Setting: 4 counties in Denmark
	<u>Enrolment</u> : participants enrolled between February 1999 to March 2000
	Follow up: no follow-up of index patient reported
Participants	562 index patients (414 women and 148 men) with a positive chlamydia swab were randomised
	Inclusion criteria
	Positive chlamydia swab
	Completed questionnaire
	Exclusion criteria
	No criteria specified
Interventions	Specimen collection package was posted to the index patient's home address. There were 5 specimen collection kits in this package. The index patient was instructed to give collection kits to his/her sexual partners of the previous 12 months. The collection kits were identical. For male partners the kit contained 10 mL tube to collect first void urine sample. The female partners received a vaginal pipette con taining 5 mL sterile normal saline to be inserted into the vagina, flushed and aspirated
	Patient referral with home sampling (n = 304)
	Samples collected by the partners at home had to be posted directly to the diagnostic laboratory in postage paid and pre-addressed envelopes
	Patient referral with office sampling (n = 258)
	Partners had to bring specimen collection kit into the office of a healthcare provider to obtain sample.

Partners also brought a letter with them, explaining the study and the importance that the healthcare provider used the provided specimen collection kit to collect sample. The healthcare provider posted the sample to the laboratory

Ostergaard 2003 (Continued)				
Outcomes	Primary outcome			
	• Proportion of index patients with at least 1 partner tested for <i>Chlamydia trachomatis</i> (laboratory results)			
	Secondary outcomes			
	• Proportion of index patients with at least 1 partner positive for C. trachomatis (laboratory results)			
Notes	Ethical approval by Danish ethics committee system			
	Implied consent			

Risk of bias

Bias	Authors' judgement	Support for judgement
Random sequence genera- tion (selection bias)	Unclear risk	The index patient was randomised based on a positive swab sample - no de- tails given
Allocation concealment (selection bias)	Unclear risk	No details on allocation concealment given
Incomplete outcome data (attrition bias) All outcomes	Low risk	Outcome data for all partners of index patients available
Selective reporting (re- porting bias)	Low risk	Outcomes in method same as in results. Protocol not available from 3 trial reg- istries
Other bias	Low risk	No other bias identified
Blinding of participants and personnel (perfor- mance bias) All outcomes	Low risk	Specimen collection kits for the 2 study groups were identical and the index patient was blinded to content of the specimen collection kit. However there is no guarantee that the index patient did not open the package before forward- ing to partner
		The healthcare provider, who did the office sampling, was not part of the study. They only collected the samples and posted it to the study centre
Blinding of outcome as- sessment (detection bias) All outcomes	Unclear risk	It is not mentioned whether laboratory personnel were blinded. However, the chlamydia test is an objective outcome measure

Peterman 1997

Methods	Setting: public health services in Broward County, Florida; Tampa, Florida; Patterson, New Jersey, US	
	Enrolment: participants were enrolled from December 1990 to March 1993	
	Follow up: no follow-up recorded of index patients	
Participants	1966 index patients with syphilis were randomised, 1042 male and 924 female	
	Inclusion criteria	
	Primary, secondary or early latent syphilis infection	



Peterman 1997 (Continued)	Exclusion criteria		
	Criteria not specifie	d	
Interventions	After syphilis diagnosis	all index patients were interviewed by DIS to identify sexual partners	
	Contract referral (n = 586) Index patient to notify partners within 2 days, or a DIS would notify them on the third day		
	Provider referral (n = 742)		
	Partner notified immediately by DIS and referral of partner for testing		
	Provider referral and field test (n = 638)		
	Partner notified immediately by DIS who could draw blood for testing in the field, if it seemed unlikely for partner to come in for testing		
Outcomes	 Numbers of partners coming for syphilis testing, treatment or prevention (name and locating information of all partners were recorded in interview before randomisation, record searching) Cost per partner treated (clinic records) 		
Notes	Details on ethical approval not given		
Risk of bias			
Bias	Authors' judgement	Support for judgement	
Random sequence genera- tion (selection bias)	Unclear risk	Individual index patients were randomly assigned. Every day the study co-or- dinator at each site generated a list of assignments by using a random num- ber table. The total number of patients in each arm differed significantly from 742, 638 and 586, this raises suspicion about whether randomisation was per- formed appropriately	
Allocation concealment (selection bias)	High risk	The assignment was known to the interviewer before contact with the patient and the method was sequentially adapted by the interviewer	
Incomplete outcome data (attrition bias) All outcomes	Low risk	Outcome data were available for all partners of index patients	
Selective reporting (re- porting bias)	Low risk	Same outcomes in methods section compared to results section. Trial reg- istries not searched	
Other bias	High risk	Deviation from protocol was reported by authors	
		Some contamination was reported by the authors and this would have re- duced the difference between the 3 groups	
Blinding of participants and personnel (perfor- mance bias) All outcomes	High risk	Blinding was not possible	
Blinding of outcome as- sessment (detection bias)	High risk	The DIS was not blinded, DIS did the interview before randomisation and also the intervention. No blinding of data entry personnel or data analyst	
All outcomes		No control in place to ensure 2-day waiting period	



Potterat 1977

otterat 1977			
Methods	Setting: El Paso, City-county health department, Colorado, US		
	Enrolment: participants were enrolled from February to September 1975		
	Follow up: index patier	nt in patient referral group was re-interviewed 7-10 days after enrolment	
Participants	187 index patients with gonorrhoea were randomised		
	Inclusion criteria		
	Heterosexual males with gonorrhoea		
	Exclusion criteria		
	Not specified		
Interventions	Simple patient referra	al (n = 93)	
	Study personnel had a short interview (3-5 minutes) with index patient where the disease and impor- tance of PN were discussed. Index patient received contact cards to be given to partners. Study person nel did not elicit any partner details		
	Contract referral (n = 94)		
	Study personnel had a longer interview (15-20 minutes) with index patient and partner contact details were elicited. Index patient was informed that health services personnel would contact partners if they did not present at the health service within 7-10 days		
Outcomes	 Partners testing positive for gonorrhoea (contact cards and self report by partner) Cost (clinic records) 		
Notes	Ethical approval details not given		
Risk of bias			
Bias	Authors' judgement	Support for judgement	
Random sequence genera- tion (selection bias)	High risk	Alternately assigned "During the period February-September 1975, we as- signed all heterosexual male patients with gonorrhea diagnosed at the El Pa- so City-County Health Department (Colorado) alternately to a Study or Contro group"	
Allocation concealment (selection bias)	Unclear risk	No information given	
Incomplete outcome data (attrition bias) All outcomes	Low risk	Outcome data for partners of all index patients available. In simple patient referral group, a second interview was performed to record contact details (91/93 index patients re-interviewed). These details were used to contact part ners to find out their subsequent clinical course and fate of contact slips	
Selective reporting (re- porting bias)	Low risk	Outcomes reported in methods section were reported in results section. Trial registries were not searched	
Other bias	Unclear risk	Baseline comparability unclear	
Blinding of participants and personnel (perfor- mance bias) All outcomes	High risk	Blinding not possible	

High risk

Potterat 1977 (Continued)

Blinding of outcome as-	
sessment (detection bias)	
All outcomes	

The personnel knew to what group the participant belonged and, due to longer time spent with control group, this could have introduced detection bias. No specifics on test used. 9 contacts in the study group were also identified through field effort although field effort was not part of the original intervention in the study group - detection bias

Methods	<u>Setting</u> : FPCs (Southern California (SC), Seattle (S) and New Orleans (NO)), adolescent clinics (Birm- ingham (B), Indianapolis (I), Northern California (NC) and S), primary care clinics (I) and STD clinics (B I, NO, SC, NC, S) or emergency and other hospital departments (B), US		
	Enrolment: participants enrolled between September 1996 and June 2000		
	<u>Follow-up</u> : index patients returned for a follow-up at 1 and 3 months after enrolment for an interview and urine test		
Participants	1889 index patients with laboratory confirmed Chlamydia trachomatis were randomised		
	Inclusion criteria		
	• Women		
	Aged 14-34 years		
	Laboratory-confirmed uncomplicated urogenital chlamydial infection		
	Exclusion criteria		
	Already been treated		
	No intercourse in 60 days before enrolment		
	Male partners already been treated for chlamydia		
	Pregnant		
	HIV infected		
	 Co-infected with <i>Neisseria gonorrhoeae</i>, <i>Treponema pallidum</i> or <i>Trichomonas vaginalis</i> History of adverse reaction to macrolide antibiotics 		
Interventions	At enrolment all women were treated for chlamydia infection and were advised to abstain from inter-		
interventions	course until 7 days after partner's treatment		
	Simple patient referral (n = 943)		
	Index patients were instructed to tell their partners that they had been exposed to chlamydial infectior and to recommend that they seek treatment. They were given an information sheet for each partner and list of clinics where the partner could obtain free care		
	EPT (n = 946)		
	Index patients were provided with up to 4 doses of medication for their partners, instructed to tell thei partners of their exposure, and to give a package with the medication, instructions, warnings, fact sheet on chlamydia and telephone number to contact if partners had any questions. Index patients were advised to abstain from intercourse until 7 days after each partner's treatment		
Outcomes	• Re-infection with <i>C. trachomatis</i> in index patient measured by DNA in urine collected 21 days or m after treatment for initial infection (laboratory results)		
Notes	Ethical approval by investigational review boards at each of participating institutions and the CDC		
	Limited power as only 1454 participants completed study to 1 follow-up. With 0.05 significance, this study only had 62% power to detect a 30% reduction in infection. For a 20% difference in infection rate		



Schillinger 2003 (Continued)

(as was observed in this study), there was only 37% power to detect a significant difference between 2 interventions. In order to have 80% power, need 2035 women in each arm

Risk of bias

Bias	Authors' judgement	Support for judgement
Random sequence genera- tion (selection bias)	Unclear risk	Study allocations were made with use of "randomly sized blocks"
Allocation concealment (selection bias)	Low risk	Study arm assignments were printed on cards and placed in sequentially num- bered, opaque envelopes and sealed at the study co-ordination centre
Incomplete outcome data (attrition bias) All outcomes	Low risk	1454/1787 (81%) participants came for at least 1 follow-up visit and gave a urine sample for the outcome measure. There was a similar proportion in each study arm. ITT was not followed because index patients who did not return for follow-up or for whom no urine test result existed were excluded
Selective reporting (re- porting bias)	Low risk	Outcomes reported in methods section were reported in results section. Pro- tocol not available from 3 trial registries
Other bias	Low risk	No other bias identified
Blinding of participants and personnel (perfor- mance bias) All outcomes	High risk	Blinding was not possible
Blinding of outcome as- sessment (detection bias) All outcomes	Low risk	1 month after treatment, women were interviewed again and urine tested with LCx/PCR. Assessor knew assignment but outcome measure was objective

Methods	Setting: Jefferson County Department of Health in Birmingham, AL, US
	Enrolment: participants were enrolled between February 2003 and June 2008
	<u>Follow-up</u> : index patients were asked to return to clinic 5-9 days after enrolment for a "test of cure". Follow-up visits to detect repeat infections were performed at the clinic, 1 and 3 months after "test-of- cure". At these visits an examination was performed, including culture for <i>Trichomonas vaginalis</i> and a follow-up questionnaire completed
Participants	484 index patients with Trichomonas vaginalis were randomised
	Inclusion criteria
	• Women
	Aged 19 years and older
	Culture or wet prep positive for trichomonas
	Exclusion criteria
	Infection with other STI pathogens
	Pregnancy
	Currently breast feeding
	• Recent (8 hours) ingestion of alcoholic beverages or intention to do so in next 24 hours

Copyright @ 2013 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.



Schwebke 2010 (Continued)	 Allergy to metronidazole Presence of sexual partner in the clinic during enrolment History of referral by a partner already treated for trichomoniasis Report of more than 4 sexual partners in the preceding 30 days 					
Interventions	Simple patient referral (n = 160) Simple patient referral: usual care - index patient were given a standard message on the importance of PN and asked to tell partners to come for treatment. If the partner did present to the clinic they were offered participation in the male substudy Contract referral (n = 162) Index patients were interviewed by a DIS who took the details of partners of previous 60 days, then entered in to a verbal contract with DIS to refer their partners to the clinic for treatment, partners were telephoned within 1-2 days of index patient's enrolment. The partners were informed that they will be eligible for remuneration if participate in male study. If treatment of partner could not be verified within 2 working days the DIS attempted to notify partner by telephone or field visits EPT (n = 162)					
				contraindications of th	ven medication for up to 4 partners. The index patients were also given a list of ne medication and a 24-hour phone number for partners if they had any ques- ation, indications for therapy and further evaluation of symptoms	
				Outcomes	 Re-infection rates 1 and 3 months post-treatment (In clinic follow-up visit where examination and culture were performed) 	
				Notes	Ethical approval by the Institutional Review Boards of the University of Alabama and the Jefferson County Department of Health	
				Risk of bias		
	Bias	Authors' judgement	Support for judgement			
Random sequence genera- tion (selection bias)	Unclear risk	No details given				
Allocation concealment (selection bias)	Unclear risk	No details given				
Incomplete outcome data (attrition bias) All outcomes	High risk	There were data available on 296/484 (61%) index patients at 1-month fol- low-up and 194/484 (40%) participants completed the study				
Selective reporting (re- porting bias)	Low risk	Protocol available from trial registries. In the protocol, the only outcome was the recurrence of trichomonas in index patient at 6 weeks. In the trial, the authors reported re-infection in index patient at 1 and 3 months post treatment				
Other bias	Low risk	Study authors planned to recruit 330 participants in each arm but after 4 years were only able to recruit about 50%. Early stopping due to lower than expected recruitment rate are not considered to be prone to bias				
Blinding of participants and personnel (perfor- mance bias) All outcomes	High risk	Participant and personnel not blinded				

All outcomes



Schwebke 2010 (Continued)

Blinding of outcome as-	Unclear risk
sessment (detection bias)	
All outcomes	

No blinding. The primary outcome was repeat infection in index patient - an objective outcome measure (positive culture or presence of motile trichomonads microscopically)

Methods	Setting: Eastern Clinic	of the Baltimore City Health Department, MD, US	
	Enrolment: index patients were enrolled between May 1984 and January 1985		
		nts returned to clinic 14 days after treatment	
	<u>Follow up</u> . Index patier	its returned to clinic 14 days after treatment	
Participants	902 index patients, wit	h a positive Gram stain for gonorrhoea, were randomised	
	Inclusion criteria		
	• Male with positive G	Fram stain for gonococci	
	Exclusion criteria		
	Not criteria specifie	d	
Interventions	All index patients received a DIS contact tracing interview and treatment from a nurse. At the time of test of cure examination an 18-item, oral test to assess the videotape's impact on knowledge and be- liefs of the index patient was performed		
	Patient referral and videotape (n = 456)		
	Index patient was interviewed by DIS to get the contact details of their partners, and was given contact cards and was invited to view a video-tape promoting PN		
	Simple patient referral (n = 446)		
	Index patient was interviewed by DIS to get the contact details of their partners, and was given contact cards		
Outcomes	Number of index patients returning for a "test of cure" evaluation (clinic records)		
	Number of partners presented for care (contact cards returned)		
	 Knowledge of the index patient (18-item, true-false, oral test) Time taken until partner presented at clinic (clinical records) 		
	• Time taken until pa	rther presented at clinic (clinical records)	
Notes	Ethical approval detail	s not given	
Risk of bias			
Bias	Authors' judgement	Support for judgement	
Random sequence genera- tion (selection bias)	Unclear risk	No details were given except that the research assistant assigned patients at random to group 1 (watching the videotape) and group 2 (not watching the videotape)	
Allocation concealment (selection bias)	Unclear risk	No mention of allocation concealment	
Incomplete outcome data (attrition bias) All outcomes	Low risk	Outcome data available for all partners of index patients	

Solomon 1988 (Continued)

Selective reporting (re- porting bias)	Low risk	Outcomes reported in methods section were reported in results section. Trial registries not searched
Other bias	Unclear risk	Baseline comparability unclear
Blinding of participants and personnel (perfor- mance bias) All outcomes	High risk	Participant and personnel not blinded
Blinding of outcome as- sessment (detection bias) All outcomes	Low risk	If a partner came to the clinic with a referral card, a clerk noted the participant number on registration. The clerk was blinded to what experimental study the colour coding belonged to. The research assistant, who performed the oral test at the test of cure evaluation, was blinded to whether participant saw the video tape or not

Methods	Setting: a publicly funded sexual health clinic in Melbourne, Vic, Australia		
	Enrolment: participants were enrolled between July 2003 and July 2004		
	<u>Follow-up</u> : 1 week after attending the clinic all index patients were contacted via telephone and inter- viewed by an experienced "contact tracer"		
Participants	105 index patients with chlamydia or NGU (76 men and 29 women) were randomised		
	Inclusion criteria		
	 Diagnosed with chlamydia or NGU 16 years or older Contactable partners who had not already been notified Spoke English 		
	Exclusion criteria		
	No criteria specified		
Interventions	Simple patient referral (n = 32)		
	Each index patient received a sealed envelope. In each envelope there were 5 standard partner letters used for contact tracing. Each index patient was asked to pass a letter to each partner		
	Patient referral with website (n = 73)		
	Each index patient received a sealed envelope. In each envelope there were 5 standard letters used for contact tracing with addition of a uniform resource locator address to a disease-specific website. Each index patient was asked to pass a letter to each partner. The sites provided information for the partner about the infection to which they had been exposed. A printable letter for the partner to take to their own doctor and an anonymous questionnaire were available on the website. Contact details of the re- searchers and ethics committee were available to report any complaints		
Outcomes	Primary outcome		
	 To determine the acceptability of the Internet for use in standard PN (follow-up telephone interview with index patient) 		
	Secondary outcome		



Tomnay 2006 (Continued)

- Partners elicited (follow-up telephone interview with index patient)
- Partners located (follow-up telephone interview with index patient)
- Index re-infection (clinic records)
- Harms complaints and reaction (follow-up telephone interview with index patient and opportunity for partner on website)

Notes

Ethical approval by the Department of Human Services, Victoria and the University of Melbourne

Risk of bias

Bias	Authors' judgement	Support for judgement
Random sequence genera- tion (selection bias)	Low risk	Statistical package for Social Sciences (SPSS Inc., Chicago, USA) to generate random numbers between 1 and 27. Block randomisation was used (blocks of 27), with 18 randomised to the website and 9 to the standard letter. This was performed so that each clinic room had 1 randomised block
Allocation concealment (selection bias)	Low risk	The envelopes with the website or standard pack were identical. Thickened opaque paper and were thoroughly sealed. No opened or missing envelopes were identified during the study
Incomplete outcome data (attrition bias) All outcomes	Low risk	97/105 (92%) index patients completed study up to telephone interview. Only 48/105 (46%) index patients returned to the clinic to evaluate re-infection
Selective reporting (re- porting bias)	Low risk	Same outcomes reported that is stated in methods. No protocol available from 3 trial registries
Other bias	Low risk	No other risk of bias identified
Blinding of participants and personnel (perfor- mance bias) All outcomes	High risk	Blinding was not possible
Blinding of outcome as-	Unclear risk	No blinding
sessment (detection bias) All outcomes		Contact tracer: not clear if contact tracer was blinded. Participants were con- tacted via telephone 1 week after attending the clinic and were interviewed by an experienced contact tracer regarding the number of partners contact- ed, the method used whether the letter had been passed on and the reaction of the partner(s) to the method used. A questionnaire was used but no details given on whether this was a structured questionnaire
		Study personnel: to assess re-infection of index patient, the study personnel looked at medical files in the 2-12 week period post-treatment

 Trent 2010

 Methods
 Setting: 5 clinical sites in 2 institutions - a large academic medical centre (John Hopkins School of Medicine) and a community hospital (Saint Agnes Hospital), Baltimore, MD, US

 The 5 sites of recruitment included the paediatrics and adult emergency department at both centres and the combined general paediatrics and adolescent medicine clinic in the large academic centre

 Enrolment: trained research assistants screened patients with mild-to-moderate PID regarding inclusion and exclusion criteria to determine eligibility - from 14 February 2006 to 25 July 2008



Trent 2010 (Continued)	<u>Follow-up</u> : index patients returned for a 72-hour follow-up after treatment, and a 2-week post-treat- ment, face-to-face interview with DIS			
Participants	162 index patients with mild-to-moderate PID, were approached about recruitment, 131 were enrolled, data gathered from 126 participants were successfully transferred at enrolment and could be ran- domised			
	Inclusion criteria			
	Permanent residents of the metropolitan area under study			
	 Mild-to-moderate PID who had an outpatient-treatment disposition 			
	Aged 15 years and older			
	Access to telephone for follow-up			
	Willing to be randomised and contacted for follow-up			
	Exclusion criteria			
	 Severe disease - potential surgical emergencies, significant nausea, vomiting or high fever; evidence of tubo-ovarian abscess; or other extenuating medical circumstances 			
	Pregnant			
	Concurrent diagnosis of sexual assault			
	Unable to communicate			
	Previously enrolled and re-diagnosed with PID			
	Aged 14 years or younger			
Interventions	Care of patients in both arms included detailed discharge instructions, a full 14-day course of medica- tion and a written hand-out to facilitate self care			
	Patient referral with video (n = 61)			
	Index patient watched a 6-minute video that tells the story of PID as related by a universal patient cre- ated by the voices and images of 7 different female adolescents. The video portrays the patient's inter- face with health provider and the male partner's interface and allows the universal girl to acknowledge the barriers and benefits of PID self care while providing cues for action			
	Simple patient referral (n = 65)			
	Index patient received standardised discharge instructions based on the 2006 CDC STI treatment guidelines			
Outcomes	Primary outcomes			
	 Index patient 72-hour follow-up (clinical records) 			
	 Medication adherence (self report during 2-weeks postenrolment interview) 			
	Secondary outcomes			
	Partner treatment (self report during 2-weeks postenrolment interview)			
	 Temporary abstinence from sexual intercourse as evidence of self care (self report during 2-weeks postenrolment interview) 			
Notes	The study was approved by the John Hopkins School of Medicine Institutional Review Board and the Saint Agnes Hospital Institutional Review Board. Additional approval was obtained from the Maryland State Attorney General for recruitment of children who were wards of the state at the time of diagnosis			
	To reach 80% power to detect a statistically significant difference for the 72-hour follow-up visit at the P value = 0.05 level an additional 240 study subjects would have been needed. The authors were contact- ed for exact numbers of partners notified and treated but these numbers were not available			
Risk of bias				



Trent 2010 (Continued)

Bias	Authors' judgement	Support for judgement
Random sequence genera- tion (selection bias)	Low risk	Computer-generated randomisation
Allocation concealment (selection bias)	Unclear risk	Envelopes containing the group assignment and pertinent information mate- rials were opened by participants after informed consent to participate had been obtained from each of them
Incomplete outcome data (attrition bias) All outcomes	High risk	Only 81/126 (62%) index patients had a 2-week follow-up interview where in- formation on PN were collected
Selective reporting (re- porting bias)	Low risk	Outcomes in method section same as in results. No protocol available from 3 trial registries
Other bias	Low risk	No other bias identified
Blinding of participants and personnel (perfor- mance bias) All outcomes	High risk	Participant and personnel not blinded
Blinding of outcome as- sessment (detection bias) All outcomes	Unclear risk	Blinding of DIS unclear. The DIS performed the follow-up standardised inter- view and completed a form. The DIS was not involved with randomisation or initial interaction with participant. Face-to-face interview can introduce bias

Wilson 2009

Methods	<u>Setting</u> : 2 STI clinics in Brooklyn, NY, US. One was a non-Department of Health clinic for STI and the oth- er a Department of Health STI clinic		
	Enrolment: index patients enrolled between January 2002 and December 2004		
	<u>Follow-up</u> : index patient was interviewed at 1 and 6 months after baseline. Testing of index patient for re-infection with <i>Neisseria gonorrhoeae</i> and <i>Chlamydia trachomatis</i> at 6 months after baseline		
Participants	600 index patients (245 women and 355 men), with chlamydia or gonorrhoea, were randomised		
	Inclusion criteria		
	 Microbiological confirmed diagnosis of <i>C. trachomatis</i> or <i>N. gonorrhoeae</i> within the previous 2 weeks Aged 18 years or older Able to complete an interview in English or Spanish Sexually active in the 2 months prior to enrolment Residing in New York City area for the evaluation period 		
	Exclusion criteria		
	No criteria specified		
Interventions	Patient referral with 2 counselling sessions (4 weeks apart) (n = 304)		
	The first session was designed to occur in the clinic at the time of STI diagnosis. This was a one-on-one counselling session with health educator discussing risk behaviour, identification of eligible sexual partners, development of a notification plan, role-play exercises and completion of a signed behaviour- al contract to notify partners. Index patients received support material including written pamphlet on		

Wilson 2009 (Continued)	PN and referral slips to give to partner with information on where to access free confidential STI testing and treatment. The second session was designed to take place by telephone or in person, 4 weeks after initial session. Review of progress and any remaining barriers to notification process were discussed		
	Simple patient referral (n = 296)		
	Index patient met with health educator at the time of STI diagnosis. The health educator asked the in- dex patient if there were any questions related to the clinic visit, diagnosis, treatment or prevention. A brief discussion period followed. Index patient was given referral slips to give to partner with informa- tion on where to access free confidential STI testing and treatment		
Outcomes Primary outcome			
	• PN (self report by in	dex patient during interview 1 month after baseline)	
	Harms - arguments month after baselin	or instances of physical violence (self report by index patient during interview 1 e)	
	Secondary outcomes		
	Re-infection of index patient at 6 months (urine test)		
		changes over last 90 days - number of partners, type of intercourse, condom use patient during interview 6 months after baseline)	
Notes	Ethical approval by institutional review board at participating sites and at the CDC Author was contacted and they were unable to account for reasons for unequal distribution of STIs at baseline		
	Authors could not provide exact numbers of partners for outcomes. Distribution of harms between 2 groups and detail on protocol obtained from authors. The randomisation process was implemented throughout recruitment as described in the study		
Risk of bias			
Bias	Authors' judgement	Support for judgement	
Random sequence genera- tion (selection bias)	Low risk	Stratified block randomisation algorithm, with stratifications by site of recruit- ment and gender within site. Computerised random number generator	
Allocation concealment (selection bias)	Unclear risk	The principal investigator pre-assigned sequential study identification num- bers according to the random number generated sequence. Participants were	

 (selection bias)
 Interprincipal investigation pre-assigned sequential study identification number generated sequence. Participants were assigned study identification numbers sequentially as they enrolled in the study. There was no explicit mention of safeguards to concealment such as opaque sealed envelopes, or signing consent before randomisation

 Incomplete outcome data
 Low risk
 263/296 (88%) in simple patient referral group completed 1 and 6 month af

 (attrition bias)
 ter baseline interview and had a valid urine test result. In the patient referral group with 2 counselling sessions, 253/304(83%) completed 1 and 6 month after baseline and had a valid urine test result

 Selective reporting (re-porting bias)
 High risk
 Protocol obtained from trial registries

 Outcome in protocol:
 Primary outcomes in protocol was PN and re-infection of index patient at 6 months

 Outcome in actual study:
 Outcome in actual study:

Primary outcomes in actual study are PN and harms

Wilson 2009 (Continued)

ochrane

In the protocol, 3 intervention arms were described, in the actual study only 2 arms were reported

Other bias	Low risk	No other bias identified
Blinding of participants and personnel (perfor- mance bias) All outcomes	High risk	No blinding of participant or personnel
Blinding of outcome as- sessment (detection bias) All outcomes	Low risk	Blinding of study interviewers was performed. The study interviewers were not employees of the study clinics neither did they engage in any health education activities. Study interviewers were not informed of participant group assign- ment. Laboratory personnel were blinded

CDC: Centers for Disease Control and Prevention; DIS: disease intervention specialist; DNA: deoxyribonucleic acid; EPT: expedited partner therapy; FPC: family planning clinic; GUM: genitourinary medicine; HIV: human immunodeficiency virus; ITT: intention to treat; NGU: non-gonococcal urethritis; PCR: polymerase chain reaction; PID: pelvic inflammatory disease; PN: partner notification; RNA: ribonucleic acid; STI: sexually transmitted infection; WHO: World Health Organization.

Characteristics of excluded studies [ordered by study ID]

Trusted evidence.

Informed decisions. Better health.

Study	Reason for exclusion	
Colvin 2006	PN was part of a package given to the index patient and the effect of PN alone cannot be evaluat- ed	
Garcia 2003	Study not on PN	
Hogben 2005	Study was discontinued due to low recruitment	
Marion 2009	Study not on PN	
Okonofua 2003	No STI diagnosis was made	
Richens 2010	Study not on PN	
Shain 2004	Study not on PN	
Sherman 2005	Study was discontinued due to low recruitment	
Thurman 2008	Not an RCT	
Wu 2009	STI diagnosis not made in all index patients	
Young 2007	Not an RCT	

PN: partner notification; RCT: randomised controlled trial; STI: sexually transmitted infections.

Characteristics of studies awaiting assessment [ordered by study ID]

Levy 1998

Methods

Setting: US, poor, high-crime urban area, neighbourhood-based service in converted store front

Levy 1998 (Continued)	<u>Enrolment</u> : over the first 12 months of the study - 386 intravenous drug users were recruited by out- reach team from the streets <u>Follow-up</u> : re-interview 3 months later
Participants	60 HIV-positive participants were randomised
	 Injecting drug users HIV positive and receiving results Have needle-sharing partners or sexual partners
Interventions	All index patients receive referral to case management services, help in identifying and naming at- risk partners, reasons to inform their partners and counselling in how to do so
	Simple patient referral
	Index patients receive help in identifying and naming partners and are counselled about notifica- tion
	Choice patient referral or provider referral
	Index patients receive help in identifying and naming partners and are counselled about notifica- tion. Outreach team notify those partners the patient does not want to notify themselves, without revealing the identity of index patient
Outcomes	Primary outcome
	Partners elicited
	Secondary outcomes
	 Partners tested Partners testing positive Domestic violence Suicide
Notes	This study is still ongoing, and apart from limited data on patient preferences, there are no data on other outcomes
	The only study conducted outside of the formal health services
	Harms are being compared

HIV: human immunodeficiency virus.

Characteristics of ongoing studies [ordered by study ID]

Cassell 2010

Trial name or title	Different Approaches to Partner Notification in Primary Care					
Methods	Cluster randomised trial					
Participants	Practices from the MRC General Practice Research Framework, South East Care Research Network or the Primary Care Research Network Greater London, UK					
	Patients with curable STIs					



Cassell 2010 (Continued)

Interventions	Patient referral, contract referral and provider referral
Outcomes	Number of partners treated. Proportion of index patients testing negative for the relevant STI at 3 months
Starting date	1 May 2010
Contact information	j.cassell@bsms.ac.uk +044 (0) 1273 641924
Notes	Trial registration number: ISRCTN24160819

Falk 2012

Trial name or title	Home-Sampling in Partner Notification of Chlamydia
Methods	Multicentre cluster-randomised controlled trial
Participants	Sexual partners to chlamydia-infected index patients
Interventions	Home sampling
Outcomes	Difference in time, measured as days from the meeting between the index patient and the counsel- lor until the date of testing of partners
Starting date	November 2006
Contact information	Not reported
Notes	Trial registration number: NCT01596946

Farquhar 2012

Trial name or title	Assisted-Partner Notification Services
Methods	Randomised controlled trial
Participants	Newly diagnosed HIV-infected patients
Interventions	Assisted partner notification
Outcomes	Rate of HIV testing of partners, newly identified HIV-infected partners, rate of linkage to HIV care, cost-effectiveness.
Starting date	June 2012
Contact information	cfarq@u.washington.edu
Notes	Trial registration number: NCT01616420

Golden 2012

Trial name or title	Washington State Community Expedited Partner Treatment (EPT) Trial
Methods	Cluster randomised trial
Participants	Male or females given a diagnosis of chlamydia or gonorrhoea. <i>Inclusion criteria</i> Aged over 14 years, not men who have sex with men
	Setting: 23 Washington state local health jurisdictions
	Enrolment: medical providers will refer selected persons for partner services
	Follow-up: no follow-up scheduled but report through public health surveillance
Interventions	Patient-delivered partner therapy packages including antibiotics, condom, written information
Outcomes	Primary outcomes: test positivity for chlamydia in women at family planning clinics, incidence of gonorrhoea among women
	Secondary outcomes: re-infection of index patient, adverse drug reactions; use of patient-delivered partner therapy by medical providers
Starting date	July 2007
Contact information	Matthew Golden, MD, University of Washington
Notes	Trial registration number: NCT01665690

HIV: human immunodeficiency virus; MRC: Medical Research Council; STI: sexually transmitted infection.

DATA AND ANALYSES

Comparison 1. Enhanced patient referral versus simple patient referral

Outcome or subgroup title	No. of studies	No. of partici- pants	Statistical method	Effect size
1 Re-infection in index patient	6		Risk Ratio (M-H, Random, 95% CI)	Subtotals only
1.1 Home sampling vs. simple pa- tient referral	1	220	Risk Ratio (M-H, Random, 95% CI)	2.14 [0.91, 5.05]
1.2 Information booklet vs. simple patient referral	2	942	Risk Ratio (M-H, Random, 95% CI)	0.55 [0.22, 1.33]
1.3 Patient referral (DIS/health ad- visor) vs. patient referral (nurse)	1	140	Risk Ratio (M-H, Random, 95% CI)	0.35 [0.01, 8.51]
1.4 Disease-specific website vs. simple referral	1	105	Risk Ratio (M-H, Random, 95% CI)	3.12 [0.17, 58.73]
1.5 Additional counselling vs. sim- ple patient referral	1	600	Risk Ratio (M-H, Random, 95% CI)	0.49 [0.27, 0.89]



Cochrane Database of Systematic Reviews

Outcome or subgroup title	No. of studies	No. of partici- pants	Statistical method	Effect size
2 Number of partners elicited	11		Mean Difference (IV, Random, 95% CI)	Subtotals only
2.1 Home sampling vs. patient re- ferral	3	516	Mean Difference (IV, Random, 95% CI)	-0.01 [-0.19, 0.18]
2.2 Additional counselling vs. pa- tient referral	3	4108	Mean Difference (IV, Random, 95% CI)	0.23 [0.03, 0.43]
2.3 Patient referral (DIS) vs. patient referral (nurse)	2	597	Mean Difference (IV, Random, 95% CI)	-0.40 [-0.57, -0.24]
2.4 Information booklet vs. patient referral	1	633	Mean Difference (IV, Random, 95% CI)	0.0 [-0.22, 0.22]
2.5 Disease-specific website vs. pa- tient referral	2	140	Mean Difference (IV, Random, 95% CI)	-0.15 [-0.72, 0.42]
3 Number of partners notified	5	1236	Mean Difference (IV, Random, 95% CI)	0.07 [-0.06, 0.20]
3.1 Home sampling vs. patient re- ferral	2	782	Mean Difference (IV, Random, 95% CI)	0.01 [-0.12, 0.14]
3.2 Additional counselling vs. pa- tient referral	1	272	Mean Difference (IV, Random, 95% CI)	0.21 [0.06, 0.36]
3.3 Disease-specific website vs. pa- tient referral	1	105	Mean Difference (IV, Random, 95% CI)	-0.17 [-0.68, 0.34]
3.4 Videotape vs. patient referral	1	77	Mean Difference (IV, Random, 95% CI)	0.0 [0.0, 0.0]
4 Number of partners presenting for care	4		Mean Difference (IV, Random, 95% CI)	Totals not selected
4.1 Home sampling vs. patient re- ferral	3		Mean Difference (IV, Random, 95% CI)	0.0 [0.0, 0.0]
4.2 Additional counselling vs. pa- tient referral	1		Mean Difference (IV, Random, 95% CI)	0.0 [0.0, 0.0]
5 Number of partners testing posi- tive	5		Mean Difference (IV, Random, 95% CI)	Subtotals only
5.1 Home sampling vs. patient re- ferral	3	878	Mean Difference (IV, Random, 95% CI)	0.11 [0.05, 0.17]
5.2 Additional counselling vs. pa- tient referral	1	1266	Mean Difference (IV, Random, 95% CI)	0.01 [-0.05, 0.07]
5.3 Patient referral (DIS) vs. patient referral (nurse)	1	457	Mean Difference (IV, Random, 95% CI)	0.0 [-0.03, 0.03]
6 Number of partners treated	6		Mean Difference (IV, Random, 95% CI)	Totals not selected

Analysis 1.1. Comparison 1 Enhanced patient referral versus simple patient referral, Outcome 1 Re-infection in index patient.

Study or subgroup	Enhanced PR	Simple PR	Risk Ratio	Weight	Risk Ratio
	n/N	n/N	M-H, Random, 95% Cl		M-H, Random, 95% Cl
1.1.1 Home sampling vs. simple p	oatient referral				
Cameron 2009	15/110	7/110		100%	2.14[0.91,5.05]
Subtotal (95% CI)	110	110		100%	2.14[0.91,5.05]
Total events: 15 (Enhanced PR), 7 (Simple PR)				
Heterogeneity: Not applicable					
Test for overall effect: Z=1.74(P=0.0)8)				
1.1.2 Information booklet vs. sim	ple patient referral				
Kissinger 2005	30/348	67/285	— —	57.01%	0.37[0.25,0.55]
Kissinger 2006	11/154	12/155		42.99%	0.92[0.42,2.03]
Subtotal (95% CI)	502	440 -		100%	0.55[0.22,1.33]
Total events: 41 (Enhanced PR), 79	(Simple PR)				
Heterogeneity: Tau ² =0.32; Chi ² =4.1	9, df=1(P=0.04); l ² =76.	13%			
Test for overall effect: Z=1.33(P=0.1	.8)				
1.1.3 Patient referral (DIS/health	advisor) vs. patient ı	eferral (nurse)			
Low 2006b	0/68	1/72		100%	0.35[0.01,8.51]
Subtotal (95% CI)	68	72		100%	0.35[0.01,8.51]
Total events: 0 (Enhanced PR), 1 (S	imple PR)				
Heterogeneity: Not applicable					
Test for overall effect: Z=0.64(P=0.5	52)				
1.1.4 Disease-specific website vs	. simple referral				
Tomnay 2006	3/73	0/32		100%	3.12[0.17,58.73]
Subtotal (95% CI)	73	32 —		100%	3.12[0.17,58.73]
Total events: 3 (Enhanced PR), 0 (S	imple PR)				
Heterogeneity: Not applicable					
Test for overall effect: Z=0.76(P=0.4	5)				
1.1.5 Additional counselling vs. s	imple patient referra	l			
Wilson 2009	15/304	30/296		100%	0.49[0.27,0.89]
Subtotal (95% CI)	304	296		100%	0.49[0.27,0.89]
Total events: 15 (Enhanced PR), 30	(Simple PR)				
Heterogeneity: Not applicable					
Test for overall effect: Z=2.36(P=0.0	02)				
Test for subgroup differences: Chi ² :		=57.29%			

Analysis 1.2. Comparison 1 Enhanced patient referral versus simple patient referral, Outcome 2 Number of partners elicited.

Study or subgroup	Enha	Enhanced PR Simple PR			Mean Difference				Weight	Mean Difference	
	N	Mean(SD)	Ν	Mean(SD)		Ra	ndom, 95ª	% CI			Random, 95% Cl
1.2.1 Home sampling vs. pa	tient referral										
Andersen 1998	45	1.4 (1.2)	51	1.3 (1.2)				•	\rightarrow	15.82%	0.11[-0.36,0.58]
Apoola 2009	100	1.1 (1.1)	100	1.2 (1.1)	. —		-			39.5%	-0.05[-0.35,0.25]
			Favo	urs simple PR	-0.4	-0.2	0	0.2	0.4	Favours enh	anced PR



Trusted evidence. Informed decisions. Better health.

Study or subgroup	Enh	anced PR	Si	mple PR	Mean Difference	Weight	Mean Difference
	N	Mean(SD)	N	Mean(SD)	Random, 95% Cl	-	Random, 95% CI
Cameron 2009	110	1.1 (1.1)	110	1.1 (1.1)		44.68%	-0.01[-0.29,0.27]
Subtotal ***	255		261			100%	-0.01[-0.19,0.18]
Heterogeneity: Tau ² =0; Chi ² =0.31, c	lf=2(P=0.8	5); I ² =0%					
Test for overall effect: Z=0.07(P=0.9	4)						
1.2.2 Additional counselling vs. p	atient ref	erral					
Cleveland undated	634	3.3 (1.8)	632	3.3 (1.8)		18.82%	0[-0.2,0.2]
Ellison undated	423	1.2 (1)	433	1 (1.1)		20.78%	0.13[-0.01,0.27]
Ellison undated	431	1.3 (1.1)	433	1 (1.1)		- 20.7%	0.25[0.11,0.39]
Ellison undated	417	1.6 (1.2)	433	1 (1.2)		20.28%	0.61[0.45,0.77]
Моуо 2002	131	0.7 (0.8)	141	0.5 (0.8)		19.42%	0.13[-0.05,0.31]
Subtotal ***	2036		2072			100%	0.23[0.03,0.43]
Heterogeneity: Tau ² =0.05; Chi ² =30.	96, df=4(P	<0.0001); l ² =87.0	08%				
Test for overall effect: Z=2.22(P=0.0	3)						
1.2.3 Patient referral (DIS) vs. pa	tient refe	rral (nurse)					
Katz 1988	240	0.8 (1)	217	1.2 (1)		83.12%	-0.41[-0.59,-0.23]
Low 2006b	68	1.3 (1.2)	72	1.7 (1.2)	<u> </u>	16.88%	-0.37[-0.77,0.03]
Subtotal ***	308		289			100%	-0.4[-0.57,-0.24]
Heterogeneity: Tau ² =0; Chi ² =0.03, c	df=1(P=0.8	6); I ² =0%					
Test for overall effect: Z=4.82(P<0.0							
1.2.4 Information booklet vs. pat	ient refer	ral					
Kissinger 2005	348	2 (1.4)	285	2 (1.4)		100%	0[-0.22,0.22]
Subtotal ***	348		285			100%	0[-0.22,0.22]
Heterogeneity: Not applicable							
Test for overall effect: Not applicab	le						
1.2.5 Disease-specific website vs	. patient r	eferral					
Kerani 2011	17	1.8 (1.4)	18	2.3 (1.4)		- 32.43%	-0.57[-1.51,0.37]
Tomnay 2006	73	2.2 (1.5)	32	2.2 (1.5)		67.57%	0.05[-0.56,0.66]
Subtotal ***	90	. ,	50			100%	-0.15[-0.72,0.42]
Heterogeneity: Tau ² =0.03; Chi ² =1.1	7, df=1(P=	0.28); I ² =14.32%					- / -
Test for overall effect: Z=0.52(P=0.6							
Test for subgroup differences: Chi ²		=1 (P<0.0001), I ² =	=84.03%				
				urs simple PR ⁻⁰	.4 -0.2 0 0.2	0.4 Favours enl	nanced PR

Analysis 1.3. Comparison 1 Enhanced patient referral versus simple patient referral, Outcome 3 Number of partners notified.

Study or subgroup	Enh	Enhanced PR		Simple PR		Mean Difference			Weight	Mean Difference	
	N	Mean(SD)	Ν	Mean(SD)		Ra	ndom, 95% CI			Random, 95% Cl	
1.3.1 Home sampling vs. pa	tient referral										
Cameron 2009	110	0.5 (0.7)	110	0.5 (0.7)			_		29.82%	0.02[-0.16,0.2]	
Ostergaard 2003	304	1.3 (1.1)	258	1.3 (1.1)			_ _		28.57%	0[-0.19,0.19]	
Subtotal ***	414		368				+		58.39%	0.01[-0.12,0.14]	
Heterogeneity: Tau ² =0; Chi ² =	0.02, df=1(P=0.8	8); I ² =0%									
Test for overall effect: Z=0.15	(P=0.88)										
			Favours simple PR		-1	-0.5	0 0.5	1	Favours en	nanced PR	



Study or subgroup	Enha	anced PR	Si	nple PR	Mean Difference	Weight	Mean Difference
	N	Mean(SD)	Ν	Mean(SD)	Random, 95% CI		Random, 95% Cl
1.3.2 Additional counselling vs. p	atient refe	erral					
Моуо 2002	131	0.5 (0.7)	141	0.3 (0.7)		35.57%	0.21[0.06,0.36]
Subtotal ***	131		141		•	35.57%	0.21[0.06,0.36]
Heterogeneity: Not applicable							
Test for overall effect: Z=2.66(P=0.0	1)						
1.3.3 Disease-specific website vs.	patient re	eferral					
Tomnay 2006	73	1.4 (1.2)	32	1.6 (1.2)	+	6.03%	-0.17[-0.68,0.34]
Subtotal ***	73		32			6.03%	-0.17[-0.68,0.34]
Heterogeneity: Tau ² =0; Chi ² =0, df=0	0(P<0.0001); I ² =100%					
Test for overall effect: Z=0.65(P=0.5	1)						
1.3.4 Videotape vs. patient referr	al						
Trent 2010	36	0.8 (0)	41	0.9 (0)			Not estimable
Subtotal ***	36		41				Not estimable
Heterogeneity: Not applicable							
Test for overall effect: Not applicab	le						
Total ***	654		582		•	100%	0.07[-0.06,0.2]
Heterogeneity: Tau ² =0.01; Chi ² =4.7	3, df=3(P=0	0.19); I ² =36.59%					
Test for overall effect: Z=1.05(P=0.2	9)						
Test for subgroup differences: Chi ² =	=4.71, df=1	(P=0.09), I ² =57.	53%				
			Favo	urs simple PR ⁻¹	-0.5 0 0.5	¹ Favours en	hanced PR

Analysis 1.4. Comparison 1 Enhanced patient referral versus simple patient referral, Outcome 4 Number of partners presenting for care.

Study or subgroup	En	hanced PR	S	imple PR	Mean Difference	Mean Difference
	N	Mean(SD)	Ν	Mean(SD)	Random, 95% CI	Random, 95% Cl
1.4.1 Home sampling vs. pa	tient referral					
Andersen 1998	45	1 (0.8)	51	0.4 (0.8)		0.61[0.28,0.94]
Apoola 2009	100	0.6 (0.8)	100	0.7 (0.8)		-0.05[-0.27,0.17]
Cameron 2009	110	0.5 (0.7)	110	0.4 (0.7)		0.04[-0.13,0.21]
1.4.2 Additional counselling	g vs. patient refe	rral				
Cleveland undated	634	0.4 (0.6)	632	0.4 (0.6)		0[-0.07,0.07]
				Favours simple PR	-0.2 -0.1 0 0.1 0.2	Favours enhanced PR

Analysis 1.5. Comparison 1 Enhanced patient referral versus simple patient referral, Outcome 5 Number of partners testing positive.

Study or subgroup	Enh	anced PR	Simple PR		Mean Difference	Weight	Mean Difference
	N	Mean(SD)	Ν	Mean(SD)	Random, 95% CI		Random, 95% Cl
1.5.1 Home sampling vs. pa	tient referral						
Andersen 1998	45	0.3 (0.5)	51	0.1 (0.5)	+	12.59%	0.13[-0.05,0.31]
Cameron 2009	110	0.3 (0.5)	110	0.2 (0.5)		25.45%	0.1[-0.03,0.23]
Ostergaard 2003	304	0.3 (0.5)	258	0.2 (0.5)	· · · · · · · · · · · · · · · · · · ·	61.97%	0.11[0.03,0.19]
			Favo	urs simple PR	-0.1 -0.05 0 0.05 0.1	Favours en	hanced PR



Study or subgroup	Enh	anced PR	Sir	mple PR	Mean Difference	Weight	Mean Difference
	Ν	Mean(SD)	Ν	Mean(SD)	Random, 95% Cl		Random, 95% Cl
Subtotal ***	459		419			100%	0.11[0.05,0.17]
Heterogeneity: Tau ² =0; Chi ² =0.07, df	=2(P=0.9	7); I ² =0%					
Test for overall effect: Z=3.37(P=0)							
1.5.2 Additional counselling vs. pa	tient ref	erral					
Cleveland undated	634	0.3 (0.5)	632	0.2 (0.5)		100%	0.01[-0.05,0.07]
Subtotal ***	634		632			100%	0.01[-0.05,0.07]
Heterogeneity: Not applicable							
Test for overall effect: Z=0.36(P=0.72)						
1.5.3 Patient referral (DIS) vs. pati	ent refe	rral (nurse)					
Katz 1988	240	0 (0.2)	217	0 (0.2)		100%	0[-0.03,0.03]
Subtotal ***	240		217		-	100%	0[-0.03,0.03]
Heterogeneity: Not applicable							
Test for overall effect: Not applicable	5						
Test for subgroup differences: Chi ² =9	9.13, df=1	L (P=0.01), I ² =78.0)9%				
			Favo	urs simple PR	-0.1 -0.05 0 0.05 0.1	Favours en	hanced PR

Analysis 1.6. Comparison 1 Enhanced patient referral versus simple patient referral, Outcome 6 Number of partners treated.

Study or subgroup	En	hanced PR	Simple PR		Mean Difference	Mean Difference
	N	Mean(SD)	Ν	Mean(SD)	Random, 95% Cl	Random, 95% Cl
Apoola 2009	100	0.6 (0.8)	100	0.6 (0.8)	— <u>+</u>	-0.03[-0.25,0.19]
Ellison undated	417	0.3 (0.5)	433	0.2 (0.5)	+	0.07[0.01,0.13]
Ellison undated	423	0.2 (0.5)	433	0.2 (0.5)	+	0.04[-0.02,0.1]
Ellison undated	431	0.2 (0.4)	433	0.2 (0.4)	+	0.02[-0.04,0.08]
Katz 1988	240	0.2 (0.5)	217	0.2 (0.5)	+	-0.04[-0.12,0.04]
Kissinger 2005	348	0.9 (0.9)	285	0.7 (0.9)	-+	0.22[0.08,0.36]
Low 2006b	68	0.6 (0.8)	72	0.7 (0.8)	— • 	-0.17[-0.44,0.1]
Trent 2010	77	0.6 (0)	41	0.5 (0)		Not estimable
				Favours simple PR	-1 -0.5 0 0.5 1	Favours enhanced PR

Comparison 2. Enhanced patient referral versus other enhanced patient referral

Outcome or subgroup title	No. of studies	No. of partici- pants	Statistical method	Effect size
1 Partners elicited	2		Mean Difference (IV, Random, 95% CI)	Totals not selected
2 Number of partners presenting for care	1		Mean Difference (IV, Random, 95% CI)	Totals not selected
3 Number of partners treated	1		Mean Difference (IV, Random, 95% CI)	Totals not selected



Analysis 2.1. Comparison 2 Enhanced patient referral versus other enhanced patient referral, Outcome 1 Partners elicited.

Study or subgroup	Enhance	d PR alternative	En	Enhanced PR		Mean Difference			Mean Difference
	N	Mean(SD)	Ν	Mean(SD)		Random, 95	% CI		Random, 95% Cl
Ellison undated	417	1.6 (1.2)	423	1.2 (1.2)		+			0.48[0.32,0.64]
Ellison undated	423	1.2 (1.1)	431	1.3 (1.1)		+			-0.12[-0.27,0.03]
Ellison undated	417	1.6 (1.2)	431	1.3 (1.2)		+			0.36[0.2,0.52]
Montesinos 1990	19	1.1 (1.1)	27	1.2 (1.1)		<u> </u>			-0.08[-0.71,0.55]
Montesinos 1990	19	1.3 (1.1)	27	1.2 (1.1)		 +	-		0.13[-0.53,0.79]
Montesinos 1990	19	1.1 (1.1)	19	1.3 (1.1)		+ <u> </u>			-0.21[-0.91,0.49]
			Fav	ours enhanced PR	-4	-2 0	2	4	Favours enhanced PR (alt)

Analysis 2.2. Comparison 2 Enhanced patient referral versus other enhanced patient referral, Outcome 2 Number of partners presenting for care.

Study or subgroup	Enhance	ed PR alternative	Enhanced PR		Mean Difference	Mean Difference
	Ν	Mean(SD)	Ν	Mean(SD)	Random, 95% Cl	Random, 95% Cl
Montesinos 1990	19	1 (1)	19	0.8 (1)		0.16[-0.45,0.77]
Montesinos 1990	19	0.8 (0.9)	27	0.7 (0.9)		0.17[-0.35,0.69]
Montesinos 1990	19	1 (0.9)	27	0.7 (0.9)	· · · · · · ·	0.33[-0.22,0.88]
			Fav	ours enhanced PR	-1 -0.5 0 0.5 1	Favours enhanced PR

(alt)

(alt)

Analysis 2.3. Comparison 2 Enhanced patient referral versus other enhanced patient referral, Outcome 3 Number of partners treated.

Study or subgroup	En	hanced PR	Enhanced PR (alternative)		Mean Difference	Mean Difference
	Ν	Mean(SD)	Ν	Mean(SD)	Random, 95% Cl	Random, 95% CI
Ellison undated	417	0.3 (0.5)	423	0.2 (0.5)		0.03[-0.04,0.1]
Ellison undated	423	0.2 (0.5)	431	0.2 (0.5)		0.02[-0.04,0.08]
Ellison undated	417	0.3 (0.5)	431	0.2 (0.5)		0.05[-0.02,0.11]
			Fav	ours enhanced PR	-0.1 -0.05 0 0.05 0.1	Favours enhanced PR

Comparison 3. Expedited partner therapy (EPT) versus simple patient referral

Outcome or subgroup title	No. of studies	No. of partici- pants	Statistical method	Effect size
1 Re-infection in index patients	6	6018	Risk Ratio (M-H, Random, 95% CI)	0.71 [0.56, 0.89]
1.1 Chlamydia	2	2007	Risk Ratio (M-H, Random, 95% CI)	0.90 [0.60, 1.35]
1.2 Trichomonas	2	631	Risk Ratio (M-H, Random, 95% CI)	0.67 [0.34, 1.28]
1.3 Chlamydia or gonorrhoea	2	3380	Risk Ratio (M-H, Random, 95% CI)	0.61 [0.39, 0.94]



Cochrane Database of Systematic Reviews

Outcome or subgroup title	No. of studies	No. of partici- pants	Statistical method	Effect size
2 Number of partners elicited	6	4339	Mean Difference (IV, Random, 95% CI)	-0.02 [-0.09, 0.04]
3 Number of partners notified	3		Mean Difference (IV, Random, 95% CI)	Totals not selected
4 Number of partners presenting for care	1		Mean Difference (IV, Random, 95% CI)	Totals not selected
5 Number of partners treated	4		Mean Difference (IV, Random, 95% CI)	Totals not selected
5.1 Chlamydia or gonorrhoea	2		Mean Difference (IV, Random, 95% CI)	0.0 [0.0, 0.0]
5.2 Trichomonas	1		Mean Difference (IV, Random, 95% CI)	0.0 [0.0, 0.0]
5.3 Any STI syndrome	1		Mean Difference (IV, Random, 95% CI)	0.0 [0.0, 0.0]
6 Number of harmful events reported	1		Mean Difference (IV, Random, 95% CI)	Totals not selected

Analysis 3.1. Comparison 3 Expedited partner therapy (EPT) versus simple patient referral, Outcome 1 Re-infection in index patients.

Study or subgroup	EPT	Simple PR	Risk Ratio	Weight	Risk Ratio
	n/N	n/N	M-H, Random, 95% Cl		M-H, Random, 95% CI
3.1.1 Chlamydia					
Cameron 2009	10/110	7/110	+	5.63%	1.43[0.56,3.62]
Schillinger 2003	87/887	108/900	— — —	29.94%	0.82[0.63,1.07]
Subtotal (95% CI)	997	1010		35.56%	0.9[0.6,1.35]
Total events: 97 (EPT), 115 (Simple P	R)				
Heterogeneity: Tau ² =0.03; Chi ² =1.28,	df=1(P=0.26); I ² =22.0	01%			
Test for overall effect: Z=0.51(P=0.61))				
3.1.2 Trichomonas					
Kissinger 2006	8/154	12/155		6.36%	0.67[0.28,1.6]
Schwebke 2010	6/162	9/160 —		4.85%	0.66[0.24,1.81]
Subtotal (95% CI)	316	315		11.21%	0.67[0.34,1.28]
Total events: 14 (EPT), 21 (Simple PR)				
Heterogeneity: Tau ² =0; Chi ² =0, df=1(P=0.98); I ² =0%				
Test for overall effect: Z=1.21(P=0.23)	1				
3.1.3 Chlamydia or gonorrhoea					
Golden 2005	92/1375	124/1376		30.6%	0.74[0.57,0.96]
Kissinger 2005	39/344	68/285	_	22.63%	0.48[0.33,0.68]
Subtotal (95% CI)	1719	1661		53.23%	0.61[0.39,0.94]
		Favours EPT	0.5 0.7 1 1.5 2	Favours simple PR	

Strategies for partner notification for sexually transmitted infections, including HIV (Review) Copyright © 2013 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.



Study or subgroup	EPT	Simple PR	Risk Ratio	Weight	Risk Ratio
	n/N	n/N	M-H, Random, 95% Cl		M-H, Random, 95% CI
Total events: 131 (EPT), 192 (Sim	ple PR)				
Heterogeneity: Tau ² =0.07; Chi ² =3	8.88, df=1(P=0.05); I ² =7	4.22%			
Test for overall effect: Z=2.26(P=0	0.02)				
Total (95% CI)	3032	2986	•	100%	0.71[0.56,0.89]
Total events: 242 (EPT), 328 (Sim	ple PR)				
Heterogeneity: Tau ² =0.03; Chi ² =8	8.15, df=5(P=0.15); I ² =3	8.65%			
Test for overall effect: Z=2.89(P=0))				
Test for subgroup differences: Ch	ii ² =1.77, df=1 (P=0.41),	l ² =0%			
		Favours EPT	0.5 0.7 1 1.5 2	Favours simple PR	

Analysis 3.2. Comparison 3 Expedited partner therapy (EPT) versus simple patient referral, Outcome 2 Number of partners elicited.

Study or subgroup		EPT	Sir	mple PR		Mean Difference	Weight	Mean Difference
	N Mean(SD) N Mean(SD) Random, 95% Cl			Random, 95% Cl				
Cameron 2009	110	1.1 (1.1)	110	1.2 (1.1)	++		4.8%	-0.08[-0.37,0.21]
Golden 2005	1375	1 (1)	1376	1 (1)			71.32%	-0.03[-0.1,0.04]
Kerani 2011	16	2.8 (1.6)	18	2.3 (1.6)	◀—		0.34%	0.42[-0.66,1.5]
Kissinger 2005	344	2.1 (1.4)	285	2 (1.4)	←	•	7.9%	0.02[-0.2,0.24]
Nuwaha 2001	192	1.2 (1.1)	191	1.2 (1.1)	←	+	8.06%	0[-0.22,0.22]
Schwebke 2010	162	1.1 (1.1)	160	1.1 (1.1)	•	•	7.57%	-0.02[-0.25,0.21]
Total ***	2199		2140				100%	-0.02[-0.09,0.04]
Heterogeneity: Tau ² =0; Chi ² =	=1.02, df=5(P=0.96	6); I ² =0%						
Test for overall effect: Z=0.74	(P=0.46)							
			Favo	urs simple PR	-0.1	-0.05 0 0.05	0.1 Favours EP	Г

Analysis 3.3. Comparison 3 Expedited partner therapy (EPT) versus simple patient referral, Outcome 3 Number of partners notified.

Study or subgroup		EPT	:	Simple PR	Mean Difference	Mean Difference
	N	Mean(SD)	Ν	Mean(SD)	Random, 95% Cl	Random, 95% CI
Cameron 2009	110	0.6 (0.7)	110	0.5 (0.7)		0.13[-0.06,0.32]
Golden 2005	1375	0.8 (0.9)	1376	0.8 (0.9)	-+-	-0.05[-0.12,0.02]
Kissinger 2005	344	1.4 (1.1)	285	1 (1.1)		0.44[0.27,0.61]
				Favours simple PR	-0.5 -0.25 0 0.25 0.5	Favours EPT

Favours simple PR

Analysis 3.4. Comparison 3 Expedited partner therapy (EPT) versus simple patient referral, Outcome 4 Number of partners presenting for care.

Study or subgroup		EPT		Simple PR		Mean Difference				Mean Difference
	Ν	Mean(SD)	Ν	Mean(SD)		Rar	dom, 95%	6 CI		Random, 95% CI
Cameron 2009	110	0.5 (0.7)	110	0.4 (0.7)	+ .			0.05[-0.13,0.23]		
				Favours simple PR	-5	-2.5	0	2.5	5	Favours EPT



Analysis 3.5. Comparison 3 Expedited partner therapy (EPT) versus simple patient referral, Outcome 5 Number of partners treated.

Study or subgroup		EPT	S	Simple PR	Mean Difference	Mean Difference
	Ν	Mean(SD)	Ν	Mean(SD)	Random, 95% CI	Random, 95% CI
3.5.1 Chlamydia or gonorrhoea						
Golden 2005	1375	0.6 (0.8)	1376	0.5 (0.8)		0.06[0,0.12]
Kissinger 2005	344	1.1 (1)	285	0.7 (1)		0.43[0.28,0.58]
3.5.2 Trichomonas						
Schwebke 2010	162	0.8 (0.7)	160	0.3 (0.7)		0.51[0.35,0.67]
3.5.3 Any STI syndrome						
Nuwaha 2001	192	0.9 (0.8)	191	0.4 (0.8)		0.5[0.34,0.66]
				Favours simple PR	-0.5 -0.25 0 0.25 0.5	Favours EPT

Analysis 3.6. Comparison 3 Expedited partner therapy (EPT) versus simple patient referral, Outcome 6 Number of harmful events reported.

Study or subgroup		EPT		Simple PR		Mean Difference				Mean Difference
	N	Mean(SD)	Ν	Mean(SD)		Rai	ndom, 95%	6 CI		Random, 95% CI
Nuwaha 2001	192	0.1 (0.3)	191	0.1 (0.3)	(0.3)		ł			0.06[-0,0.12]
				Favours simple PR	-5	-2.5	0	2.5	5	Favours EPT

Comparison 4. Expedited partner therapy (EPT) versus enhanced patient referral

Outcome or subgroup title	No. of studies	No. of partici- pants	Statistical method	Effect size
1 EPT vs. enhanced patient re- ferral	3		Risk Ratio (M-H, Random, 95% CI)	Subtotals only
1.1 Re-infection in index pa- tients	3	1220	Risk Ratio (M-H, Random, 95% CI)	0.96 [0.60, 1.53]
2 EPT vs. enhanced patient re- ferral	3		Mean Difference (IV, Random, 95% CI)	Subtotals only
2.1 Number of partners elicit- ed	3	945	Mean Difference (IV, Random, 95% CI)	0.07 [-0.18, 0.32]
2.2 Number of partners noti- fied	1	220	Mean Difference (IV, Random, 95% CI)	0.11 [-0.08, 0.30]
2.3 Number of partners pre- senting for care	1	220	Mean Difference (IV, Random, 95% CI)	0.01 [-0.01, 0.03]
2.4 Number of partners treat- ed	1	692	Mean Difference (IV, Random, 95% CI)	0.22 [0.21, 0.23]

Outcome or subgroup title	No. of studies	No. of partici- pants	Statistical method	Effect size
3 Enhanced patient referral plus EPT vs. simple patient re- ferral	1		Mean Difference (IV, Random, 95% CI)	Totals not selected
3.1 Number of partners elicit- ed	1		Mean Difference (IV, Random, 95% CI)	0.0 [0.0, 0.0]

Analysis 4.1. Comparison 4 Expedited partner therapy (EPT) versus enhanced patient referral, Outcome 1 EPT vs. enhanced patient referral.

Study or subgroup	EPT	Enhanced PR			Risk Ratio			Weight	Risk Ratio
	n/N	n/N		м-н,	Random, 95	% CI			M-H, Random, 95% Cl
4.1.1 Re-infection in index pat	tients								
Cameron 2009	10/110	15/110						27.51%	0.67[0.31,1.42]
Kissinger 2005	39/344	30/348						50.67%	1.32[0.84,2.07]
Kissinger 2006	8/154	11/154			-+-			21.81%	0.73[0.3,1.76]
Subtotal (95% CI)	608	612			•			100%	0.96[0.6,1.53]
Total events: 57 (EPT), 56 (Enha	nced PR)								
Heterogeneity: Tau ² =0.06; Chi ² =	=2.99, df=2(P=0.22); I ² =33.	2%							
Test for overall effect: Z=0.18(P=	=0.86)								
		EPT	0.01	0.1	1	10	100	Enhanced PR	

Analysis 4.2. Comparison 4 Expedited partner therapy (EPT) versus enhanced patient referral, Outcome 2 EPT vs. enhanced patient referral.

Study or subgroup		EPT	Enh	anced PR	Mean Difference	Weight	Mean Difference
	N	Mean(SD)	Ν	Mean(SD)	Random, 95% Cl		Random, 95% CI
4.2.1 Number of partners elicited	l						
Cameron 2009	110	1.1 (1.1)	110	1.1 (1.1)		41.54%	0.01[-0.27,0.29]
Kerani 2011	16	2.8 (1.5)	17	1.8 (1.5)		5.65%	0.99[-0.04,2.02]
Kissinger 2005	344	2.1 (1.4)	348	2 (1.4)		52.82%	0.02[-0.19,0.23]
Subtotal ***	470		475			100%	0.07[-0.18,0.32]
Heterogeneity: Tau ² =0.02; Chi ² =3.3	4, df=2(P=	0.19); l ² =40.12%					
Test for overall effect: Z=0.55(P=0.5	9)						
4.2.2 Number of partners notified	đ						
Cameron 2009	110	0.6 (0.7)	110	0.5 (0.7)		- 100%	0.11[-0.08,0.3]
Subtotal ***	110		110			100%	0.11[-0.08,0.3]
Heterogeneity: Not applicable							
Test for overall effect: Z=1.12(P=0.2	26)						
4.2.3 Number of partners present	ting for ca	ire					
Cameron 2009	110	0.5 (0.1)	110	0.5 (0.1)	<u> </u>	100%	0.01[-0.01,0.03]
Subtotal ***	110		110		•	100%	0.01[-0.01,0.03]
Heterogeneity: Not applicable							
			Favours	enhanced PR	-0.2 -0.1 0 0.1 0.2	Favours EP1	-



Study or subgroup		EPT		inced PR	Mean Difference	Weight	Mean Difference
	N	Mean(SD)	N	Mean(SD)	Random, 95% CI		Random, 95% Cl
Test for overall effect: Z=0.8	82(P=0.41)						
4.2.4 Number of partners	treated						
Kissinger 2005	344	1.1 (0.1)	348	0.9 (0.1)	+	100%	0.22[0.21,0.23]
Subtotal ***	344		348		•	100%	0.22[0.21,0.23]
Heterogeneity: Tau ² =0; Chi	² =0, df=0(P<0.0001); I ² =100%					
Test for overall effect: Z=36	6.93(P<0.0001)						
			Favours	enhanced PR	-0.2 -0.1 0 0.1 0.2	Favours EPT	

Analysis 4.3. Comparison 4 Expedited partner therapy (EPT) versus enhanced patient referral, Outcome 3 Enhanced patient referral plus EPT vs. simple patient referral.

Study or subgroup		PR+EPT	En	hanced PR		Меа	n Differe	nce		Mean Difference
	Ν	Mean(SD)	Ν	Mean(SD)		Rar	dom, 95%	CI		Random, 95% Cl
4.3.1 Number of partners elicited										
Kerani 2011	24	2.9 (1.5)	17	1.8 (1.5)	I.		ł			1.15[0.22,2.08]
			Fav	ours enhanced PR	-100	-50	0	50	100	Favours PR+EPT

Comparison 5. Contract referral versus simple patient referral

Outcome or subgroup title	No. of studies	No. of partici- pants	Statistical method	Effect size
1 Number of partners elicited	5	2006	Mean Difference (IV, Random, 95% CI)	-0.22 [-0.37, -0.06]
2 Number of partners notified	1		Mean Difference (IV, Random, 95% CI)	Totals not selected
3 Number of partners presenting for care	3	1610	Mean Difference (IV, Random, 95% CI)	0.25 [0.18, 0.32]
4 Number of partners testing positive	4	1684	Mean Difference (IV, Random, 95% CI)	0.13 [0.07, 0.18]
5 Number of partners treated	2		Mean Difference (IV, Random, 95% CI)	Totals not selected
6 Number of harmful events reported	1		Mean Difference (IV, Random, 95% CI)	Totals not selected

Analysis 5.1. Comparison 5 Contract referral versus simple patient referral, Outcome 1 Number of partners elicited.

Study or subgroup		CR	Sir	nple PR	Mean Difference	Weight	Mean Difference
	Ν	Mean(SD)	Ν	Mean(SD)	Random, 95% CI		Random, 95% CI
Brown 2011	82	1.2 (1.1)	77	1.2 (1.1)	+	16.97%	-0.06[-0.4,0.28]
Cleveland undated	632	2.9 (1.8)	632	3.3 (1.8)		37.17%	-0.4[-0.59,-0.21]
Landis 1992	39	4 (2.1)	35	4.4 (2.1)	4	2.67%	-0.34[-1.28,0.6]
Potterat 1977	94	2 (1.4)	93	2.1 (1.4)	+ +	- 12.21%	-0.09[-0.5,0.32]
Schwebke 2010	162	1 (1)	160	1.1 (1)		30.98%	-0.13[-0.36,0.1]
Total ***	1009		997			100%	-0.22[-0.37,-0.06]
Heterogeneity: Tau ² =0.01; Cl	hi²=5.16, df=4(P=	0.27); l ² =22.48%					
Test for overall effect: Z=2.77	7(P=0.01)						
			Favo	urs simple PR	-0.2 -0.1 0 0.1 0.2	Favours CR	

Analysis 5.2. Comparison 5 Contract referral versus simple patient referral, Outcome 2 Number of partners notified.

Study or subgroup		CR		Simple PR		Me	an Differe	nce		Mean Differen	ice
	Ν	Mean(SD)	N Mean(SD)		Random, 95% CI			Random, 95%	CI		
Landis 1992	39	2 (1.1)	35	0.3 (1.1)	1				1.72[1.	.24,2.2]	
				Favours simple PR	-100	-50	0	50	100	Favours CR	

Analysis 5.3. Comparison 5 Contract referral versus simple patient referral, Outcome 3 Number of partners presenting for care.

Study or subgroup		CR	Sir	nple PR	Mean Difference		Weight	Mean Difference	
	Ν	Mean(SD)	Ν	Mean(SD)		Rando	om, 95% Cl		Random, 95% Cl
Brown 2011	82	0.6 (0.6)	77	0.3 (0.6)				12.77%	0.29[0.09,0.49]
Cleveland undated	632	0.6 (0.7)	632	0.4 (0.7)			-	82.3%	0.25[0.17,0.33]
Potterat 1977	94	1.3 (1.1)	93	1.2 (1.1)		-	+	4.93%	0.12[-0.2,0.44]
Total ***	808		802				•	100%	0.25[0.18,0.32]
Heterogeneity: Tau ² =0; Chi ² =	0.81, df=2(P=0.6	7); I ² =0%							
Test for overall effect: Z=6.96	(P<0.0001)							1	
			Favo	urs simple PR	-1	-0.5	0 0.5	1 Favours CF	2

Analysis 5.4. Comparison 5 Contract referral versus simple patient referral, Outcome 4 Number of partners testing positive.

Study or subgroup		CR	Si	nple PR	Mean Difference	Weight	Mean Difference
	N	Mean(SD)	Ν	Mean(SD)	Random, 95% Cl		Random, 95% CI
Brown 2011	82	0.3 (0.5)	77	0.2 (0.5)		13.48%	0.1[-0.04,0.24]
Cleveland undated	632	0.4 (0.6)	632	0.2 (0.6)		71.82%	0.13[0.07,0.19]
Landis 1992	39	0.2 (0.4)	35	0 (0.4)		10.35%	0.2[0.04,0.36]
Potterat 1977	94	0.7 (0.9)	93	0.8 (0.9)		4.35%	-0.04[-0.29,0.21]
Total ***	847		837		•	100%	0.13[0.07,0.18]
			Favo	urs simple PR	-1 -0.5 0 0.5	¹ Favours CR	



Study or subgroup		CR		Simple PR		Меа	n Differe	nce		Weight	Mean Difference
	N	Mean(SD)	Ν	Mean(SD)		Random, 95% Cl				Random, 95% Cl	
Heterogeneity: Tau ² =0; Chi ² =2.7	72, df=3(P=0.4	44); I ² =0%									
Test for overall effect: Z=4.8(P<	0.0001)										
			Favoi	urs simple PR	-1	-0.5	0	0.5	1	Favours CR	

Analysis 5.5. Comparison 5 Contract referral versus simple patient referral, Outcome 5 Number of partners treated.

Study or subgroup		CR		Simple PR		Меа	n Differ	ence		Mean Difference
	Ν	Mean(SD)	Ν	Mean(SD)	Random, 95% Cl			Random, 95% Cl		
Potterat 1977	632	0.1 (0.3)	632	0.1 (0.3)	+			0[-0.04,0.04]		
Schwebke 2010	162	0.6 (0.7)	160	0.3 (0.7)				0.28[0.14,0.42]		
				Favours simple PR	-0.5	-0.25	0	0.25	0.5	Favours CR

Analysis 5.6. Comparison 5 Contract referral versus simple patient referral, Outcome 6 Number of harmful events reported.

Study or subgroup		CR		Simple PR		Me	an Differe	nce		Mean Dif	ference
	Ν	Mean(SD)	Ν	Mean(SD)		Rai	ndom, 95%	6 CI		Random	, 95% CI
Brown 2011	82	0 (0.1)	77	0 (0.1)		1		1			0[-0.03,0.04]
				Favours simple PR	-100	-50	0	50	100	Favours CR	

Favours simple PR

Comparison 6. Contract referral versus enhanced patient referral

Outcome or subgroup title	No. of studies	No. of partici- pants	Statistical method	Effect size
1 Number of partners elicited	1		Mean Difference (IV, Random, 95% CI)	Totals not selected
2 Partners presenting for care	1		Mean Difference (IV, Random, 95% CI)	Totals not selected
3 Partners testing positive	1		Mean Difference (IV, Random, 95% CI)	Totals not selected

Analysis 6.1. Comparison 6 Contract referral versus enhanced patient referral, Outcome 1 Number of partners elicited.

Study or subgroup	Exp	erimental Control		Mean Difference					Mean Difference	
	N	Mean(SD)	Ν	Mean(SD)	Random, 95% CI			Random, 95% CI		
Cleveland undated	632	2.9 (1.8)	634	3.3 (1.8)						-0.4[-0.59,-0.21]
			Fav	ours experimental	-100	-50	0	50	100	Favours control

Analysis 6.2. Comparison 6 Contract referral versus enhanced patient referral, Outcome 2 Partners presenting for care.

Study or subgroup	Experimental			Control		Me	an Differe	nce		Mean Difference
	N	Mean(SD)	Ν	Mean(SD)		Random, 95% Cl			Random, 95% CI	
Cleveland undated	632	0.6 (0.7)	634	0.4 (0.7)		1	1			0.25[0.17,0.33]
			Fav	ours experimental	-100	-50	0	50	100	Favours control

Analysis 6.3. Comparison 6 Contract referral versus enhanced patient referral, Outcome 3 Partners testing positive.

Study or subgroup	Exp	Experimental		Control		Me	an Differe	nce		Mean Difference
	N	Mean(SD)	Ν	Mean(SD)		Rai	ndom, 95%	6 CI		Random, 95% CI
Cleveland undated	632	0.4 (0.6)	634	0.3 (0.6)				1		0.12[0.06,0.18]
			Fave	ours experimental	-100	-50	0	50	100	Favours control

Comparison 7. Contract referral versus expedited partner therapy (EPT)

Outcome or subgroup title	No. of studies	No. of par- ticipants	Statistical method	Effect size
1 Re-infection in index patient	1		Risk Ratio (M-H, Random, 95% CI)	Totals not selected

Analysis 7.1. Comparison 7 Contract referral versus expedited partner therapy (EPT), Outcome 1 Re-infection in index patient.

Study or subgroup	CR	EPT	Risk Ratio	Risk Ratio
	n/N	n/N	M-H, Random, 95% Cl	M-H, Random, 95% CI
Schwebke 2010	5/162	10/162		0.5[0.17,1.43]
Schwebke 2010	15/162	6/162		2.5[0.99,6.28]
		Favours CR 0.0	01 0.1 1 10	100 Favours EPT

Comparison 8. Provider referral versus simple patient referral

Outcome or subgroup title	No. of studies	No. of partici- pants	Statistical method	Effect size
1 Provider referral vs. simple pa- tient referral	2		Mean Difference (IV, Random, 95% CI)	Subtotals only
1.1 Number of partners elicited	2	596	Mean Difference (IV, Random, 95% CI)	-0.10 [-0.65, 0.46]
1.2 Number of partners testing positive	2	596	Mean Difference (IV, Random, 95% CI)	0.06 [0.02, 0.11]



Outcome or subgroup title	No. of studies	No. of partici- pants	Statistical method	Effect size
1.3 Number of partners treated	1	438	Mean Difference (IV, Random, 95% CI)	0.5 [0.37, 0.63]
1.4 Number of harmful events re- ported	1	158	Mean Difference (IV, Random, 95% CI)	-0.01 [-0.04, 0.02]
2 Choice between provider or simple patient referral vs. simple patient referral	1		Mean Difference (IV, Random, 95% CI)	Totals not selected
2.1 Number of partners elicited	1		Mean Difference (IV, Random, 95% CI)	0.0 [0.0, 0.0]
2.2 Number of partners notified	1		Mean Difference (IV, Random, 95% CI)	0.0 [0.0, 0.0]
2.3 Number of partners present- ing for care	1		Mean Difference (IV, Random, 95% CI)	0.0 [0.0, 0.0]

Analysis 8.1. Comparison 8 Provider referral versus simple patient referral, Outcome 1 Provider referral vs. simple patient referral.

Pi	rovider			Mean Difference	Weight	Mean Difference	
N	Mean(SD)	Ν	Mean(SD)	Random, 95% Cl		Random, 95% Cl	
ed							
81	1.4 (1.2)	77	1.2 (1.2)	—	46.22%	0.21[-0.15,0.57]	
221	0.8 (1)	217	1.2 (1)		53.78%	-0.36[-0.55,-0.17]	
302		294			100%	-0.1[-0.65,0.46]	
7.65, df=1(P=	0.01); l ² =86.93%						
0.73)							
ng positive							
81	0.3 (0.5)	77	0.2 (0.5)	++-	10.01%	0.1[-0.04,0.24]	
221	0.1 (0.3)	217	0 (0.3)	+	89.99%	0.06[0.01,0.11]	
302		294		•	100%	0.06[0.02,0.11]	
8, df=1(P=0.6)); I ² =0%						
0)							
ed							
221	0.7 (0.7)	217	0.2 (0.7)	-+	100%	0.5[0.37,0.63]	
221		217		•	100%	0.5[0.37,0.63]	
0.0001)							
s reported							
81	0 (0.1)	77	0 (0.1)	+	100%	-0.01[-0.04,0.02]	
81		77		•	100%	-0.01[-0.04,0.02]	
0.44)							
	N 81 221 302 7.65, df=1(P= 0.73) ng positive 81 221 302 3, df=1(P=0.6 0) 221 221 221 221 221 221 0.0001) cs reported 81 81	N Mean(SD) ted 81 1.4 (1.2) 221 0.8 (1) 302 7.65, df=1(P=0.01); $ ^2=86.93\%$ 0.73) ng positive 81 0.3 (0.5) 221 0.1 (0.3) 302 $8, df=1(P=0.6); ^2=0\%$ 0 $0)$ 221 0.7 (0.7) ted 221 0.7 (0.7) 221 0.7 (0.7) 221 0.0001) st 0 (0.1) 81 0 (0.1) 81	N Mean(SD) N ied 81 1.4 (1.2) 77 221 0.8 (1) 217 302 294 7.65, df=1(P=0.01); l²=86.93% 294 7.65, df=1(P=0.01); l²=86.93% 0.73) 217 a02 294 3.01 (0.3) 217 302 294 3.01 (0.3) 217 302 294 3.01 (0.3) 217 302 294 3.01 (0.7) 217 302 294 3.01 (0.7) 217 302 294 3.01 (0.7) 217 302 294 3.01 (0.7) 217 302 294 3.01 (0.7) 217 303 221 0.7 (0.7) 217 304 0.7 (0.7) 217 305 3.01 (0.7) 217 306 3.01 (0.7) 217 307 3.01 (0.7) 3.01 (0.7) 3.01 (0.7) 308 3.01 (0.1) 77 3.01 (0.1)	N Mean(SD) N Mean(SD) Mean(SD) N Mean(SD) Mean(SD) ied 81 1.4 (1.2) 77 1.2 (1.2) 221 0.8 (1) 217 1.2 (1.2) 302 294 765, df=1(P=0.01); l ² =86.93% 77 0.2 (0.5) 0.73) 81 0.3 (0.5) 77 0.2 (0.5) 221 0.1 (0.3) 217 0 (0.3) 302 294 302 294 302 294 302 294 302 294 302 294 302 294 302 294 302 294 302 294 302 294 302 294 302 294 302 294 302 203 302 204 302 302 204 302 302 302 302 302 302 302 303 303 303 303 303 303 303 303 303 303 303 303 303 303	N Mean(SD) N Mean(SD) Random, 95% CI red 81 1.4 (1.2) 77 1.2 (1.2) 221 0.8 (1) 217 1.2 (1) 302 294 7.65, df=1(P=0.01); l ² =86.93% 0.73) ng positive 4 81 0.3 (0.5) 77 0.2 (0.5) 221 0.1 (0.3) 217 0 (0.3) 302 294 4 8, df=1(P=0.6); l ² =0% 4 0,0001) 221 0.7 (0.7) 217 0.2 (0.7) 221 0.7 (0.7) 217 0.2 (0.7) 4 900001 5 5 5 5 81 0 (0.1) 77 0 (0.1) 4 81 0 (0.1) 77 0 (0.1) 4	N Mean(SD) N Mean(SD) Random, 95% CI ed 46.22% 46.22% 46.22% 221 0.8 (1) 217 1.2 (1.2) 46.22% 302 294 46.22% 53.78% 302 294 100% 73.78% ng positive 10.01% 89.99% 302 294 81 0.3 (0.5) 77 0.2 (0.5) 10.01% 221 0.1 (0.3) 217 0 (0.3) 89.99% 302 294 100% 89.99% 302 294 100% 89.99% 302 294 100% 89.99% 302 294 100% 100% 8, df=1(P=0.6); l ² =0% 100% 100% 100% 0.0001) sreported 100% 100% 100%	



Analysis 8.2. Comparison 8 Provider referral versus simple patient referral, Outcome 2 Choice between provider or simple patient referral vs. simple patient referral.

Study or subgroup		Choice	Simple	patient referral	Mean Difference	Mean Difference
	N	Mean(SD)	Ν	Mean(SD)	Random, 95% Cl	Random, 95% CI
8.2.1 Number of partners	elicited					
Faxelid 1996	196	1.8 (1.4)	200	1.9 (1.4)	+	-0.04[-0.31,0.23]
8.2.2 Number of partners	notified					
Faxelid 1996	196	1.6 (1.2)	200	1.2 (1.2)	+	0.41[0.18,0.64]
8.2.3 Number of partners	presenting for care					
Faxelid 1996	196	1.5 (1.1)	200	1 (1.1)	+	0.46[0.24,0.68]
			I	avours simple PR	-2 -1 0 1 2	Favours choice

Comparison 9. Provider referral versus enhanced patient referral (disease intervention specialist)

Outcome or subgroup title	No. of studies	No. of partici- pants	Statistical method	Effect size
1 Number of partners elicited	1		Mean Difference (IV, Random, 95% CI)	Totals not selected
2 Number of partners testing positive	1		Mean Difference (IV, Random, 95% CI)	Totals not selected
3 Number of partners treated	1		Mean Difference (IV, Random, 95% CI)	Totals not selected

Analysis 9.1. Comparison 9 Provider referral versus enhanced patient referral (disease intervention specialist), Outcome 1 Number of partners elicited.

Study or subgroup	F	Provider	Enhanced PR (DIS)			Me	an Differei		Mean Difference	
	N	Mean(SD)	Ν	Mean(SD)		Rai	ndom, 95%	CI		Random, 95% Cl
Katz 1988	221	0.8 (0.9)	240	0.8 (0.9)						-0.05[-0.21,0.11]
			Favours	nhanced PR (DIS)	-100	-50	0	50	100	Favours provider

Analysis 9.2. Comparison 9 Provider referral versus enhanced patient referral (disease intervention specialist), Outcome 2 Number of partners testing positive.

Study or subgroup	Р	Provider		Enhanced PR (DIS)		Me	an Differe		Mean Difference	
	N	Mean(SD)	Ν	Mean(SD)		Rar	1dom, 95%	6 CI		Random, 95% Cl
Katz 1988	240	0 (0.3)	221	0.1 (0.3)						-0.06[-0.11,-0.02]
			Favours e	enhanced PR (DIS)	-100	-50	0	50	100	Favours provider



Analysis 9.3. Comparison 9 Provider referral versus enhanced patient referral (disease intervention specialist), Outcome 3 Number of partners treated.

Study or subgroup	Р	Provider		Enhanced PR (DIS)		Me	an Differei	nce		Mean Difference	
	Ν	Mean(SD)	Ν	Mean(SD)		Rai	ndom, 95%	5 CI		Random, 95% CI	
Katz 1988	240	0.2 (0.7)	221	0.7 (0.7)				-0.54[-0.66,-0.42]			
			Favours e	enhanced PR (DIS)	-100	-50	0	50	100	Favours provider	

Comparison 10. Provider referral versus contract referral

Outcome or subgroup title	No. of studies	No. of partici- pants	Statistical method	Effect size
1 Number of partners elicited	2		Mean Difference (IV, Random, 95% CI)	Totals not selected
2 Number of partners presenting for care	1	163	Mean Difference (IV, Random, 95% CI)	0.03 [-0.19, 0.25]
3 Number of partners located	2	2129	Mean Difference (IV, Random, 95% CI)	0.10 [-0.00, 0.20]
4 Number of partners tested	1		Mean Difference (IV, Random, 95% CI)	Totals not selected
5 Partners testing positive	2	2129	Mean Difference (IV, Random, 95% CI)	0.02 [-0.02, 0.06]
6 Number of partners treated	1		Mean Difference (IV, Random, 95% CI)	Totals not selected
7 Number of harmful events reported	1		Mean Difference (IV, Random, 95% CI)	Totals not selected

Analysis 10.1. Comparison 10 Provider referral versus contract referral, Outcome 1 Number of partners elicited.

Study or subgroup		CR Pi		Provider	Provider Mean Difference			nce	ce Mean Difference		
	Ν	Mean(SD)	Ν	Mean(SD)	Random, 95% Cl		Random, 95% CI				
Brown 2011	82	1.2 (1.1)	81	1.4 (1.1)			-+-			-0.27[-0.62,0.08]	
Peterman 1997	586	6.4 (2.3)	1380	4.2 (2.5)	1	+			2.2[1.97,2.43]		
				Favours provider	-5	-2.5	0	2.5	5	Favours CR	

Analysis 10.2. Comparison 10 Provider referral versus contract referral, Outcome 2 Number of partners presenting for care.

Study or subgroup		CR	P	Provider Mean Differe		nce		Weight	Mean Difference		
	Ν	Mean(SD)	Ν	Mean(SD)		Ra	ndom, 95%	6 CI			Random, 95% CI
Brown 2011	82	0.6 (0.7)	81	0.5 (0.7)						100%	0.03[-0.19,0.25]
Total ***	82		81							100%	0.03[-0.19,0.25]
Heterogeneity: Tau ² =0; Chi ² =0), df=0(P<0.0001	L); I ² =100%									
Test for overall effect: Z=0.26(P=0.79)							1			
			Fav	ours provider	-100	-50	0	50	100	Favours CR	

Analysis 10.3. Comparison 10 Provider referral versus contract referral, Outcome 3 Number of partners located.

Study or subgroup		CR	Provider Mean Difference			Weight	Mean Difference				
	Ν	Mean(SD)	Ν	Mean(SD)		Ra	ndom, 95%	6 CI			Random, 95% Cl
Brown 2011	82	1.1 (1)	81	1 (1)			+			10%	0.06[-0.25,0.37]
Peterman 1997	586	1.2 (1.1)	1380	1.1 (1.1)			+			90%	0.1[-0,0.2]
Total ***	668		1461				•			100%	0.1[-0,0.2]
Heterogeneity: Tau ² =0; Chi ² =0.	.06, df=1(P=0.8	1); I ² =0%									
Test for overall effect: Z=1.9(P=	=0.06)										
			Fav	ours provider	-5	-2.5	0	2.5	5	Favours CR	

Analysis 10.4. Comparison 10 Provider referral versus contract referral, Outcome 4 Number of partners tested.

Study or subgroup		CR		Provider		Mean Difference				Mean Difference	
	N	Mean(SD)	Ν	Mean(SD)		Rar	1dom, 95%	6 CI		Random, 95% Cl	
Peterman 1997	586	0.9 (1)	1380	0.9 (1)		1	ł			0.06[-0.03,0.15]	
				Favours provider	5	-2.5	0	2.5	5	Favours CR	

Analysis 10.5. Comparison 10 Provider referral versus contract referral, Outcome 5 Partners testing positive.

Study or subgroup		CR	P	rovider		Меа	n Difference		Weight	Mean Difference
	N	Mean(SD)	Ν	Mean(SD)		Ran	dom, 95% CI			Random, 95% Cl
Brown 2011	82	0.3 (0.5)	81	0.3 (0.5)		_	+		6.87%	0[-0.16,0.16]
Peterman 1997	586	0.2 (0.4)	1380	0.2 (0.4)					93.13%	0.02[-0.02,0.06]
Total ***	668		1461				•		100%	0.02[-0.02,0.06]
Heterogeneity: Tau ² =0; Chi ² =0	0.06, df=1(P=0.8	1); I ² =0%								
Test for overall effect: Z=0.89(P=0.37)									
			Fav	ours provider	-0.5	-0.25	0 0.25	0.5	Favours CR	



Analysis 10.6. Comparison 10 Provider referral versus contract referral, Outcome 6 Number of partners treated.

Study or subgroup		CR		Provider	er Mean Difference				Mean Difference	
	Ν	Mean(SD)	Ν	Mean(SD)		Rar	1dom, 95%	6 CI		Random, 95% CI
Peterman 1997	586	0.7 (0.8)	1380	0.6 (0.8)			t			0.06[-0.02,0.14]
				Favours provider	-5	-2.5	0	2.5	5	Favours CR

Analysis 10.7. Comparison 10 Provider referral versus contract referral, Outcome 7 Number of harmful events reported.

Study or subgroup		CR		Provider		Mean Difference				Mean Difference	
	N	Mean(SD)	Ν	Mean(SD)		Rar	dom, 95%	6 CI		Random, 95% CI	
Brown 2011	82	0 (0.1)	81	0 (0.1)	1	1			1	0.01[-0.01,0.03]	
				Favours provider	-5	-2.5	0	2.5	5	Favours CR	

ADDITIONAL TABLES

Table 1. Burden of disease

Disease	DALYs
HIV	58.5 million
Chlamydia trachomatis	3.7 million
Gonorrhoea	3.5 million
Other	280,000

Source: WHO 2004.

DALY: disability adjusted life years.

Table 2. Summary of comparisons with data available and STI studied

Partner notification strategy, interven- tion	Partner no trials)	otification con	STI included in trials			
	Simple patient referral	patient patient		Contract referral	Other en- hanced patient referral	
Enhanced patient re- ferral	1 (16)	-	-	-	2 (2)	Gonorrhoea, chlamydia, non- gonococcal urethritis, tri- chomonas, pelvic inflammatory disease, STI syndromes
Expedited partner therapy	3 (8)	4 (5)*	-	-	Not applicable	Gonorrhoea, chlamydia, tri- chomonas, STI syndromes
Contract referral	5 (5)	6 (1)	7 (1)	-	Not applicable	Gonorrhoea, trichomonas, HIV



Table 2. Summary of comparisons with data available and STI studied (Continued)

Provider referral	8 (3)†	9 (1)	No trials	10 (2)	Not applicable	Non-gonococcal urethritis, syphilis, HIV	
-------------------	--------	-------	-----------	--------	----------------	---	--

* Comparison includes one trial comparing combinations of expedited partner therapy and patient referral.

† Comparison Includes one trial comparing a choice between provider or simple patient referral and simple patient referral.

- Indicates combinations of an intervention and comparison that are covered elsewhere in the table; HIV: human immunodeficiency virus; STI: sexually transmitted infection.

Table 3. Summary of included studies and outcomes reported by authors, according to partner notification strategies and comparisons

Partner notifica- tion strategy Comparison num- ber, comparison	N (stud- ies)	n (partici- pants)	Outcomes, as reported in any included RCT	Study ID
ENHANCED PATIENT	REFERRAL			
1. Enhanced patient	16	7642	Index patient returning for a test of cure	Andersen 1998
referral vs. simple patient referral			Knowledge of the index patient	Apoola 2009
			Number of partners notified and referral of partners for treat- ment	Cleveland undat- ed
			Proportion of index patients with at least 1 partner tested	Cameron 2009
			Proportion of index cases with at least 1 sexual partner treat-	Ellison undated
			ed	Kerani 2011
			Proportion of index patients with at least 1 partner positive for <i>C. trachomatis</i>	Katz 1988
			Number of partners treated per index patient 6 weeks after	Kissinger 2005
			randomisation	Kissinger 2006
			Number of partners elicited	Low 2005
			Proportion of index cases with a positive chlamydia test result 6 weeks after randomisation	Moyo 2002
			Proportion of index cases with all sexual partners treated	Ostergaard 2003
			Acceptability of Internet for use in standard partner notifica-	Solomon 1988
			tion	Tomnay 2006
			Partners located	Trent 2010
			Index re-infection	Wilson 2009
			Harms - adverse effects of medication	
			Index patient 72-hour follow-up	
			Medication adherence	
			Temporary abstinence from sexual intercourse as evidence of self care	
			Behavioural change	

trategies and com			Partners contacted	
			Partners tested	
			Partners testing positive	
			Time until testing of partners	
			Number of partners treated per index case	
			Number of partners identified per index	
			Number of traceable partners	
			Number of partners treated within 28 days	
			Proportion of index patients with at least 1 partner treated within 28 days per index case	
2. Enhanced patient	2	1336	Partners presenting for care	Montesinos 199
referral vs. other enhanced patient			Partners elicited	Ellison undated
referral method			Partners treated	
EXPEDITED PARTNER	THERAPY			
3. EPT vs. simple	8	6537	Re-infection rate of index patient	Cameron 2009
patient referral			Number of partners notified	Golden 2005
			Partner treatment	Kerani 2011
			Sexual outcomes such as having unprotected sex before part-	Kissinger 2005
			ner took medication, re-initiated sex with partner, unprotect- ed sex with any partner	Kissinger 2006
			Partners elicited	Nuwaha 2001
			Index patient 2-week post-treatment return	Schillinger 2002
			Harms - fighting and refusal of intercourse	Schwebke 2010
			Side effects of drugs	
			Partner testing	
4.1 EPT vs. en-	4	1253	Re-infection rate of index patient	Cameron 2009
nanced patient re- erral			Number of partners notified	Kerani 2011
			Partner testing	Kissinger 2005
			Partner treatment	Kissinger 2006
			Sexual outcome (unprotected sex, re-initiated sex with un- treated partner)	
.2 EPT and en- 1 41		41	Number of partners notified	Kerani 2011
ferral vs. simple pa-	anced patient re- rral vs. simple pa-		Number of partners treated	
tient referral			Method (telephone or in person) of partner notification used	

Table 3. Summary of included studies and outcomes reported by authors, according to partner notification



Table 3. Summary of included studies and outcomes reported by authors, according to partner notification

strategies and comparisons (Continued)

Partner tested for HIV/syphilis

			Adverse events	
CONTRACT REFERRAL	-			
5 Contract referral vs. simple patient referral	5	2006	Number of partners notified Partners presenting to health service	Brown 2011 Cleveland undat- ed
			Partners testing positive	Landis 1992
				Potterat 1977
				Schwebke 2010
C. Contract refer	1	1200	Deute and a second in a few second	Cleveland undat-
6. Contract refer- ral vs. enhanced pa-	1	1266	Partners presenting for care	ed
tient referral			Partners testing positive	
7. Contract referral vs. EPT	1	324	Re-infection index patient	Schwebke 2010
8. PROVIDER REFERRA	4L			
8.1 Provider referral	2	596	Partners located	Brown 2011
vs. simple patient referral		Partners treated	Katz 1988	
		Partner visit to the clinic during the 30 days after index enrol- ment		
			Harms	
			Partners testing positive	
8.2 Choice between	1	396	Partners elicited	Faxelid 1996
provider or simple patient referral vs.			Number of partners notified	
simple patient re- ferral			Partners treated	
			Harms	
9. Provider referral	1	461	Partners elicited	Katz 1988
vs. enhanced pa- tient referral			Partners testing positive	
			Partners treated	
10. Provider referral vs. contract referral	2	2206	Partners tested	Brown 2011
vs. contract referrat			Partners treated	Peterman 1997
			Partner presenting for care	
			Harms	
			Partners testing positive	

The outcomes listed are those reported by the authors of the RCTs. Not all were named primary or secondary outcomes in the review. EPT: expedited partner therapy; HIV: human immunodeficiency virus; RCT: randomised controlled trial.

Comparison	Ν	n	Study ID	RR	Test for het- erogeneity	
	(studies)	(partici- pants)		(95% CI)	l ² ; Chi ² , P val-	
		pants			ue	
Home sampling kit vs. simple patient refer- ral	1	220	Cameron 2009	2.14 (0.91 to 5.05)	n/a	
Information booklet vs. simple patient refer- ral	2	942	Kissinger 2005; Kissinger 2006	0.55 (0.22 to 1.33)	76%; 4.19, P value = 0.04	
Patient referral (DIS/health adviser) vs. pa- tient referral (nurse)	1	140	Low 2005	0.35 (0.01 to 8.51)	n/a	
Disease-specific website vs. simple patient referral	1	105	Tomnay 2006	3.12 (0.17 to 58.73)	n/a	
Additional counselling vs. simple patient re- ferral	1	600	Wilson 2009	0.49 (0.27 to 0.89)	n/a	

Table 4. Enhanced patient referral versus simple patient referral, re-infection in the index patient, effect size

Enhanced patient referral is taken as the experimental group. Risk ratio (RR) < 1 indicates a lower re-infection risk after enhanced patient referral than simple patient referral. If RR = 1, the risk of re-infection is the same in both groups. If RR > 1, there is a higher risk of re-infection in the enhanced patient referral group. In the trial by Low et al., the outcome was assessed in a minority of index patients. CI: confidence interval; DIS: disease intervention specialist; n/a: not applicable; RR: risk ratio.

Table 5. Enhanced patient referral versus simple patient referral, number of partners elicited per index patient randomised, effect size

,					
Comparison	N	n	Study ID	MD	⊺est for heterogeneity
	(studies)	(partici- pants)		(95% CI)	I ² ; Chi ² , P value
Home sampling kit vs. sim- ple patient referral	3	516	Cameron 2009; Andersen 1998; Apoola 2009	0.00 (-0.19 to 0.19)	0%; 0.32, P value = 0.85
Additional counselling vs. simple patient referral	3	2401	Cleveland undated; Elli- son undated; Moyo 2002	0.1 (0.00 to 0.19)	0%; 1.17, P value = 0.56
Patient referral (DIS) vs. pa- tient referral (nurse)	2	597	Katz 1988; Low 2005	-0.40 (-0.57 to -0.24)	0%; 0.03, P value = 0.87
Information booklet vs. sim- ple patient referral	1	633	Kissinger 2005	0.0 (-0.22 to 0.22)	n/a
Disease-specific website vs. simple patient referral	2	140	Kerani 2011; Tomnay 2006	-0.15 (-0.72 to 0.42)	13%; 1.15, P value = 0.28

Enhanced patient referral is taken as the experimental group. Mean difference (MD) < 0 indicates that simple patient referral resulted in more partners elicited; MD = 0 indicates no difference between groups; MD > 0 indicates more partners elicited in the enhanced patient referral group.

CI: confidence interval; MD: mean difference; n/a indicates not applicable.

Table 6. Enhanced patient referral versus simple patient referral, number of partners notified per index patient	
randomised, effect size	

Comparison	Ν	n	Study ID	MD Test for heter	
	(studies)	(partici-		(95% CI)	geneity
		pants)			I ² ; Chi ² , P value
Home sampling kit vs. simple pa- tient referral	2	782	Cameron 2009; Ostergaard 2003	0.01 (-0.12 to 0.14)	0%; 0.01, P value = 0.93
Additional counselling vs. simple	2	272	Moyo 2002;	0.21 (0.05 to 0.36)	n/a
patient referral			Wilson 2009	data not available	
Disease-specific website vs. sim- ple patient referral	1	105	Tomnay 2006	-0.17 (-0.68 to 0.35)	n/a
Videotape vs. simple patient re- ferral	1	77	Trent 2010	data not available	n/a

Enhanced patient referral group is taken as the experimental group. Mean difference (MD) < 0 indicates that simple patient referral resulted in more partners notified; MD = 0 indicates no difference between groups; MD > 0 indicates more partners notified in the enhanced patient referral group.

CI: confidence interval; MD: mean difference; n/a indicates not applicable.

Table 7. Enhanced patient referral versus simple patient referral, number of partners treated per index patient randomised, effect size

Comparison	Ν	n	Study ID	MD	Test for het- erogeneity
	(studies)	(partici- pants)		(95% CI)	l ² ; Chi ² , P val- ue
Home sampling kit vs. simple patient re- ferral	1	200	Apoola 2009	-0.03 (-0.25 to 0.19)	n/a
Additional counselling vs. simple patient referral	1	863	Ellison undated	0.04 (-0.02 to 0.1)	n/a
Patient referral (DIS) vs. patient referral (nurse)	2	597	Katz 1988; Low 2005	-0.05 (-0.13 to 0.03)	0%; 0.71, P val- ue = 0.40
Information booklet vs. simple patient re- ferral	1	633	Kissinger 2005	0.22 (0.08 to 0.36)	n/a
Videotape vs. simple patient referral	1	12,677	Trent 2010	not reported	n/a

Enhanced patient referral group is taken as the experimental group. Mean difference (MD) < 0 indicates that simple patient referral resulted in more partners treated; MD = 0 indicates no difference between groups; MD > 0 indicates more partners treated in the enhanced patient referral group.

CI: confidence interval; MD: mean difference; n/a indicates not applicable.



APPENDICES

Appendix 1. MEDLINE search strategy

Database: PubMed (2001-2012)

Date: 18 March 2011, 29 January 2012, and 31 August 2012

Search	Most Recent Queries
#7	Search #3 AND #4 AND #5 Limits: Publication Date from 10 May 2001 to 18 March 2011
#6	Search #3 AND #4 AND #5
#5	Search partner notification[tiab] OR partner notifications[tiab] OR contact tracing[mh] OR contact tracing[tiab] OR (expedited[tiab] AND partner[tiab]) OR patient delivered[tiab] OR referral[tiab] OR referrals[tiab] OR partner tracing[tiab]
#4	Search (randomized controlled trial [pt] OR controlled clinical trial [pt] OR randomized [tiab] OR placebo [tiab] OR drug therapy [sh] OR randomly [tiab] OR trial [tiab] OR groups [tiab]) NOT (ani- mals [mh] NOT humans [mh])
#3	Search #1 OR #2
#2	Search HIV Infections[MeSH] OR HIV[MeSH] OR hiv[tw] OR hiv-1*[tw] OR hiv-2*[tw] OR hiv1[tw] OR hiv2[tw] OR hiv infect*[tw] OR human immunodeficiency virus[tw] OR human immunedeficien- cy virus[tw] OR human immuno-deficiency virus[tw] OR human immune-deficiency virus[tw] OR ((human immun*) AND (deficiency virus[tw])) OR acquired immunodeficiency syndrome[tw] OR acquired immunedeficiency syndrome[tw] OR acquired immuno-deficiency syndrome[tw] OR ac- quired immune-deficiency syndrome[tw] OR ((acquired immun*) AND (deficiency syndrome[tw]))
#1	Search sexually transmitted infections[mh] OR sexually transmitted disease*[tiab] OR sexual- ly transmissible disease*[tiab] OR sexually transmitted infection*[tiab] OR sexually transmissible infection*[tiab] OR sexually transmitted infectious disease*[tiab] OR sexually transmissible infectious disease*[tiab] OR sexually transmitted disorder*[tiab] OR sexually transmissible dis- order*[tiab] OR STI[tiab] OR STIs[tiab] OR STD[tiab] OR STIs[tiab] OR venereal disease*[tiab] OR venereal infection*[tiab] OR venereal disorder*[tiab] OR genital herpes[tiab] OR herpes genital- is[mh] OR herpes genitalis[tiab] OR genital infection*[tiab] OR genital disorder*[tiab] OR herpes simplex[tiab] OR herpes virus[tiab] OR thereat disorder*[tiab] OR chancroid[mh] OR chancroid* [tiab] OR haemophilus ducreyi[tiab] OR chlamydia infection*[tiab] OR chlamydia trachomatis[mh] OR chlamydia trachomatis[tiab] OR gonorrhea[mh] OR gonorrhoea*[tiab] OR gonorrhea*[tiab] OR syphilis[mh] OR syphilis[tiab] OR syphillis[tiab] OR condylomata lata[tiab] OR chancre*[tiab] OR lymphogranuloma venereum[mh] OR lymphogranuloma venereum[tiab] OR calymma- tobacterium[mh] OR calymmatobacterium granulomatis[tiab] OR klebsiella granulomatis[tiab] OR klebsiella granulomatis[tiab] OR treponema pallidum[mh] OR treponema pallidum[tiab] OR geni- tal wart*[tiab] OR venereal wart*[tiab] OR condylomata acuminata[mh] OR human papillomavirus 6[mh] OR hpv-6[tiab] OR hpv-11[tiab] OR hpv6[tiab] OR human papillomavirus[tiab] OR geni- tal wart*[tiab] OR novenital ulcer*[tiab] OR hpv6[tiab] OR human papillomavirus[tiab] OR geni- tal wart*[tiab] OR hpv-11[tiab] OR hpv6[tiab] OR human papillomavirus[tiab] OR penital ulcer*[tiab] OR anogenital ulcer*[tiab] OR anorectal ulcer*[tiab] OR penital ulcer*[tiab] OR nogenital ulcer*[tiab] OR penital ulcer*[tiab] OR nogenital ulcer*[tiab] OR penital ulcer*[tiab] OR anogenital ulcer*[tiab] OR anorectal ulcer*[tiab] OR penital ulcer*[tiab]

SEXUALLY TRANSMITTED DISEASES[MH] OR HERPES GENITALIS[MH] OR GONORRHEA[MH] OR SYPHILIS[MH] OR GRANULOMA INGUINALE[MH] OR CONDYLOMATA ACUMINATA[MH] OR LYMPHOGRANULOMA VENEREUM[MH]

Appendix 2. EMBASE search strategy

Database: EMBASE (2001-2012)



Date: 18 March 2011, 29 January 2012 and 31 August 2012

No.	Query
#7	#3 AND #4 AND #5 AND [humans]/lim AND [EMBASE]/lim AND [1-5-2001]/sd NOT [18-3-2011]/sd
#6	#3 AND #4 AND #5
#5	'contact examination'/syn OR 'contact detection':ab,ti OR 'contact tracing':ab,ti OR 'partner notifi- cation':ab,ti OR 'partner notifications':ab,ti OR 'expedited partner':ab,ti OR 'patient delivered':ab,ti OR referral*:ab,ti OR 'partner tracing':ab,ti
#4	#1 OR #2
#3	random*:ti OR random*:ab OR factorial*:ti OR factorial*:ab OR cross?over*:ti OR cross?over*:ab OR crossover*:ti OR crossover*:ab OR placebo*:ti OR placebo*:ab OR (doubl*:ti AND blind*:ti) OR (doubl*:ab AND blind*:ab) OR (singl*:ti AND blind*:ti) OR (singl*:ab AND blind*:ab) OR assign*:ti OR assign*:ab OR allocat*:ti OR allocat*:ab OR volunteer*:ti OR volunteer*:ab OR 'crossover proce- dure'/exp OR 'crossover procedure'/de OR 'crossover procedure' OR 'double-blind procedure'/exp OR 'double-blind procedure'/de OR 'double-blind procedure' OR 'single-blind procedure'/exp OR 'single-blind procedure'/de OR 'single-blind procedure' OR 'randomized controlled trial'/exp OR 'randomized controlled trial'/de OR 'randomized controlled trial'
#2	'human immunodeficiency virus infection'/exp OR 'human immunodeficiency virus infection'/de OR 'human immunodeficiency virus infection' OR 'human immunodeficiency virus'/exp OR 'hu- man immunodeficiency virus'/de OR 'human immunodeficiency virus' OR hiv:ti OR hiv:ab OR 'hiv-1':ti OR 'hiv-1':ab OR 'hiv-2':ti OR 'hiv-2':ab OR 'human immunodeficiency virus':ti OR 'human immunodeficiency virus':ab OR 'human immuno-deficiency virus':ti OR 'human immuno-deficiency virus':ab OR 'human immune-deficiency virus':ti OR 'human immuno-deficiency virus':ab OR 'human immune-deficiency virus':ti OR 'human immune-deficiency virus':ab OR 'human immune-deficiency virus':ab OR 'acquired immune-defi- ciency syndrome':ti OR 'acquired immune-deficiency syndrome':ab OR 'acquired immunedeficien- cy syndrome':ti OR 'acquired immunedeficiency syndrome':ab OR 'acquired immuno-deficiency syndrome':ti OR 'acquired immunedeficiency syndrome':ab OR 'acquired immuno-deficiency syndrome':ti OR 'acquired immunedeficiency syndrome':ab OR 'acquired immuno-deficiency syndrome':ti OR 'acquired immuno-deficiency syndrome':ab OR 'acquired immuno-deficiency syndrome':ti OR 'acquired immuno-deficiency syndrome':ab OR 'acquired immuno-deficiency syn- drome':ti OR 'acquired immuno-deficiency syndrome':ab
#1	'sexually transmitted infections'/exp OR 'sexually transmitted infections, bacterial'/exp OR 'sex- ually transmitted infections, viral'/exp OR (sexually AND transmitted AND disease*:ti OR sexually AND transmitted AND disease*:ab) OR (sexually AND transmissible AND disease*:ti OR sexually AND transmissible AND infection*:ab) OR (sexually AND transmitted AND infection*:ti OR sexually AND transmitted AND infection*:ab) OR (sexually AND transmissible AND infection*:ti OR sexually AND transmissible AND infection*:ab) OR (sexually AND transmissible AND infection*:ti OR sexually AND transmissible AND infection*:ab) OR (sexually AND transmissible AND infections AND disease*:ti OR sexually AND transmitted AND infectious AND disease*:ab) OR (sexually AND transmissible AND disease*:ab) OR (sexu- ually AND transmitted AND disorder*:ti OR sexually AND transmissible AND disorder*:ab) OR (sexu- ually AND transmissible AND disorder*:ti OR sexually AND transmissible AND disorder*:ab) OR (sexu- ally AND transmissible AND disorder*:ti OR sexually AND transmissible AND disorder*:ab) OR (sexu- ually AND transmissible AND disorder*:ti OR genital AND ulcer*:ab) OR (ulcerative AND sexu- ally AND transmisted*:ti OR ulcerative AND sexually AND transmitted*:ab) OR (genital AND 'ulcer/exp AND disease*:ti OR genital AND 'ulcer'/exp AND disorder*:ab) OR (ulcerative AND sexu- ally AND transmitted*:ti OR ulcerative AND sexually AND transmitted*:ab) OR (genital AND disorder*:ab) OR (venereal AND disease*:ti OR venereal AND disorder*:ti OR genital AND disorder*:ab) OR (venereal AND disease*:ti OR venereal AND disorder*:ti OR venereal AND disorder*:ab) OR (venereal AND disorder*:ab) OR ('herpes'/exp AND genitalis:ab) OR (genital AND herpes: simplex'/exp OR 'herpes genitalis':ti OR 'herpes'/exp AND genitalis:ab) OR (genital AND herpes: simplex'/exp OR 'herpes:/exp AND granulomatis:ab) OR (onovania:ab OR ('granu- loma'/exp AN

(Continued)

OR 'syphilis'/exp OR syphilis:ti OR syphilis:ab OR syphillis:ab OR syphillis:ti OR ('treponema'/exp AND pallidum:ti OR 'treponema'/exp AND pallidum:ab) OR chancre:ti OR chancre:ab OR ('condylomata'/exp AND lata:ti OR 'condylomata'/exp AND lata:ab) OR chancroid:ti OR chancroid:ab OR ('haemophilus'/exp AND ducreyi:ti) OR (soft AND chancre:ti OR soft AND chancre:ab) OR 'chlamydia trachomatis'/exp OR 'lymphogranuloma venereum'/exp OR (lymphogranuloma AND venereum:ti OR lymphogranuloma AND venereum:ab) OR ('chlamydia'/exp AND trachomatis:ti OR 'chlamydia'/exp AND trachomatis:ab) OR ('chlamydia'/exp AND infections:ti OR 'chlamydia'/exp AND infections:ab) OR lgv:ti OR lgv:ab OR (vaginal AND ulcer*:ti OR vaginal AND ulcer*:ab) OR (anogenital AND ulcer*:ti OR anogenital AND ulcer*:ab) OR (genital AND ulcer*:ti OR anorectal AND ulcer*:ab) OR (penile AND ulcer*:ti OR penile AND ulcer*:ab) OR (genital AND wart*:ti OR genital AND wart*:ab) OR (venereal AND wart*:ti OR venereal AND wart*:ab) OR 'condyloma acuminatum'/exp OR 'human papillomavirus 6'/exp OR ('hpv 6':ti OR 'hpv 6':ab OR hpv6:ti OR hpv6:ab OR human AND papillomavirus:ti OR human AND papillomavirus:ab) OR 'hepatitis b'/exp OR 'hepatitis b':ti OR 'hepatitis b':ab OR 'gonorrhea'/exp OR gonorrhea*:ti OR gonorrhea*:ab OR gonorrhoea*:ti OR gonorrhoea*:ab

Appendix 3. CENTRAL search strategy

Database: The Cochrane Library 2011, Issue 1 (2001-2012)

Date: 22 March 2011, 29 January 2012 and 31 August 2012

Number of clinical trials retrieved: 191 records

ID	Search		
#1	MeSH descriptor Sexually Transmitted Diseases explode all trees		
#2	MeSH descriptor Herpes Genitalis, this term only		
#3	MeSH descriptor Chancroid, this term only		
#4	MeSH descriptor Chlamydia trachomatis, this term only		
#5	MeSH descriptor Gonorrhea, this term only		
#6	MeSH descriptor Syphilis, this term only		
#7	MeSH descriptor Lymphogranuloma Venereum, this term only		
#8	MeSH descriptor Granuloma Inguinale, this term only		
#9	MeSH descriptor Calymmatobacterium, this term only		
#10	MeSH descriptor Treponema pallidum, this term only		
#11	MeSH descriptor Condylomata Acuminata, this term only		
#12	MeSH descriptor Human papillomavirus 6 explode all trees		
#13	MeSH descriptor Hepatitis B explode all trees		
#14	MeSH descriptor Trichomonas Vaginitis, this term only		

(Continued)	
#15	(#1 OR #2 OR #3 OR #4 OR #5 OR #6 OR #7 OR #8 OR #9 OR #10 OR #11 OR #12 OR #13 OR #14)
#16	sexually transmitted disease*:ti,ab,kw OR sexually transmissible disease*:ti,ab,kw OR sexually transmitted infection*:ti,ab,kw OR sexually transmissible infection*:ti,ab,kw OR sexually trans- mitted infectious disease*:ti,ab,kw OR sexually transmissible infectious disease*:ti,ab,kw OR sex- ually transmitted disorder*:ti,ab,kw OR sexually transmissible disorder*:ti,ab,kw OR STI:ti,ab,kw OR STIs:ti,ab,kw OR STD:ti,ab,kw OR STIs:ti,ab,kw OR venereal disease*:ti,ab,kw OR venereal in- fection*:ti,ab,kw OR venereal disorder*:ti,ab,kw OR genital herpes:ti,ab,kw OR herpes genital- is:ti,ab,kw OR genital infection*:ti,ab,kw OR genital disorder*:ti,ab,kw
#17	herpes simplex:ti,ab,kw OR herpes virus:ti,ab,kw OR HSV-1:ti,ab,kw OR HSV-2:ti,ab,kw OR chan- croid*:ti,ab,kw OR haemophilus ducreyi:ti,ab,kw OR chlamydia infection*:ti,ab,kw OR chlamy- dia trachomatis:ti,ab,kw OR gonorrhoea*:ti,ab,kw OR gonorrhea*:ti,ab,kw OR syphilis:ti,ab,kw OR syphillis:ti,ab,kw OR condylomata lata:ti,ab,kw OR chancre*:ti,ab,kw OR lymphogranu- loma venereum:ti,ab,kw OR granuloma inguinale:ti,ab,kw OR donovania:ti,ab,kw OR dono- vanosis:ti,ab,kw OR calymmatobacterium granulomatis:ti,ab,kw OR klebsiella granuloma- tis:ti,ab,kw OR klebsiella granulomatis:ti,ab,kw OR treponema pallidum:ti,ab,kw OR genital wart*:ti,ab,kw OR venereal wart*:ti,ab,kw OR hpv-6:ti,ab,kw OR hpv-11:ti,ab,kw OR hpv6:ti,ab,kw OR human papillomavirus:ti,ab,kw OR hepatitis b:ti,ab,kw OR trichomonas vaginitis:ti,ab,kw OR genital ulcer*:ti,ab,kw OR anogenital ulcer*:ti,ab,kw OR anorectal ulcer*:ti,ab,kw OR anorectal ul- cer*:ti,ab,kw OR penile ulcer*:ti,ab,kw
#18	(#15 OR #16 OR #17)
#19	MeSH descriptor HIV Infections explode all trees
#20	MeSH descriptor HIV explode all trees
#21	hiv OR hiv-1* OR hiv-2* OR hiv1 OR hiv2 OR HIV INFECT* OR HUMAN IMMUNODEFICIENCY VIRUS OR HUMAN IMMUNEDEFICIENCY VIRUS OR HUMAN IMMUNE-DEFICIENCY VIRUS OR HUMAN IM- MUNO-DEFICIENCY VIRUS OR HUMAN IMMUN* DEFICIENCY VIRUS OR ACQUIRED IMMUNODEFICIEN- CY SYNDROME OR ACQUIRED IMMUNEDEFICIENCY SYNDROME OR ACQUIRED IMMUNO-DEFICIEN- CY SYNDROME OR ACQUIRED IMMUNE-DEFICIENCY SYNDROME OR ACQUIRED IMMUN* DEFICIENCY SYNDROME
#22	MeSH descriptor Lymphoma, AIDS-Related, this term only
#23	(#19 OR #20 OR #21 OR #22)
#24	(#18 OR #23)
#25	MeSH descriptor Contact Tracing, this term only
#26	partner notification:ti,ab,kw OR partner notifications:ti,ab,kw OR contact tracing:ti,ab,kw OR expe- dited partner:ti,ab,kw OR patient delivered:ti,ab,kw OR referral:ti,ab,kw OR referrals:ti,ab,kw OR partner tracing:ti,ab,kw
#27	(#25 OR #26)
#28	(#24 AND #27)
#29	(#24 AND #27), from 2001 to 2011

WHAT'S NEW

Date	Event	Description
30 September 2013	New citation required but conclusions have not changed	The conclusions of the review are essentially unchanged from the previously published version of the review.
11 September 2012	New search has been performed	Major update completed which include a new search, 16 new studies, new review format and methodology.

CONTRIBUTIONS OF AUTHORS

Adel Ferreira co-ordinated the update of the review. She was involved in screening the results and eligibility assessment of the studies. She was involved in data extraction, data management, risk of bias assessment and data interpretation. She performed the data analysis and was responsible for writing the first draft of the update.

Taryn Young provided methodological support for the review update. She was involved in eligibility assessment of studies, conducted data extraction and risk of bias assessment, assisted in resolving disagreements, contributed to data analysis and interpretation of results, and commented on and revised the manuscript.

Catherine Mathews was involved in the conception and design of the original review. In the update, she was involved in the screening of search results, analysis and interpretation of the data, and commented on and revised the manuscript.

Moleen Zunza was involved in screening of search results, assessing eligibility of studies, data extraction and risk of bias assessment. She commented on and revised the manuscript.

Nicola Low contributed to the analysis and interpretation of the results. She commented on and revised the manuscript.

All authors approved the final version of the updated review.

DECLARATIONS OF INTEREST

Taryn Young and Catherine Mathews are co-authors of studies cited in the Background section.

Nicola Low is a co-author on one of the included RCTs and a systematic review that is cited in the Background and Discussion section.

SOURCES OF SUPPORT

Internal sources

• Centre for Evidence-based Health Care, Stellenbosch University, South Africa.

External sources

• Effective Health Care Research Consortium, UK.

DIFFERENCES BETWEEN PROTOCOL AND REVIEW

This was an update of an existing Cochrane Review.

INDEX TERMS

Medical Subject Headings (MeSH)

Chlamydia Infections [therapy] [transmission]; Contact Tracing [*methods]; Gonorrhea [therapy] [transmission]; Randomized Controlled Trials as Topic; Sexual Partners; Sexually Transmitted Diseases [prevention & control] [*transmission]; Urethritis [therapy]; Uterine Cervicitis [therapy]

MeSH check words

Female; Humans; Male